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Abstract
In the present study, bioassay and NMR approaches were used in combination to guide
isolation of two new and three known compounds. An extract library of New Zealand
and Tongan marine invertebrates was screened for activity inhibiting the growth of
Saccharomyces cerevisiae. From this, ‘hits’ were identified and validated and three
New Zealand sponges and a Tongan ascidian were chosen for bulk extraction. These
invertebrates were extracted in methanol and purified using normal and reversed-phase
chromatography to isolate the compounds of interest. The isolation of compounds was
guided by either inhibitory activity towards S. cerevisiae, 1H NMR spectroscopy or a
combination of the two.
The known trihydroxylated steroid (14) was isolated from the calcareous sponge Leu-
cosolenia sp. A fatty acid and mixture of phthalate esters were isolated from an
unidentified Tongan ascidian. The fatty acid was proposed to be cis-vaccenic acid (13) on
the basis of 1H and 13C NMR data. The phthalate ester mixture was not purified further.
Work on these two compounds was discontinued due to a lack of activity observed in the
S. cerevisiae assay and the well-known nature of fatty acids and phthalate esters.
Work was also done on an assay targeting the large mechanosensitive channel (MscL) of
bacteria. Some parameters were optimised for this assay, however some work remains
to be done. The screening of the extract library of New Zealand and Tongan marine
invertebrates using this assay was unsuccessful. More studies to better understand the
behaviour of this assay are required, some of which are proposed herein.
The extraction of the New Zealand marine sponge Haliclona sp. yielded one known and
two new 3-alkyl pyridinium alkaloid (3-APA) monomers. The structures of these 3-APA
monomers—dehydrohaliclocyclin C (58), dehydrohaliclocyclin F (59) and the known
haliclocyclin C (20)—were elucidated using a combination of NMR spectroscopy, mass
spectrometry (MS) and chemical degradation. This is the first report of a 3-APA cyclic
monomer with unsaturation in the alkyl chain being isolated. 3-APAs were identified as
the source of inhibitory activity in the S. cerevisiae assay, however, no inhibitory activity
was found for 58, 59 and 20 against the clinically relevant fungus C. albicans.
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Chapter 1
Introduction
1.1 Natural Products Chemistry
For thousands of years humans have relied on plant sources for medicines. Documents
from Mesopotamia, Ancient Egypt, China and India all provide records of the use of
plants for medicine. Some plant extracts employed as early as 2600 BC are still in
use today, including oil extracted from Papaver somniferum (poppy), which is used in
cough medicines. Compounds isolated from poppies are also used as painkillers such as
morphine (1) and codeine (2).1,2 The discovery of the natural product penicillin in 1928
eventually lead to the ‘Golden Age of Antibiotics’ from the 1940s to the 1970s.1,3 This
discovery was also very important as penicillin is still used today to treat some bacterial
infections.
O
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Natural products still play an important role in drug development; between 1981 and
2008 a study of the sources of drugs showed that 63% of new drugs could be classed as
being naturally derived compounds.4,5 Furthermore, 68% of new antibacterial, antifungal,
antiviral and antiparasitic drugs were found to be naturally derived.5 Naturally derived
compounds include those that are natural products, derivatives of natural products,
synthetic compounds based on a natural product pharmacophore or synthetic compounds
that show competitive inhibition of a natural product substrate. Natural products are not
often used as drugs in their directly isolated form, they often serve as lead compounds
1
resulting in the development of analogues with optimised pharmacological properties.5
Natural products chemistry can, therefore, be considered the first step in the journey to
finding new, naturally-derived drugs for clinical use.
1.2 Marine Natural Products
The marine environment provides a rich source of interesting and previously unknown
compounds, which is why it is so extensively explored in the search for new drugs.2,4,6
To date, most new compounds with interesting biological activities that have been found
from marine organisms have been extracted and isolated from marine sponges, corals and
other invertebrates.4 In 2010, 1003 new compounds from marine organisms were reported
in the literature and 28% of these were from sponges.7 In 2011, 1152 new compounds
were reported from marine organisms and, of these, 26% were from sponges.8 It should
also be noted that the bacteria and fungi that live in association with marine sponges,
algae and corals have also been found to produce potent bioactive compounds. These
microorganisms can often contribute to a significant amount of the observed biomass
of their marine invertebrate host. This can result in compounds isolated from a marine
invertebrate extract actually having been produced by the microorganisms associated with
that invertebrate.2,4,9,10
Only a handful of drugs derived from marine natural products have been approved for
clinical use today.11 By 2010, despite the 1003 new compounds that were reported in the
literature for that year alone,7 only four drugs derived from marine organisms had been
approved for clinical use by the United States Food and Drug Administration (FDA) and
one drug had been approved by the European Medicines Agency (EMEA).11
Ziconotide (3, Prialt R©) was the first marine-derived drug that was approved by the
FDA in December 2004, and by the EMEA in February 2005.11,12 Ziconotide joined
the naturally-derived synthetic drugs cytarabine (4, Ara-C, Cytosar-U R©, Depocyt R©) and
vidarabine (5, Ara-A, Vira-A R©), which were approved by the FDA in 1969 and 1976,
respectively.2,4,11 Ecteinascidin-743 (6, trabectedin, ET-743, Yondelis R©) was registered
with the European Union in October 2007 and the drug eribulin mesylate (7, Halaven R©)
was approved by the FDA in November 2010.2,4,13 Ziconotide is the synthetic equivalent
of the peptide ω-conotoxin MVIIA. It contains 25-amino acids and was isolated from
the venom of the fish-hunting marine cone snail Conus magus. Ziconotide is used
as an analgesic, specifically for management of chronic or severe pain.2,11 Cytarabine
and vidarabine are synthetic pyrimidine nucleosides that are derivatives of nucleosides
isolated from the Carribean sponge Tethya crypta. Cytarabine is used in the treatment
of leukemia, while vidarabine was used as an antiviral agent but was discontinued
in June 2001.11 Ecteinascidin-743 is a tetrahydroisoquinoline alkaloid containing three
2
fused tetrahydroisoquinoline rings. It was isolated from the tropical ascidian (sea
squirt) Ecteinascidia turbinata. Ecteinascidin-743 is used to treat refractory soft tissue
sarcomas and ovarian carcinoma.2,11 Eribulin mesylate is a simplified ketone analogue
of the macrocyclic halichondrin B, which is a potent cell growth inhibitor that has been
isolated from several unrelated sponges. Eribulin mesylate is the methansulfonate salt of
eribulin (7) and is now used in the treatment of late-stage metastatic breast cancer.2,13,14
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Of particular interest in the search for biologically active molecules are secondary
metabolites. It is thought that secondary metabolites must provide some ecological
advantages to the organism producing them as they are often very structurally complex
and an organism would not waste the energy to produce these compounds if it was not an
advantage to them.15 Secondary metabolites were initially thought to be waste products
of the organisms producing them, but it was later shown that these compounds were
developed as a means of defence, communication and predation.5 For sessile marine
invertebrates, the action of these secondary metabolites is often thought to be defensive
due to the lack of physical defences in these organisms.5 As a result of this, marine
invertebrates have been found to be a rich source of secondary metabolites with unusual
chemistry.6,15,16 These secondary metabolites can have activities in the organism to deter
or paralyse predators, slow or suppress the growth of competing organisms, prevent
3
bacterial growth on their surface (fouling) and shield from ultraviolet radiation.5,15,16
These metabolite activities are particularly useful due to the sessile nature of most of
these marine invertebrates, which feed by filtration of seawater.10 Biologically active
compounds isolated from marine invertebrates are often found to be very potent. This
potency is necessary for these organisms because of the rapid dilution that occurs when
a compound is released into the ocean. As a result, if the compounds are going to have a
biological effect, they will have to be very potent.10,16
A significant problem with the bioactive compounds isolated from marine organisms is
that there is often difficulty in isolating enough of the compound for complete biological
testing; this is due to the natural products only being produced in trace quantities.4,5,10
As little as 40 to 50 years ago the lack of suitable spectroscopic and chromatographic
techniques may have prevented the isolation and structural elucidation of compounds
present in trace amounts.10,17 This difficulty in acquiring enough mass can lead to
few marine natural products actually entering clinical trials and so can be considered
a contributing factor to the low number of marine natural products that have actually
been approved for use as drugs.4,10 However, in the last 50 years, the development and
improvement of nuclear magnetic resonance (NMR) spectroscopy hardware and software
has led to a greatly improved ability to solve the structure of new compounds. Further
developments over the past 30 years have allowed the mass required to collect useful
NMR data from a moderately sized molecule (≤500 Da) to fall from 20-50 mg to less than
1 mg.17 This has greatly increased the ability of natural products chemists to identify new
biologically active compounds, resulting in thousands of new compounds being reported
every year.
In order for comprehensive biological tests to be performed on isolated marine natural
products it is often important to develop successful chemical syntheses. This can allow
the biological activity of these, often very structurally complex, compounds to be fully
characterised, thus allowing their potential for use as drugs to be assessed. Most of
the compounds that are currently undergoing clinical trials are being produced by total
synthesis as this is often the easiest and most reliable way to produce these compounds.4
Other methods used to overcome the issue of low mass availability are: aquaculture (also
known as mariculture, the farming of marine organisms), semi-synthesis (modification of
natural compounds, often isolated from bacteria) and synthesis of analogues.2
1.2.1 Marine Sponges
Sponges are sessile metazoans (multicellular organisms) of the phylum Porifera. They
have existed for millions of years. Evidence of their existence dates back to the
Precambrian period and they are thought to have been well established by the Cambrian
period.18 They are the most ancient multicellular organisms on the planet. There are an
4
estimated 15,000 sponge species living in marine and freshwater habitats worldwide, but
this is thought to only be a small fraction of all the species of sponges that have ever
lived.18 There do not appear to have been any significant changes in sponge morphology
over the last 509 million years in which they have existed, in fact, some sponges alive
today appear to be almost identical to their ancient counterparts. Consequently, sponges
are regarded to be one of the most successful life forms to have ever lived.18
Classification of sponges can be very difficult, mainly due to the physical characteristics
of the sponge being highly influenced by environmental factors.18 This can lead to
sponges of the same species having very different colours, shapes and sizes. Sponges feed
by filtering sea water through channels from external pores using choanocytes (flagellated
cells) that create a unidirectional water current through the sponge. These choanocytes
are unique to sponges and, along with various other cells, they remove food particles
and oxygen from the water.18 This simple nature of sponges means that they do not have
complex digestive, circulatory or neurological systems seen in other animals, adding to
the difficulty in classifying them. Sponges are made up of highly mobile totipotent cells,
which give them the ability to adapt to a diverse range of environments (plasticity) and
contribute to the many different morphologies of sponges that have been observed.18 The
firmness of a sponge’s structure is made up of collagen fibrils (located in the mesohyl; the
gelatinous matrix of the sponge), spongin fibres and silica (SiO2) or calcium carbonate
(CaCO3) spicules, which form an inorganic skeleton for many sponge species.18 It is
these spicules that form the basis for sponge classification.
There are three distinct classes of sponges: Hexactinellida, Demospongiae and Calcarea.
Within these there are currently seven subclasses, 25 orders, 127 families and 682
genera.18 Demospongiae sponges are the most common sponges (about 85% of living
sponges) and they are usually characterised by siliceous monaxone or tetraxone spicules
and/or spongin fibres. Hexactinellida sponges are characterised by siliceous triaxone
and/or hexactine spicules while Calcarea sponges are characterised by calcium carbonate
spicules, which are usually triactine or tetractine.18 Silica spicules can be revealed by
dissolving the organic matter of a small piece of sponge in concentrated nitric acid
(HNO3) while calcium carbonate spicules can be found by dissolving the organic matter
of a small piece of sponge in bleach (NaOCl). There are further features of sponges that
can be used to identify the separate classes, these features can be used, for example, to
determine the classes of sponges without spicules or to identify the order or family of a
sponge within a class. The details of the full classification system is beyond the scope
of this research and so will not be discussed here. For a comprehensive review on the
taxonomic classification of sponges see Systema Porifera. A Guide to the Classification
of Sponges.18
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1.3 Natural Products Screening and Isolation
The great range and diversity of marine organisms makes it hard to decide where to
start in the search for bioactive marine natural products. It is for this reason that
screening techniques have been developed to identify organisms containing compounds
of interest. The two main screening approaches utilised by marine natural products
chemists to identify interesting compounds are bioassay and spectroscopic screens. Both
of these methods use the crude extraction of a marine organism that is then assessed for
interesting chemical functionality or biological activity. The use of bioassays to screen
extracts means that any compounds identified will have biological activity. However, a
limitation of the use of bioassays is that they specifically target one receptor or organism
meaning that compounds that may have activity in other biological systems will not
be identified. Another limitation of this approach is that compounds that are already
known to show biological activity cannot be distinguished from novel biologically active
compounds leading to re-isolation of already known compounds. Spectroscopic screens
of crude extracts look to identify interesting functional groups or masses and fragment
masses (for NMR and MS screens, respectively). An advantage of this technique is that
known compounds can be identified a lot earlier in the isolation procedure. However, a
disadvantage of this technique is that the compounds isolated using this method will not
necessarily be biologically active.
Bioassay-guided isolation of marine natural products is done by screening a library
of extracts to identify organisms containing compounds that are biologically active.
Once these have been identified, purification of the bioactive compound from all the
other compounds present in the initial extract is required. This is typically done using
chromatographic techniques, with tests for bioactivity performed at each stage during
purification to ensure that the desired bioactive compound is being isolated. Spectroscopic
techniques can then be used to determine the chemical structure of these isolated bioactive
compounds.16 Spectroscopic-guided isolation is very similar to the above methods, with
the obvious difference of the spectroscopy of choice being used for the initial screen and
after each stage of purification to ensure the compound of interest is being isolated. The
research described herein will use a combination of bioassay and NMR-guided isolation
to identify bioactive compounds and identify any other compounds of interest found
during purification of the initial extracts. The assays in this work will target antifungal
compounds and compounds that interact with the large mechanosensitive channels of
bacteria.
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1.3.1 Antifungals
Fungi are eukaryotic organisms and, as such, they have metabolisms very similar to that
of mammals. This means that there are few clinically viable antifungal agents due to
the severe side effects that can occur with these compounds.1 Amphotericin B (8) is
a well known antifungal agent but it has severe side-effects such as chills, fever and
nephrotoxicity.1,19,20 Although many compounds with antifungal activity in vitro have
been reported, when tested in animal models the adsorption, distribution, metabolism
and excretion of these compounds have indicated that they are not suitable for use as
antifungal agents for the treatment of humans without further chemical development.1
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Generally, invasive fungal infections are not a major threat to healthy individuals,
as their natural immune response is sufficient to defeat these pathogens.21 However,
for individuals with compromised immunity, often due to disease (e.g. AIDS) or
chemotherapy, fungal infections from these opportunistic pathogens can be a dangerous
complication.22,23 For this reason, effective antifungal agents with minimal side effects
are extremely desirable due to the already fragile health of these patients.23 Some
potentially pathogenic fungi (also called mycoses) can be found in soil as saprophytes,
where they will compete for nutrients and need to adapt quickly to a rapidly changing
environment, for example Aspergillus fumigatus.21,24 However, one of the most common
and successful human fungal pathogens, Candida albicans, is rarely found free-living
without a mammalian host.25 C. albicans is a common fungus that can commensally live
in various areas of the human body, it is also an opportunistic pathogen that will respond
to changes in a hosts physiology (affecting their immune system or microflora) resulting
in a fungal infection.25,26 There are a limited number of antifungal drugs active against
C. albicans. These drugs also have significant limitations including the emergence of
drug-resistant strains and severe side-effects. This highlights the need for new antifungal
drugs to be developed.27
Fungal infections in plants are also a huge concern on a worldwide scale. For many
years plant diseases caused by fungi or fungal-like oomycetes have caused devastating
losses of crops worth millions of dollars and this has had a significant impact on human
history.24,28,29 For example, the Irish potato famine from 1845 to 1851 was due to potato
7
blight, which is caused by the fungus-like oomycete Phytophthora infestans. This caused
starvation and economic ruin in Ireland.24,28 Potato blight is still considered to be the
worlds most dangerous potato disease. Fungicides are available to treat potato blight but
these can be costly and harmful to human health.28 Another fungal plant pathogen that is
estimated to cost around $66 billion in crops is Magnaporthe oryzae, which causes rice
blast. This fungus is found worldwide and has the capability to destroy up to 100% of
crops in some rice paddies. M. oryzae is particularly difficult to control as resistant rice
cultivars do not display resistance to all strains of this fungus and, generally, the fungus
will overcome the resistance in two to three growing seasons. Fungicides, however, are
able to kill M. oryzae, once again showing their importance.28 Synthetic compounds
currently dominate the fungicide market and issues that have arisen from their repeated
use include disruption to natural biological systems caused by their environmental
pollution, the development of fungicidal resistance and the residual toxicity of these
fungicides resulting in human health concerns.29 There is now a movement to develop
more biopesticides, such as natural product fungicides, which cause less environmental
disruption and are safer for humans so that the synthetic pesticides can be phased out.29
Fungal infections in animals have also proven to be an increasing concern. For example,
the emergence of white-nose syndrome (WNS) in bats, first documented in the United
States (US) in New York State in February 2006, has led to fears of regional extinction of
the little brown bat, which was previously a common bat species in the US.30,31 WNS is a
psychrophilic fungal infection caused by the fungus Geomyces destructans that affects
hibernating bats. The disease is named for the white fungal growth observed on the
muzzle, ears and wing membranes of affected bats.30,32 One of the effects of this fungus
on the bats is a loss of fat reserves, which are crucial for a successful hibernation.30 It is
also thought that this disease has effects on the bats’ behaviour.31,33 WNS now occurs in
northeastern and mid-Atlantic regions in the US as well as the provinces of Ontario and
Que´bec in Canada.31 It is fast spreading and can cause drops in bat populations ranging
from 30 to 99% per year once a hibernaculum is infected. The regional mean decrease
in bat population for infected hibernacula is 73% per year and hibernacula are generally
infected within 2 years of WNS being observed in that region.31 WNS is known to affect
at least seven species of hibernating bats.31 It has been predicted that there is a 99%
chance of regional extinction of the little brown bats in the next 13 years if the trends
observed in 2010 for WNS continue.31 Even if circumstances such as WNS mortality
reduces over time, the regional population of little brown bats is expected to drop to
1% of its size prior to the emergence of WNS in less that 20 years time.31 This decline
in the insectivorous bat population is expected to have significant detrimental effects on
the ecology and economy of these regions in coming years.30,33 The development of an
antifungal treatment for WNS could save the regional little brown bat populations and
reduce the detrimental ecological and economic effects in affected regions.
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1.3.2 Antibacterials
The discovery of penicillin (9) in 1928 did not gather much interest until its rediscovery as
an antibiotic in the early 1940s by scientists at Oxford University.34 Since this rediscovery,
antibiotics have been used to treat infectious diseases and, in particular, many natural
product antibacterials have been discovered and used to treat bacterial infections.3,35
However, a major problem that has developed with the widespread use of antibacterials
is the emergence of antibacterial-resistant bacterial strains. Within five years of the first
use of penicillin, 50% of isolated Staphylococcus aureus exhibited resistance.34 Bacteria
and fungi have very rapid reproduction rates and so they can mutate and evolve quickly,
adapting to new threats. The widespread use of antibacterials was thus able to trigger
the evolution of antibacterial resistant strains of bacteria.3,35 New classes of antibacterials
are being sought to combat the drug-resistant strains of bacteria by affecting different
targets. Synthetic tailoring of known antibacterial scaffolds has been used in the past to
develop new antibacterial drugs but these are only short term solutions in treating multi-
drug resistant bacterial infections as resistance inevitably develops.34,36,37
A particularly concerning bacteria that has developed resistance to current drug treatments
is methicillin-resistant Staphylococcus aureus (MRSA).3,38 Methicillin (10), an analogue
of penicillin, was developed in 1960 in order to combat the penicillin resistant strains
of S. aureus, which were becoming more common.3,34 However, resistance to methicillin
quickly developed in S. aureus and by the 1970s and late 1980s MRSA had been identified
widely in Europe and the US, respectively.34 Between 1999 and 2005, the estimated
number of S. aureus-related infections resulting in hospitalisation in the US increased by
62% and the number of estimated MRSA hospitalisations increased by 119%.38 Patients
with MRSA bacteremia have a higher risk of mortality than patients with methicillin-
susceptible S. aureus bacteremia. However, whether this increased risk of mortality
is due to enhanced virulence of MRSA, poor efficacy of drugs used for treatment,
delayed MRSA-appropriate treatment or another as yet unidentified reason has not been
determined.39
MRSA is a nosocomial (acquired in hospital) infection due to the frequent use of
antibiotics in that environment.3 MRSA does not just exhibit resistance to methicillin but
it is resistant to all of the β-lactam antibiotics that are otherwise used to treat infections
caused by S. aureus such as penicillin, oxacillin and amoxicillin.40–43 While MRSA is
most commonly acquired in hospitals, community-acquired MRSA is also becoming
more common.44,45 Community-acquired MRSA is defined as MRSA contracted by a
patient who has not had recent contact with the healthcare system. Usually, community-
acquired MRSA presents itself as a skin infection and can be treated without long-
term effects on the patient. In contrast, nosocomial invasive MRSA infections are
more severe and can be life-threatening.40,41,44,46 Vancomycin (11) is an antibacterial that
was previously used as a last resort against MRSA but is now more commonly used
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in its treatment. Unfortunately, even resistance to vancomycin has started to emerge
highlighting the need for new classes of antibacterials to be developed.3,41,45,47 Antibiotic
resistance in the bacteria Streptococcus pneumoniae and Mycobacterium tuberculosis,
which are common respiratory pathogens, are also causing great concern in the medical
community. The growing resistance of these and other bacterial pathogens have resulted
in a critical need for the discovery of new antibacterial agents with novel modes of
action.36,48
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1.4 Research Aims
The aim of the current research was to isolate and identify bioactive compounds from
marine invertebrates. The marine invertebrates being studied were a range of New
Zealand and Tongan sponges, algae and tunicates of which a library of extracts had been
made. In particular, compounds that have antifungal or antibacterial activity were to
be studied. This involved using an assay to test the ability of extracts to inhibit the
growth of the yeast Saccharomyces cerevisiae to find antifungal compounds. To find
antibacterial compounds, a new assay targeting the opening of large mechanosensitive
channels (MscL) of Escherichia coli was further developed and tested against extracts.
10
By screening extracts of marine invertebrates for antimicrobial activity, a chemically
diverse range of compounds are able to be tested. This results in a chance for completely
new structural classes of antimicrobial drugs to be discovered. New structural classes
being developed for antimicrobial drugs is advantageous over synthesising analogues of
existing drugs as microbes that are already resistant to a drug are likely to have some
resistance to its analogues as well. It is therefore likely that new structural classes of
antimicrobials will have more success in clinical development.34–37
The MscL assay was modified to be performed at VUW to screen the invertebrate extract
library for extracts with molecules capable of locking MscL in an open conformation.
The S. cerevisiae assay was used to identify invertebrate extracts with molecules that were
cytotoxic or cytostatic towards the growth of yeast. Once active extracts were identified
from the S. cerevisiae assay, extractions were repeated in bulk and the active compounds
isolated using chromatographic techniques. The isolation of the bioactive compounds was
guided using a combination of bioassays and 1H NMR spectroscopy. The structures of the
isolated bioactive compounds were then identified using 1D and 2D NMR spectroscopy
and mass spectrometry (MS). The activity of these isolated compounds was finally tested
in assays against the clinically relevant fungi Candida albicans.
11
Chapter 2
Bacterial Mechanosensitive Channels
2.1 Discovery of Mechanosensitive Channels
Bacterial cells have an optimal turgor pressure (pressure of the cytoplasm on the cell
membrane, holding it against the cell wall), which they work to keep constant despite
changes in the osmolarity of their environment. Different bacteria have different optimal
turgor pressures. Bacteria grown in a high osmolarity (high solute concentration)
environment maintain their turgor pressure by accumulating solutes (such as potassium
ions, glutamate and proline) in the cytosol, so that water will not diffuse out into the
environment. Cells will also accumulate solutes when transferred from a low osmolarity
environment to a high osmolarity environment to counteract the water leaving the cell as
a result of this osmolarity change (hyperosmotic shock).49,50 When these cells are then
transferred to lower osmolarity environments, water will rapidly diffuse into these cells
that have a higher osmolarity; this is known as hypoosmotic shock. This can increase the
turgor pressure in the cell by approximately 10 atmospheres in a few milliseconds. The
increase in turgor pressure will increase the membrane tension and can cause the cell to
burst if there is no release of pressure (Figure 2.1).49,50
Mechanosensitive channels (Msc) are channels located in the cytoplasmic cell membrane
that open in response to mechanical forces acting on the cell membrane; this includes
stretch-activated and stretch-inactivated channels.51–53 Msc have been found in bacteria,
fungi, plants and animals. While these channels all have mechanosensitive functions, it
is possible that their protein sequences and therefore mechanism of mechanosensitivity
could be unrelated.54,55 The most studied Msc in bacteria are poorly selective channels
that are stretch-activated. The mechanical force acting on the bacterial cell membrane is
typically an increase in membrane tension (stretch) caused by osmotic swelling as a result
of hypoosmotic shock.51–53,55 In response to this, Msc will open and passively release
solutes from the cell until the osmolarity of the cell and media are equal, the Msc will
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then close and allow normal growth to resume in the cell (Figure 2.1).50,56 Modifications
to mechanosensitive processes to sense external mechanical stimuli may have led to the
evolution of many sensory functions that are currently used by different organisms, such
as touch or hearing.57 It is hoped that a better understanding of bacterial Msc can give
some insights into the poorly understood molecular basis of such senses.56
 
HYPOOSMOTIC 
SHOCK 
A B 
Figure 2.1. Msc in osmotic regulation. When a cell in osmotic balance is moved to a lower
osmolarity media than its internal osmolarity, hypoosmotic shock will occur and the cell will
begin to accumulate water increasing the turgor pressure. At this point either (A) Msc will sense
the increase in membrane tension caused by the accumulation of water and open, releasing
solutes into the media and allowing normal cell growth to occur once an ideal turgor pressure is
reached, or (B) if Msc do not open or no Msc are present, the cell will continue to accumulate
water, increasing the turgor pressure until the cell eventually lyses. This figure is adapted from
Booth et al. (2007).50
Berrier et al. found that when inducing hypoosmotic shock in Escherichia coli cells,
the amount of internal ATP, lactose, glutamate and potassium ions reduced. By altering
the concentration of solute (NaCl) in the solution that the cells were transferred to (to
cause hypoosmotic shock) they were able to show that the extent of internal solute loss
depended on the degree of hypoosmotic shock. Also, reducing the temperature of the
solution increased the amount of efflux occurring as well. The 90% viability found when
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culturing the hypoosmotic stress-induced cells was evidence that the release of internal
solutes was not due to complete cell lysis and hence could be due to the presence of
Msc. Further evidence for Msc was that the internal solutes travelled out of the cells
very fast, indicating that the route by which efflux occurred was not that of conventional
transport systems.53 Studies conducted by Levina et al. on the transfer of E. coli from
high osmolarity to low osmolarity media have shown that the threshold at which Msc
are significantly activated is when a hypoosmotic shock from a difference of more than
150 mM of NaCl occurs. This was found by transferring E. coli cells that had been grown
in media with a set concentration of 300 mM NaCl to media with lower concentrations of
NaCl that had been acidified so that cell death would occur upon opening of the poorly
selective Msc.49
2.2 Techniques for Measuring Msc
A common technique used to study Msc is the patch-clamp technique; this has provided
a lot of information to further understand Msc.58 The patch-clamp technique allows the
current through individual ion channels to be recorded by using a recording patch-pipette
to suck a section of the cell membrane of an enlarged cell into the tip, forming a high
resistance “gigaohm” seal. Pressure and a voltage can then be applied to this ‘patch’ of
the membrane and measurement of the current amplitude of the Msc at a known pressure
and membrane voltage (‘holding potential’) can then be recorded.50,52,54–56,59,60 Negative
pressure (suction) in the pipette is required to open these Msc as it pinches a section
(patch) of the cell membrane increasing the membrane tension in that section, thus causing
the Msc to open.54 It has been found that larger diameter pipettes require lower pressures
(greater suction) to activate the Msc, indicating that it is in fact the tension and not the
pressure that is activating these channels.61 The channels with greater conductance have
been found to require greater suction to be opened. The actual pressure required to open
the channels, however, is not as important as the relative magnitudes due to the variations
that occur from patch to patch (e.g. different radii of curvature).52 In general, the strength
of suction required to open the Msc of large conductance (MscL) is about 1.5 times the
magnitude of the suction required to open the Msc of small conductance (MscS).62 For
representative images of a patch-clamp and a trace of the current and pressure information
extracted from a patch-clamp experiment see Figure 2 of Booth et al. (2007).50
Mechanosensitive channel activity can be measured from reconstituted proteoliposomes
and giant bacterial spheroplasts. The reason for using giant spheroplasts is that the
patch pipette opening is too large for the patch-clamp technique to be used on normal
bacterial cells, therefore larger objects need to be used.52,54,59 Proteoliposomes are made
from liposomes fused or reconstituted with purified membrane fractions of bacteria (often
E. coli) or purified Msc proteins.52,59,62,63 The observation that single patches in these
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proteoliposomes often have several channels with a single type of conductance has led to
the hypothesis that these membrane channels separate in the reconstitution procedure and
then form clusters of one type of channel in the formation of the proteoliposomes.52
Giant spheroplasts can be formed in different ways. One way of forming these
spheroplasts involves growing cells in the presence of chemicals such as mecillinam
(6-amidinopenicillanic acid) that prevent peptidoglycan synthesis, inhibiting the forma-
tion of the cell wall.54,63,64 Giant spheroplasts can also be formed by growing cells in the
presence of cephalexin, which prevents cell division. These long, thin (filamentous) cells
can then be treated with lysozyme and EDTA (ethylenediaminetetraacetic acid), which
will dissolve the cell wall.52,54,59 Bacteria with mutations to give a round phenotype
can also be used to give giant round spheroplasts.52 It should be noted that when
patch-clamp experiments were performed on E. coli membrane vesicles fused with
azolectin liposomes, the pressure required to open the Msc was lower than the pressure
used to open the Msc in E. coli giant spheroplasts.59 Mechanosensitive channels that have
been reconstituted into proteoliposomes have been found to remain closed in the absence
of suction (membrane tension) regardless of the voltage applied to the membrane. When
suction is applied causing the channels to open, once the suction (and therefore tension)
is released, the channels will close again.52
2.3 Distinction of Mechanosensitive Channels
In bacteria there are two different subfamilies of Msc—the mechanosensitive channel
of large conductance (MscL) subfamily and the mechanosensitive channel of small
conductance (MscS) subfamily. In E. coli, only one homologue of MscL and at least
six MscS homologues exist: the canonical MscS, the subsequently identified MscK
(potassium-dependant mechanosensitive channel; originally KefA), the YbdG channel
(previously thought to be the mechanosensitive channel of mini conductance, MscM)
and a further three MscS homologues, which have recently been characterised by
electrophysiology and functional analyses (YjeP, YbiO and YnaI). Where the channel
YjeP is now proposed to be the major component of the MscM channel activity that
has been observed.56,65 MscL and MscS are the most well studied of these Msc and
therefore they are the best understood. The MscL and MscS are so named based on
the relative conductance of the channels in the (inner) cytoplasmic membrane of E. coli
as measured by Sukharev et al. using the patch-clamp technique.59 The conductance of
E. coli MscL (Ec-MscL) was found to be about 3100 pS and the conductance of E. coli
MscS (Ec-MscS) was about 900 pS in giant spheroplasts in a buffer solution with a KCl
concentration of 200 mM.59 Higher suction pressures (and therefore higher membrane
tension, which is related by Laplace’s law using the radius of curvature of a membrane
patch) on the cell membrane were required to open the MscL as compared with the MscS.
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In fact, the membrane tension required to open MscL is close to the tension at which
cell lysis will occur.52,55,59,61 The presence of both MscL and MscS in E. coli could allow
the cells to lose only small ions such as potassium and keep larger metabolites (whose
loss would be the least favourable) in the cell when only small reductions in osmolarity
of the bacterial cell environment occur.53 The number of different Msc that have been
found may also be required for redundancy, due to the importance of their function in
osmoregulation.52 The MscS stay open for longer durations compared with MscL, which
only open for brief periods.52,59 In the study by Sukharev et al., MscL also appeared to
gate at subconducting levels where the channel appeared to be partially open due to a
lower conductance being observed. MscS also appeared to have a very slight preference
for anions to pass through the channel.59
In a further study Berrier et al. identified three Msc in reconstituted giant liposomes and
giant round spheroplasts that were made from E. coli cells. They identified an MscL
channel that showed conductance over a range of 1000 to 2300 pS and an MscS channel
that showed conductance of 300 to 500 pS in a KCl concentration of 100 mM. They also
identified a previously unknown Msc conductance of 100 to 150 pS with even slower
kinetics than the MscS (it stayed open even longer). It was concluded that this was a
third family of Msc and so it was named MscM for Msc of mini conductance.52 However,
recent studies indicate that MscM belongs to the subfamily of MscS-like channels.65
2.4 Large Mechanosensitive Channels (MscL)
2.4.1 MscL Gene
In 1994 Sukharev et al. identified the gene responsible for producing the MscL protein in
E. coli. This gene was named mscL. From the sequencing of this gene it was predicted that
the MscL protein had 136 amino acid residues and a molecular weight of approximately
17 kDa.66 The MscL channel protein was, however, thought to be approximately 60 to
80 kDa based on the elution profile of the protein when purified using size-exclusion
chromatography, performed under non-denaturing conditions.59 This was thought to
indicate oligomerization of the 17 kDa protein to form the MscL.66 In this study, an mscL
knock-out mutant of E. coli was created. The removal of the mscL gene did not inhibit
viability of these bacteria, indicating that the MscL protein is not necessary to survival
with transient osmotic changes. It was proposed that the reason for this is redundancy
between MscL and MscS.66
After the mscL gene had been identified in E. coli, homologues of MscL were able to be
identified in many other prokaryotes from unfinished sequences of genome sequencing
projects and by DNA sequencing of bacteria closely related to E. coli.62,67 The UniProt
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database currently lists 2296 members of the MscL subfamily, with homologues identified
in Gram-negative and Gram-positive bacteria as well as phytoplasma and mycoplasma
(which are specialised cell-wall deficient bacteria).68–70 As seen in E. coli, these MscL
homologues, when expressed in E. coli cells devoid of native MscL, have no effect on
the activity of the native MscS, indicating no interaction between the two proteins. These
homologues also showed a requirement for pressures higher (about 1.5 times the size)
than those required to activate MscS to be activated, as was also observed for native
Ec-MscL.62 The conductances of these channels were measured to be between 3000 and
5000 pS and they also showed poor ion selectivity. These factors seem to indicate that
only minor differences exist between these channel homologues. The kinetics of these
channels, however, appears to vary. The channels can be grouped into two classes, a rapid
class and a slow class. The rapid class have channel open times of less than 4 ms to
10 ms, and the slow class have channel open times above 10 ms to greater than 30 ms.
The Ec-MscL showed open times of 35 ms on average and so falls into the slow MscL
class.62
Conceptual translation of each of the genes studied showed similar hydropathy profiles
with two hydrophobic segments (thought to be the transmembrane segments) and
hydrophilic termini (both thought to lie in the cytoplasm of the cell) being found for
all the proteins investigated. The carboxy-terminus showed some conservation amongst
the homologues but complete divergence was also seen between the two most distantly
related homologues. Also, a periplasmic loop (that connects the two transmembrane
segments) appears to vary in size, with sequence similarity only being observed between
the Gram-negative MscL homologues. The amino-terminus also appears to show some
degree of conservation between these homologues.62
2.4.2 Crystal Structure
In 1998, Rees and co-workers reported the crystal structure of MscL isolated from
the bacteria Mycobacterium tuberculosis (Tb-MscL), determined at 3.5 A˚ resolution.
This crystal structure was subsequently refined by Steinbacher et al. in 2007 using
the diffraction data collected by Rees and co-workers.67,71 The Tb-MscL protein has
151 amino acids with a 37% sequence identity to the MscL of E. coli (Ec-MscL).
The protein was found to be a homopentamer and can be divided into transmembrane,
periplasmic and cytoplasmic domains. It is approximately 85 A˚ long and, of this, about
50 A˚ is the transmembrane domain (with about 35 A˚ actually spanning the membrane),
which is also about 50 A˚ wide. The cytoplasmic domain is about 35 A˚ long and 18 A˚
wide. For each of the subunits of the Tb-MscL homopentamer, the amino- and carboxy-
termini were thought to be disordered in the original structure refinement in 1998.67 In the
structure refinement in 2007, the first 12 residues of each subunit, at the amino-terminus,
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are modelled to be an α-helix. It is proposed that this amino-terminal helix would sit at
the membrane surface in the cytoplasm.71 The transmembrane domain is made up of two
transmembrane α-helices from each subunit, which start from the amino-terminus on the
cytoplasmic face of the membrane and are joined by a loop on the periplasmic side.67
This periplasmic loop structure was also corrected in the structural refinement in 2007.71
The cytoplasmic domain is made up of an α-helix that starts from a short loop joining
it to the second transmembrane helix of the subunit and ends with the carboxy-terminus
(Figure 2.2).67 A register error of six of the residues of this cytoplasmic helix was also
corrected in the structural refinement of 2007.71
The pore of this Tb-MscL structure runs through the five-fold axis of the homopentamer.
The first transmembrane (TM1) helices (that are closest to the amino-termini) of each
subunit form the inner lining of the pore and the second transmembrane (TM2) helices
run down the outside of these. The transmembrane helices are tilted at an angle of
approximately 28◦ to the fivefold axis and the cytoplasmic helices are tilted at an angle
of approximately 15◦ according to the original structural refinement in 1998.67 In the
2007 refinement, the transmembrane helices are described as forming a “right-handed
helix bundle” whereas the cytoplasmic helices are described as forming a “left-handed”
helix bundle.71 The TM1 helix of each subunit is in contact with its corresponding
TM2 helix, the TM1 helices of two adjacent subunits and the TM2 helix of one of the
adjacent subunits. The TM2 helix of each subunit is about 20 A˚ from the TM2 helix of
the neighbouring subunits.67,71 The amino-terminal α-helix of a subunit is positioned in
between the TM1 and TM2 helices of neighbouring subunits in an almost perpendicular
orientation, with the amino-terminal pointing towards the adjacent cell membrane.71 The
pore of Tb-MscL forms a funnel shape with a pore size ranging from approximately 18 A˚
at the periplasmic face to 2 A˚ at the cytoplasmic face. The pore is partially obstructed at
the cytoplasmic face. In the transmembrane domain of this protein the inner lining of the
pore is hydrophilic, except for near the cytoplasmic surface where the pore is lined with
hydrophobic residues.67,71 The small (approximately 2 A˚) pore size and the hydrophobic
lining at the cytoplasmic end of the channel could create a seal indicating that this is a
crystal structure of the closed form of Tb-MscL.50,67 The open pore diameter for MscL in
E. coli (Ec-MscL) has been previously approximated to be about 40 A˚.72
In 2009, Rees and co-workers reported the crystal structure of the MscL from Staphylo-
coccus aureus (Sa-MscL) with a truncation of the carboxy-terminus (Sa-MscL(C∆26)).
This crystal structure was obtained at a resolution of 3.8 A˚. The Sa-MscL protein has
120 amino acid residues before the truncation and this has a 40% sequence homology
with Tb-MscL and a 51% sequence homology with Ec-MscL.76 The open state of the
Sa-MscL appears to be less stable than that of Ec-MscL, this is indicated by shorter open
dwell times, which had been previously reported when the conductance of homologues
of Ec-MscL were measured.62 Sa-MscL(C∆26) was proposed to be more stable than
the full-length Sa-MscL. In patch-clamp experiments on Sa-MscL(C∆26) reconstituted
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Figure 2.2. Crystal structure of the MscL protein isolated from Mycobacterium tuberculosis
(Tb-MscL). It shows the homopentameric structure that is divided into a transmembrane domain
and a cytoplasmic domain. For each subunit it can be seen that the transmembrane domain starts
from the α-helix amino-terminal (N), followed by the two transmembrane helices that are joined
by a periplasmic loop (P). The cytoplasmic domain starts from a second loop (L) that connects
the two transmembrane helices to the α-helix of the cytoplasmic domain that ends with the
carboxy-terminal (C). The image on the left is the view through the pore axis from the
periplasmic face and the image on the right is the view through the membrane. This Figure has
been adapted from Chang et al. (1998).67 This structure file was downloaded from the Protein
Data Bank73 and was rendered using RasMol Molecular Renderer, version 2.7.5.2.74,75
in azolectin liposomes, the gating and conductance of these channels was found to be
comparable to that of Ec-MscL. Both Sa-MscL and Sa-MscL(C∆26) were found to be
able to rescue hypoosmotically-shocked Msc-knockout E. coli cells, indicating that the
truncated protein is still active as a MscL channel.76
The crystal structure of Sa-MscL(C∆26) showed that the protein is approximately 69 A˚
in diameter and 37 A˚ long. Like Tb-MscL, the subunits of Sa-MscL(C∆26) have two
transmembrane helices (TM1 and TM2) that start from the irregularly structured carboxy-
terminus at the cytoplasmic face. TM1 of Sa-MscL(C∆26) is joined to TM2 by a
periplasmic loop as is also seen in Tb-MscL. The transmembrane domain in the crystal
structure of Sa-MscL(C∆26) is about 13 A˚ shorter than the transmembrane domain of
Tb-MscL and it is also up to 17 A˚ wider. This corresponds to a wider pore being observed
in the Sa-MscL(C∆26) crystal structure. The constricted end of the funnel shaped pore,
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which is approximately 2 A˚ wide and thought to form a seal due to the hydrophobic
residues in Tb-MscL, is approximately 6 A˚ wide in the Sa-MscL(C∆26) crystal structure.
The biggest difference between the Tb-MscL and Sa-MscL(C∆26), which is also likely
to be the reason for other discrepancies observed in the crystal structures, is that the
Sa-MscL(C∆26) was crystallised as a homotetramer.76 More recent studies have shown
that in vivo the Sa-MscL and Sa-MscL(C∆26) proteins are predominantly pentamers. It
is proposed that the tetrameric structure of Sa-MscL is not physiologically relevant but is
formed as a detergent-dependent reorganisation. This tetrameric reorganisation has been
found to be reversible when the detergent used to solubilize the Sa-MscL is exchanged
for a more appropriate one.77,78 It is proposed that the Sa-MscL(C∆26) crystal structure,
which was originally thought to be in an intermediate state in the transition from a closed
to open form, is actually a strained closed state that forms as a result of the tetrameric
reorganisation.
2.4.3 Mechanism
Considerable effort has gone into elucidating the mechanisms of MscL. This is because
of the proposed ability for such mechanosensitive channels to provide insight into
understanding phenomena such as touch, hearing, gravitropism and other processes that
require mechanosensors, by providing a simplified model system.71,79 Understanding the
mechanism of these mechanosensitive channels could also provide information on the
relationship between a protein and the membrane in channel gating.71 It is thought that
Msc proteins are responsible for detecting the change in membrane tension without the
aid of other proteins; this is due to the fact that Msc proteins are able to be purified and
incorporated into liposomes and these reconstituted Msc are still able to sense membrane
tension and open and close reversibly.61,80 MscL and MscS are gated channels and, as
such, the change in conductance between the open and closed state is able to occur via
conformational changes of the protein.81
Since the crystal structure of Tb-MscL was proposed, more research has been directed
towards elucidating the mechanism for the channel gating in Msc. It has been found
that the MscL has multiple conducting states, and so is not just simply open or closed.
Thermodynamic calculations have been used to show that the rate limiting step in the
MscL gating process is the transition from the closed state to the lowest subconducting
state. The states above this lowest subconducting state are all about the same energy and
so applying tension to the membrane lowers the energy of these states equally.61 From the
crystal structure of Tb-MscL it is expected that the pore size will have to undergo a drastic
change in size (both reducing the pore length and increasing the width) in order to have
an approximately 3000 pS conductance. It is thought the pore size will have to increase
by approximately 600 A˚2 from the closed state in order to accommodate the observed
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conductance (forming an open pore diameter of 30 to 40 A˚).61
Martinac and co-workers used electron paramagnetic resonance (EPR) spectroscopy and
site-directed spin labelling (SDSL) to identify the structural changes involved in the
opening of MscL. From the results obtained using this technique, they proposed that the
crystal structure of Tb-MscL obtained by Rees and co-workers was a good representation
of the active protein in a membrane environment.67,80 One of the problems that had to be
overcome to use this method in identifying the changes in the protein structure was how
to open the MscL without using pressure.80 Using phosphatidylcholine (PC) liposomes
to reconstitute the MscL protein and performing patch-clamp analyses on these, Martinac
and co-workers found that thinner bilayers (with monosaturated chains of 16 carbons,
PC16) required less pipette pressure to open MscL than the control (with 18-carbon
chains, PC18) and more pipette pressure was required to open MscL in fatter bilayers
(with 20-carbon chains, PC20). This change of MscL gating with the thickness of the
membrane formed is called hydrophobic mismatch due to the mismatch of interactions
between the membrane and the protein.63,80
EPR spectroscopy of the MscL incorporated into thinner PC bilayers with carbon chains
of 10 to 16 carbons (PC10-PC16) seemed to indicate a slightly altered structure from
the closed state. This altered structure, however, still appeared to have a closed pore.
This was proposed to be an intermediate state in the transition from closed to open MscL.
Based on this data, the transition from the closed to the intermediate state was proposed to
represent a significant energy barrier; this is due to the fact that the proposed intermediate
state of MscL found in the thin bilayers is able to be opened at significantly lower
pressures than the closed state. This is consistent with the rate limiting step proposed by
Sukharev et al.61,80 To form the fully open state of MscL hydrophobic mismatch alone was
not sufficient, so a different approach involving distortion of the bilayer was attempted.
When a lysophosphatidylcholine (LPC) was added to the PC liposome membrane, it
disrupted the normal membrane resting state thus driving MscL to the open state. The
LPC has been described as a ‘cone-shaped’ lipid due to its tendency to form micelles,
whereas the phospholipids that form bilayers are described as rods (these shapes are
approximations based on behaviour rather than actual descriptions of shape). The LPC
disrupts the membrane by its ability to distort the lipid bilayer shape causing asymmetric
lateral pressure between the two leaflets in the bilayer (Figure 2.3), thus triggering MscL
to open.79,80,82
Since these developments, much work has been done to improve our knowledge of
the mechanism of MscL, as it is still not well understood.83–89 Mechanisms have been
proposed and adapted as new information has come to light, but our current understanding
of MscL is insufficient to fully describe its gating mechanism. This further highlights the
need to find a compound that is capable of opening MscL by a direct interaction with
the protein in order to better understand its gating mechanism. For recent reviews on
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Figure 2.3. When an LPC molecule (red) is added to a lipid bilayer (A) it causes it to distort (B)
resulting in asymmetric lateral pressure between the two layers, this triggers the opening of
MscL.
the research into MscL gating and the conclusions that have been drawn see Booth and
Blount (2012)90, Haswell et al. (2011)91 and Iscla and Blount (2012).92 For a review
on the research and proposed mechanisms prior to the revision of the Tb-MscL crystal
structure in 2007 see Perozo (2006).63
2.5 MscL Bioassay
A new bioassay has been developed by Professor Boris Martinac and colleagues at
the Victor Chang Cardiac Research Institute. This assay is used to test the activity
of compounds on the gating of Ec-MscL that has been reconstituted into azolectin
liposomes containing carboxyfluorescein (a self-quenching, fluorescent material). The
aim of this project was to screen our library of marine invertebrate extracts against these
MscL-containing liposomes to find compounds capable of locking the channel in the
open conformation. If the channel were able to be locked in the open conformation in
pathogenic bacterial cells, then these cells would not be able to maintain their cellular
homeostasis resulting in the slowing down of cell processes and eventually death.
This bioassay was still in the developmental stages and the protocol needed to be adapted
to allow the assay to be performed using the equipment available at Victoria University
of Wellington (VUW) and Environmental Science and Research (ESR), Kenepuru. The
assay was conducted under the supervision of Dr. Penny Truman (ESR). The fragility of
the azolectin liposomes meant that they needed to be prepared the same day that the assay
was performed. They were also very sensitive to the conditions used to make them, so
their preparation needed to be optimised before the assay could be run. Consistent and
reproducible results were required from this assay before it could be tested against the
library of extracts.
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In this assay, the liposomes were made with carboxyfluorescein incorporated into them.
They were then passed through a lipid extruder to allow the collection of liposomes of
the desired size (in this case 400 nm liposomes were used). MscL protein suspended
in detergent was then added to these liposomes and allowed to incorporate into the
membranes. MscL had been isolated from E. coli and suspended in detergent by
Prof. Martinac’s group who kindly supplied this for our use. Once the liposomes
containing reconstituted MscL were made, they could be tested. As a positive control
1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (12), an LPC was used to open the
MscL channel (the mechanism of this was discussed in Section 2.4.3). As a measure
for the total releasable carboxyfluorescein possible from the liposomes, a 10% TritonTM
X-100 solution was used as this causes complete lysis of the liposomes.
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The assay worked by measuring the fluorescence of the liposomes in the presence of
different compounds. CF being a self-quenching fluorescing agent meant that when
the CF molecules were in the liposomes the molecules would be in a concentrated
environment leading to lower fluorescence being observed. When the CF molecules were
released from the liposomes they would be in a more dilute environment and so more
fluorescence would be observed. The assay was performed in a 96-well black plate and
the fluorescence of the wells was read using a fluorescence plate reader (fluorometer).
What was observed in the assay was that a solvent control showed the least fluorescence,
the liposomes with the LPC added showed an intermediate amount of fluorescence (due
to some carboxyfluorescein molecules being able to escape from the liposome) and the
liposomes exposed to the 10% TritonTM solution showed the highest fluorescence (due to
the all the carboxyfluorescein in the liposomes being released into the well).
LPC is able to be used as a positive control due to its ability to distort the membrane. It
works by altering the transbilayer pressure profile in a cell or liposome membrane trig-
gering MscL to open.93 However, because it works by incorporating into the membrane
and distorting it (resulting in the opening of MscL), the LPC molecules will eventually
equilibrate by inserting themselves in both layers of the membrane, thus cancelling out
the effect of distortion on the membrane and allowing the MscL to close again.93,94 For
this reason, the current research aims were to find a compound that interacts directly with
the MscL protein, locking it in an open state so that it is irreversibly opened. Such a
compound would be of use as a more reliable positive control for future assays. It would
also act as a probe to allow further studies to be performed on the structure and mechanism
of MscL, as well as being a potential antibacterial drug lead.
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Chapter 3
Screening
3.1 Antifungal Assay
Antifungal assays were chosen because of the readily available resources and facilities
for performing this assay with the Chemical Genetics group (in the School of Biological
Sciences at VUW) who were able to provide assistance with screening and dose-response
assays. The resources were also available to do testing on yeast gene deletion mutant
libraries to determine the mode of action of antifungal compounds isolated, however
these assays could only be performed if large masses (e.g. >20 mg) of these compounds
had been isolated. The screening assays were performed in liquid culture on 96-well
plates with each extract dissolved in 50% DMSO in H2O and added to the culture. Only
one well was used to test each extract in the assay. Positive controls, growth controls,
solvent controls and media controls were also set out on each assay plate for accurate
comparisons between plates and across assays. The screening assay was performed twice
so that each extract was initially tested for activity in duplicate. The dose-response assay
used to validate the ‘hits’ from the screening assays were also performed in liquid culture
using 96-well plates and the same controls were applied. The extracts were tested in
triplicate with the highest concentration of wells being 100 µg/mL and all subsequent
wells being diluted by 50% (e.g. concentrations across the plate were: 100 µg/mL,
50 µg/mL, 25 µg/mL etc.). The plates for both assays were incubated for 18 hours and
then yeast growth was determined using optical density (OD) measurements.
The extract library of New Zealand and Tongan marine invertebrates was tested for
activity that inhibits the growth of the yeast Saccharomyces cerevisiae at a concentration
of 100 µg/mL. If an extract inhibited yeast growth by at least 35% it was considered to be
a ‘hit’. Extract ‘hits’ were then validated in a dose-response assay against S. cerevisiae.
From this work two sponges of interest were initially identified and bulk extractions
done. The sponge MNP 0999 showed very good inhibitory activity with more than 90%
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inhibition of yeast growth at a concentration of 12.5 µg/mL. The sponge MNP 1001
showed moderate inhibitory activity with more than 90% inhibition at a concentration of
50 µg/mL. These sponge extracts were then purified using chromatography. Later in the
project an ascidian and sponge that were hits in the initial screens were also extracted and
purified. The ascidian PTN3 40G showed good inhibitory activity in the initial screens
(with an average inhibition of 88% at a concentration of 100 µg/mL) but no activity in
the dose-response validation. The sponge PTN2 67C showed weaker inhibitory activity
in both the initial screening (with an average inhibition of 50% at a concentration of
100 µg/mL) and validation assays. It was hoped that weak activity that had been observed
would become stronger upon purification of these extracts.
In the current work several different types of chromatographic media were used for
purification. Reversed-phase HP20, poly(styrene-divinylbenzene) stationary support, was
used in the first step of purification of the crude extract. It was used by cyclic loading the
crude extract on to the HP20 column and eluting the column with the relevant fractions of
acetone in water to gain the desired separation. This was followed by the use of HP20ss,
which was eluted using fractions of methanol in water and followed by an acetone strip
to reduce the risk of sample and activity loss. However, it should be noted that even
using 100% acetone to strip the HP20 and HP20ss columns will not eliminate the risk of
sample and activity loss completely.95 It has been shown that separation using silica gel
can lead to a significant loss of mass and bioactivity in certain natural product extracts, for
this reason a Diol bonded phase was used instead for normal-phase separation.95 When
further purification was required after HP20ss, Diol was often used. Diol columns were
eluted with stepped gradients, starting with ethyl acetate in hexanes through ethyl acetate
to a gradient of methanol in ethyl acetate until 100% methanol was reached. The column
was finally stripped with 25% and 50% water in methanol. For further purification after
the use of Diol (or after HP20ss if Diol was not used), HPLC was used in normal (Diol) or
reversed (C18) phase modes. The conditions for these HPLC separations were optimised
for each compound or group of compounds.
3.1.1 MNP 0999
MNP 0999 (Figure 3.1) was a dark-brown, brittle sponge identified as Haliclona sp. that
was collected off Port Hardy, d’Urville Island, New Zealand in April 2000 and stored
frozen. In validation assays against S. cerevisiae MNP 0999 had a 94% inhibition at
12.5 µg/mL but showed no inhibition at 6.25 µg/mL. This gave an approximate IC50 of
11.0 µg/mL with a large margin of error. A mass of 189 g of this sponge was extracted
with methanol twice and cyclic loaded onto HP20. The MNP 0999 extract was then eluted
from the HP20 using 20%, 40%, 60%, 80% and 100% acetone in water, these fractions
were then backloaded and eluted with acetone to remove water from the fractions. The
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Figure 3.1. Surface photograph of MNP 0999 collected off Port Hardy, d’Urville Island, New
Zealand. Photograph courtesy of Associate Professor Peter Northcote.
20% (VD1 96A) and 40% (VD1 96B) acetone in water fractions had masses of 128 mg
and 388 mg, respectively. These samples both had IC50 values of 1.5 ± 1 µg/mL when
tested against S. cerevisiae and showed similar 1H NMR spectra (Figure 3.2). Further
purification of VD1 96A was done using HP20ss followed by Diol and finally HPLC was
used several times to isolate three 3-alkyl pyridinium alkaloid (3-APA) monomers. Two
of the 3-APAs isolated have not been previously reported in the literature and one is a
known compound. Further purification of VD1 96B was done using HP20ss followed
by reversed-phase (C18) HPLC. This produced a 3-APA that was not able to be fully
characterised. The isolation and structural elucidation of the 3-APAs will be discussed in
Chapter 4.
0.00.51.01.52.02.53.03.54.04.55.05.56.06.57.07.58.08.59.09.510.0
f1 (ppm)
VD1_96A_MeOD_H_600MHz
VD1_96B_MeOD_H_600MHz
Figure 3.2. 1H NMR spectra of VD1 96A and VD1 96B (600 MHz, CD3OD).
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3.1.2 MNP 1001
Figure 3.3. Surface photograph of MNP 1001 collected off Port Hardy, d’Urville Island, New
Zealand. Photograph courtesy of Associate Professor Peter Northcote.
MNP 1001 (Figure 3.3) was a soft, light brown-green sponge, finger-like in shape. It
has been identified as Callyspongia sp. and was collected off Port Hardy, d’Urville
Island, New Zealand in April 2000 and stored frozen. In initial validation assays against
S. cerevisiae, MNP 1001 inhibited 99% of yeast growth at a concentration of 50 µg/mL
but only 24% inhibition was observed at a concentration of 25 µg/mL. This gave an
approximate IC50 of 26.6 µg/mL with a large margin of error. A mass of 112 g of
this sponge was extracted twice with methanol and purified on HP20 using the same
procedure used for MNP 0999, very low masses were recovered from this fractionation
in the range of 4.9 to 72.3 mg. These fractions were tested against S. cerevisiae where they
showed no significant inhibition. Less than 10% inhibition was observed in all fractions at
concentrations of 200 µg/mL (the highest concentration tested). This assay was repeated
to ensure that the compounds were not active before work on this sponge was ceased in
favour of other, more promising, leads. The repeat assay included testing the activity
of the recombined fractions in case the mechanism of inhibition was synergistic. This
recombined fraction, however, showed no activity either and so this isolation is likely to
be an example of the active component of an extract irreversibly binding to HP20.95 The
lack of activity of this sponge in combination with the low masses recovered meant that
work on this sponge was not pursued further.
3.1.3 PTN3 40G
PTN3 40G (Figure 3.4) was an unidentified ascidian that had been collected at Swallows
Cave in Vava’u, Tonga in November 2009. Only 17.92 g of this ascidian had been
collected and so the entire mass was extracted in methanol. The solution was a dark
orange-red colour. In initial validation assays against S. cerevisiae, PTN3 40G showed
weak inhibition with 65% inhibition of yeast growth at a concentration of 100 µg/mL (the
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Figure 3.4. Surface photograph of PTN3 40G collected at Swallows Cave in Vava’u, Tonga.
Photograph courtesy of Associate Professor Peter Northcote.
highest concentration tested). PTN3 40G was cyclic loaded on to HP20 and eluted using
30%, 75% and 100% acetone in water. The fractions containing water were backloaded
on to HP20 and eluted to remove the water. The 75% acetone in water fraction (VD3 64B)
had a mass of 51.1 mg and was shown to inhibit 27% of yeast growth at a concentration
of 100 µg/mL when tested against S. cerevisiae. This fraction was further purified on
HP20ss and tested for activity against S. cerevisiae again. Two fractions collected from
this HP20ss column from 80% methanol in water (VD3 80G and VD3 80H) showed
some inhibition in the assay with a 35% and 76% inhibition of growth observed at a
concentration of 100 µg/mL for VD3 80G and VD3 80H, respectively. However, no
inhibition was observed at a concentration of 50 µg/mL. These fractions were less than
4 mg in mass each and so were not practical to continue purification from. Instead, the
acetone strip of the column (VD3 80C), which showed no activity against S. cerevisiae,
was further purified on Diol followed by Diol HPLC because of its mass of 14.1 mg and
the 1H NMR spectrum showing several signals of interest. From the first Diol column,
VD3 98G was isolated from 50% ethyl acetate in hexanes. A full set of NMR experiments
(1H, 13C, COSY, HSQC and HMBC) were run on this compound and these were used to
propose an unsaturated fatty acid structure. VD3 98E, which was also isolated from the
50% ethyl acetate in hexanes fraction of the Diol column, was further purified using Diol
HPLC. A full set of NMR experiments were run on this purified fraction (VD4 17B) and
these were used to propose a phthalate ester structure. The isolation of these compounds
from PTN3 40G is shown in Scheme 3.1.
VD3 98G
The 1H NMR spectrum of VD3 98G (Figure 3.5) comprised of an alkene triplet at
5.35 ppm, a methylene triplet at 2.22 ppm, a methylene doublet at 2.01 ppm, a methylene
quintet at 1.63 ppm, a methylene envelope from 1.24 to 1.34 ppm and a methyl triplet
at 0.88 ppm. The 13C NMR spectrum of VD3 98G (Figure 3.6) contained a carbonyl
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Fatty acid
1.3 mg
HPLC Diol 7% EA/H
VD4_17A
1.2 mg
VD4_17B
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3.2 mg
VD4_17C
0.7 mg
Scheme 3.1. Isolation procedure for unsaturated fatty acid (VD3 98G) and phthalate ester
(VD4 17B) from the sponge PTN3 40G.
resonance at 175.6 ppm, alkene resonances at 130.1 and 130.0 ppm, several methylene
resonances between 36.1 and 22.9 ppm and a methyl resonance at 14.3 ppm. These
assignments were consistent with HSQC data and suggested a fatty acid structure. This
was further supported by the COSY spectrum that showed the methyl proton resonance
coupling to the methylene envelope, the alkene protons coupling to the resonance at
2.01 ppm that further coupled to the methylene envelope, and the methylene triplet at
2.22 ppm coupling to the quintet at 1.63 ppm that further coupled to the methylene
envelope. The HMBC showed correlations from the protons at 2.22 and 1.63 ppm to
the carbonyl carbon and correlations from the protons at 2.01 ppm and the methylene
envelope to the alkene carbons, which further supported this proposal. The MS data,
however, was not able to give a clear molecular ion for this compound consistent with
any of the fatty acid structural possibilities proposed based on the NMR information,
this prevented the conclusive determination of this structure. A C18 alkyl chain length
of the fatty acid was proposed based on the number of methylene groups that could be
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distinguished in the 13C NMR spectrum. Comparison of the 1H and 13C NMR data of this
fatty acid with some well known C18 fatty acids allowed this compound to be tentatively
assigned as cis-vaccenic acid (13).
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Figure 3.5. 1H NMR spectrum of VD3 98G (600 MHz, CDCl3).
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f1 (ppm)
Figure 3.6. 13C NMR spectrum of VD3 98G (150 MHz, CDCl3).
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VD4 17B
VD4 17B was isolated as a mix of very similar compounds that eluted at the same time;
this was indicated by a single peak in the UV/Vis trace on the HPLC and the many
overlapping resonances that occurred in the NMR spectra. The 1H NMR spectrum of
VD4 17B (Figure 3.8) contained two highly second order multiplets that appeared to be
overlapping doublets or doublets of doublets at 7.73–7.71 ppm and 7.63–7.61 ppm that
were characteristic of a 1,2-disubstituted benzene ring. There was also a multiplet of
overlapping resonances around 4.35–4.26 ppm as well as many overlapping resonances
in the methylene and methyl regions of the 1H NMR spectrum. The 13C NMR spectrum
(Figure 3.9) contained a broad carbonyl resonance at 167.9 ppm that was characteristic
of an ester and aromatic resonances at 132.1, 130.9 and a broad resonance at 128.4 ppm
that could be attributed to a symmetrical benzene ring. There were several 13C resonances
from 65.8 to 63.8 ppm, the major resonance being 65.8 ppm, which was likely to be
due to a carbon attached to oxygen in an ester functionality. The 13C NMR spectrum
also contained many resonances between 46.5 and 10.4 ppm that were characteristic
of methylene and methyl carbons. The HMBC spectrum of VD4 17B showed the two
aromatic proton resonances correlating to the carbonyl carbon and the other aromatic
carbons. It also showed the resonances between 4.35 and 4.26 ppm correlating to the
carbonyl carbon and the methylene carbon resonances. This information indicated that a
mixture of phthalate esters had been isolated. Further purification using HPLC would
allow the individual phthalate esters to be separated out and individually identified,
however, the lack of activity observed and the well-known nature of these compounds
meant that this sample was not pursued further. It should, however, be noted that
biologically active, novel phthalate esters have been isolated from marine organisms
previously.96,97
O
O
O
O
R
R
Figure 3.7. A phthalate ester structure
(R = saturated alkyl chains of unknown length in VD4 17B).
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Figure 3.8. 1H NMR spectrum of VD4 17B (600 MHz, CD3OD).
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Figure 3.9. 13C NMR spectrum of VD4 17B (150 MHz,CD3OD).
3.1.4 PTN2 67C
PTN2 67C (Figure 3.10) was a soft, cream-coloured sponge that consisted of many small,
tightly packed tube-like structures. It was a calcareous sponge collected at Cape Karikari
in New Zealand in December 2003 and stored frozen. This sponge has been tentatively
identified as Leucosolenia sp. In validation assays against S. cerevisiae PTN2 67C
showed weak activity with approximately 30% inhibition of the growth of yeast at a
concentration of 100 µg/mL (the highest concentration tested). A mass of 93 g of this
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Figure 3.10. Surface photograph of PTN2 67C collected at Cape Karikari, New Zealand.
Photograph courtesy of Associate Professor Peter Northcote.
sponge was extracted twice with methanol and this extract was purified on HP20 following
the same procedure used for PTN3 40G. The 30% acetone in water fraction (VD3 68A)
had a mass of 30.5 mg and the 75% fraction (VD3 68B) had a mass of 185.5 mg.
When tested against S. cerevisiae, VD3 68A inhibited the growth of yeast by 86% at a
concentration of 25 µg/mL and by 13% at 12.5 µg/mL, this gave an IC50 of 16± 1 µg/mL.
VD3 68B inhibited the growth of yeast by 92% at a concentration of 50 µg/mL and an
average of 47% at a concentration of 25 µg/mL. This resulted in an IC50 of 25± 1 µg/mL.
Purification of VD3 68B was continued while purification of VD3 68A was not because
of the much larger mass of VD3 68B. HP20ss was used to further fractionate VD3 68B
and these fractions were tested against S. cerevisiae again.
The fraction with the highest mass recovered (30.1 mg) and the most activity in the
assay was VD3 79B, this was collected in bulk as the 100% methanol fraction from
the HP20 column. VD3 79B inhibited the growth of yeast by 74% at a concentration
of 100 µg/mL and by 25% at a concentration of 50 µg/mL (IC50 94 ± 2 µg/mL). The
80% methanol in water fraction from the HP20ss (VD3 79F) also showed some activity
with 51% growth inhibition at a concentration of 100 µg/mL and the 100% acetone strip
(VD3 79C) also showed some minor activity with 31% growth inhibition at the same
concentration. However, the fractions VD3 79F and C had masses of 3.2 and 7.9 mg,
respectively, and so were not pursued further. VD3 79B was then further purified on
Diol and, from the 75% ethyl acetate in hexanes fraction, several trihydroxylated steroids
were isolated. The steroidal fractions were pooled together (VD4 05KLM) and a full set
of NMR experiments were run on this. The steroid fraction was then further purified on
reversed-phase (C18) HPLC. The steroids had very similar structures and so were difficult
to separate on HPLC. A relatively clean fraction (VD5 71J) was chosen and a full set of
NMR experiments were run in order to solve the structure of a trihydroxylated steroid.
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This trihydroxylated steroid was proposed to have the structure 14, this compound was
not submitted for biological testing due to the small mass recovered (0.3 mg), the low
activity of parent fractions and time constraints. The isolation of the trihydroxylated
steroid VD5 71J from the sponge PTN2 67C is shown in Scheme 3.2.
VD5 71J
HO
OHOH
14
The full set of NMR experiments run on the steroids VD4 05KLM showed that the
mixture of trihydroxylated steroids isolated only differed in the structure of the side
chain. The steroidal resonances of this full set were all the same and the only overlapping
resonances of different structures were in the methylene and methyl regions. After HPLC
purification the structure of VD5 71J (14), which is a known compound, was solved
as a representative structure of the mixture of trihydroxylated steroids that had been
isolated. Fraction VD5 71J was chosen because it had the highest mass of the clean
fractions and so was the best candidate for getting a full set of NMR data on. The
mass of VD5 71J that was isolated after HPLC purification was 0.3 mg, this meant that a
carbon spectrum was not able to be obtained and all other spectra were relatively weak.
Longer NMR experiments were run in order to get as much information as possible for
this compound. The 1H NMR of VD5 71J (Figure 3.11) showed a triplet of triplets at
3.97 ppm (J=4.8, 11.4 Hz) that integrated for one proton. This proton was characteristic
of a proton at the 3-position of a steroidal structure, with a larger axial-axial coupling of
11.4 Hz to two protons and a smaller axial-equatorial coupling of 4.8 Hz to two protons.
The 1H NMR spectrum also showed the presence of six methyl groups; two methyl
singlets at 1.06 and 0.65 ppm and four methyl doublets at 1.04, 0.94, 0.87 and 0.85 ppm.
The methyl singlets could be attributed to the two angular methyls (CH3-18 and CH3-19)
of the steroid and the methyl doublets were attributed to the four methyls that appear on
the alkyl side chain. There were two alkene multiplet resonances at 5.27 and 5.20 ppm
that integrated for one and two protons, respectively. The remaining resonances that could
be attributed to the steroid were methylene resonances between 2.12 and 1.29 ppm that
were very close together or overlapping. All remaining resonances in the 1H NMR of
VD5 71J were due to impurities.
Although the sample VD5 71J was too small to obtain carbon data, the chemical
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Scheme 3.2. Isolation procedure for the steroid VD5 71J from the sponge PTN2 67C. Note that
IC50 values are approximate (µg/mL).
shift information for carbons could be obtained from HSQC and HMBC data. This
information was used in combination with the steroid structure assigned from the full set
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Figure 3.11. 1H NMR spectrum of VD5 71J (600 MHz, CD3OD).
of VD4 05KLM to propose chemical shifts of the carbons of VD5 71J. It was necessary
to assign the chemical shifts from the spectra of VD5 71J instead of from VD4 05KLM
as the former NMR experiments were run in CD3OD due to being less soluble in CDCl3.
The 13C chemical shifts identified from the HSQC and HMBC data of VD5 71J were
attributable to three alkene methines (δC 137.0, C-22; 133.0, C-23; 118.8, C-7), two
oxygenated methines (δC 68.1, C-3; 73.9, C-6), six methines (δC 57.0, C-17; 55.6, C-14;
44.3, C-24; 44.0, C-9; 41.7, C-20; 34.2, C-25), one oxygenated non-protonated carbon
(δC 76.6, C-5), two non-protonated carbons (δC 44.4, C-13; 37.8, C-10), four methylenes
(δC 40.1, C-4; 33.6, C-1; 31.5, C-2; 40.4, C-12), and six methyl groups (δC 21.4, C-21;
20.4, C-26; 19.8, C-27; 18.6, C-19; 18.4, C-28; 12.4, C-18).
The position of the steroidal alkene and hydroxyl groups were able to be assigned using
the impure VD4 05KLM spectra (run in CDCl3) in combination with the weaker, pure
VD5 71J spectra (run in CD3OD). The A ring structure was as able to be solved using
COSY correlations in both sets of spectra as four out of the six ring carbons have hydrogen
attached (H-1 to H-4). Remaining correlations to the non-protonated carbons could be
seen in the HMBC correlations of VD4 05KLM, these showed that the C-5 position was
oxygenated and the quaternary C-10 position had a methyl attached. The alkene resonance
of the cyclic portion could be seen to integrate for only one proton from both sets of
spectra (although this was clearer in the 1H NMR spectra of VD5 71J); this indicated that
the other end of the alkene was fully substituted. The alkene proton clearly coupled to an
oxygenated methine in both COSY spectra (the methine functionality was confirmed by
both HSQC spectra). In the impure HMBC spectrum, the oxygenated proton adjacent
to the alkene showed correlations to both of the alkene carbons, the C-5 oxygenated
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centre and the quaternary carbon C-10. The alkene proton also correlated to both of
the oxygenated centres in this HMBC spectrum. This analysis indicated the A and B ring
substructure shown in Figure 3.12, as this is the only possible arrangement of an alkene
with one end fully saturated given the structure of the A ring (Figure 3.12).
HO
OHOH
H
H
H
H
H
HMBC
COSY
Figure 3.12. Key COSY and HMBC correlations establishing the A and B ring structure of
steroid VD5 71J.
The C and D rings of the steroid structure were much harder to solve as their correlations
were both weak and overlapping. This meant that the D ring structure was not able
to be fully assigned from observed correlations. Given the lack of notable functional
groups, it was assumed that the C and D rings were non-functionalised steroid rings.
Some correlations from the C and D ring structure could be seen in the impure spectra
of VD4 05KLM (Figure 3.13). The methyl groups in both sets of spectra (which show
the strongest correlations in the HSQC and HMBC spectra) were able to be used to help
assigning the resonances of the C and D rings as well as confirming the proposed structure
of the A and B ring. Most of the side chain structure was able to be solved using COSY
data of VD5 71J and this could then be confirmed by using the HMBC data because of the
four methyl groups in the side chain giving characteristic strong correlations. This enabled
the full side chain structure proposed from the COSY data to be confirmed (Figure 3.14).
This structure was confirmed using positive ion mode HRESIMS data that showed an
[M+Na]+ ion of m/z 453.3305 (m/z ∆ = −0.0040) that indicated a molecular formula of
C28H46O3Na. This steroidal structure has previously been reported from marine sponges
and a bryozoan,98–102 because of this and limited time, no attempt was made to assign
stereochemistry of the C-28 methyl, which shows very similar shifts in both the R and S
configurations.98–100,102 All other spectroscopic data matched the data in the literature and
confirmed this structural assignment.98–102
HO
OHOH
H
H
HMBC
COSYH
Figure 3.13. Key COSY and HMBC correlations providing evidence for the C and D ring
structure of steroid VD5 71J.
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HO
OHOH
HMBC
COSY
Figure 3.14. Key COSY and HMBC correlations establishing the side chain and structure
fragments of steroid VD5 71J. Double headed arrows represent reciprocal HMBC correlations.
3.2 MscL Assay
The MscL assay was initially designed as a means of identifying compounds that affect
Msc. The assay was used in this study to try and find compounds that can inhibit the
growth of bacteria by interacting with the MscL channel. The aim was to lock the
MscL channel in the open conformation so that bacteria would be unable to control
their homeostasis and this would eventually result in cell death. Alternatively, the MscL
being locked in the open conformation would mean that bacteria could not control what
enters (as well as leaves) the cell and so a combination approach could be taken where
one drug locks the channels open, allowing a second drug to enter the cells and kill the
bacteria. In order to find a compound that interacts with MscL, the assay first needed
to be optimised for use at VUW and then tested against the extract libraries available,
however, the optimisation of the assay proved to be more difficult than expected, resulting
in inconsistency across the assays with poor reproducibility.
The carboxyfluorescein-containing liposomes for this assay were made using a thin film
of azolectin in carboxyfluorescein (CF) buffer (DR buffer with carboxyfluorescein and
KOH). Once the liposomes had been formed using vortexing and sonication, they were
forced through a 400 nm pore membrane using a lipid extruder to give a uniform size.
The MscL protein was then incorporated into the liposomes by constant mixing and the
liposomes were separated from the unincorporated CF using Sephadex gel filtration. The
liposomes collected from the gel filtration were ready to be used in the assay, however,
first they needed to be diluted in DR buffer so that a fluorescence difference that is
detectable by the fluorometer was achieved. CF is a self-quenching fluorescing agent
and so it will fluoresce less at concentrations above a certain threshold compared with
lower concentrations, this results in a greater difference in fluorescence observed at
concentrations dilute enough to minimise self-quenching behaviours. The fluorescent
liposome solutions were transferred to black 96-well plates for the assay so that when
the fluorescence was read there would be no transfer of fluorescence detected across the
wells. The liposomes made in this work were very fragile and so were only able to be
used the same day; most of the liposomes in a solution would have burst by the following
day.
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3.2.1 Optimising Parameters
A dilution curve of the CF buffer was created (Figure 3.15) in order to determine
the optimal fluorescence to be used for the fluorometer and identify the corresponding
concentration of CF buffer. This showed that the peak fluorescence was achieved at a
concentration of 0.4–0.5 mM and above this concentration self-quenching occurred. This
exercise also showed that the level of fluorescence observed could be altered by changing
the number of flashes the fluorometer used, however, at higher flash levels (e.g. 100)
the shape of the dilution curve was altered, possibly due to saturation of the detector
(Figure 3.16). Blank plates were read on the fluorometer in order to determine whether
cleaning methods used were sufficient to remove residual CF from the plates. These
plates were filled with DR buffer and the fluorescence was read at 10 and 20 flashes.
Reading the plates at 10 flashes was not suitable for this assay as fluorescences above
zero were found for almost all of the wells, whereas, when using 20 flashes most of the
wells had a fluorescence of zero. These inconsistencies in fluorescence in blank plates is
undesirable because small fluctuations in the fluorescence reading in an assay could create
false positives or negatives, it is for this reason that 20 flashes were used in all subsequent
plate readings.
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Figure 3.15. Carboxyfluorescein (CF) buffer dilution curve measuring excitation at 485 nm and
emission at 535 nm and using 20 flashes.
The most important parameter that needed to be established for this assay was the ability
to reproducibly create liposomes with MscL incorporated into them. This was tested
by using controls that would later be used in the screening assays. The positive control
(LPC, see Section 2.5 of Chapter 2) was used to model the opening of MscL, a negative
solvent control was used to test the sensitivity of the liposomes to the solvent, a negative
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Figure 3.16. Carboxyfluorescein (CF) buffer dilution curve testing the effect of using 1 flash (top
left, blue), 10 flashes (top right, maroon) and 100 flashes (bottom, green). Excitation was
measured at 485 nm and emission at 535 nm.
buffer control was used to determine the fluorescence of the liposomes in the absence of
other additives and a TritonTM X-100 control was used to measure the total fluorescence
of a burst liposome. All of these controls were used on both MscL-containing and
control liposomes with all tested in triplicate where possible. This number of controls is
necessary due to the fragility of these liposomes and their sensitivity to subtle variations
in conditions. For example, the MscL liposomes were often found to be more fragile than
the control liposomes and would start to leak CF over time, even in the solvent controls.
The fluorescence of these assays had to be read over an extended period of time due
to the mode of action of the positive control LPC, which needed time to incorporate
into the liposome membrane causing a distortion, thus opening the MscL. This meant
that the LPC was the last control to be added to the plate and the fluorescence was then
read in 5 or 10 minute intervals after the LPC addition over a period of 30–60 minutes.
Reading these plates over time allowed the increase in fluorescence occurring in the
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MscL-containing liposomes that had been exposed to LPC to be seen and compared
to the increase in fluorescence occurring in the negative control liposomes over time.
Ideally, the MscL-containing liposomes would show the greatest increase in fluorescence
when exposed to LPC as opposed to the negative controls. However, this was not always
the case, the LPC effect on the MscL would sometimes show only a small increase in
fluorescence, bringing into question whether the MscL had actually been incorporated
into the liposomes and if it had, if the liposomes were too fragile to give reliable results.
Another possible reason for this inconsistency may be the variable size of MscL channel
clusters that have been shown to form upon MscL reconstitution into liposomes. Upon
MscL channel activation these clusters separate into clusters of closed and clusters of
open channels, with the number of channels in each of these clusters varying depending
on the membrane tension activating the channels.103 This would mean that the number of
MscL channels opened by the LPC would vary depending on the nature of the channel
clusters occurring.
In testing the liposomes, both the control liposomes and MscL liposome concentrations
were made up to achieve a similar fluorescence in the fluorometer, in both the intact
and burst states. The fluorescence of the liposomes was analysed as a percentage of
the total fluorescence possible (from the TritonTM control). This meant that the results
could be compared between the MscL and control liposomes (as well as across assays)
without exactly matching the concentration (and hence fluorescence) of the liposomes.
The optimal fluorescence to aim for when diluting the liposomes, which would show the
greatest difference in fluorescence between the closed and burst liposomes, had to be
established to allow for maximal sensitivity in the assay.
Since the actual concentration of liposomes cannot be established in the solution
recovered from the gel filtration, only concentrations relative to this solution can be
reported. An experiment using this liposome solution alongside 1
10
, 1
20
, 1
30
, 1
40
, 1
50
, 1
60
and 1
70
dilutions was performed, testing both intact and burst liposomes (Table 3.1).
This showed that the greatest differences in fluorescence values could be seen with
increasing concentrations of liposomes, however, it is the percentage of the burst
liposome fluorescence that is important for the intact liposomes. The lower this relative
fluorescence, the easier to note the difference in relative fluorescence when MscL
incorporated in the liposome is opened. From this experiment, it was proposed that
liposome solutions with fluorescences of approximately 20000 in the closed state and
50000 in the open state would fit the requirements for this assay. This showed a reasonable
difference in fluorescence with the closed liposomes having 38% the fluorescence of the
burst liposomes. In this experiment such fluorescence intensities were achieved with a
dilution of approximately 1
40
. It should be noted that the 1
30
, 1
50
and 1
60
dilutions would have
been equally as effective and the 1
40
dilution was chosen arbitrarily as it was a reasonable
dilution. The 1
70
dilution with 42% difference in fluorescence is an outlier of the data, this
value is a good example of the inconsistencies encountered over the course of this work.
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Table 3.1. Comparison of fluorescence in control and burst CF-containing liposomes.
Average Fluorescence
Dilution Control liposomes Burst liposomes Difference Percentage (%)
1 62,679 129,698 67,019 48
1
10
40,497 94,578 54,081 43
1
20
29,721 73,395 43,674 40
1
30
23,219 60,042 36,823 39
1
40
20,081 52,943 32,862 38
1
50
18,504 47,915 29,411 39
1
60
16,119 42,722 26,603 38
1
70
16,302 38,679 22,377 42
The relative fluorescence is not the only variable that needs to be taken into consideration
when choosing the dilution of liposomes to use. The concentration of LPC and liposomes
used have to be balanced for maximal LPC effect without causing lysis or leakage of the
liposomes from too many LPC molecules inserting into the membrane. In order to test
this, assays altering the liposome concentrations and LPC concentrations were performed.
Also, a concentration of liposomes that show the maximal effect from active extracts while
not being affected by the inactive extracts was desired. Assays testing control liposomes
in varying concentration of crude extract were used to test this.
Before assays against crude extracts could be performed, a suitable solvent for adding
the extracts that would not affect the liposomes needed to be identified. This was done
by testing control liposomes with an equivalent of 2 µL of methanol or DMSO to 98 µL
of liposome solution, or an equivalent of 4 µL of a 1:1 methanol to water mixture or a
1:1 DMSO to water mixture to 96 µL of liposome solution. The fluorescence of these
wells were then compared to the fluorescence of control liposomes with an equivalent of
2 µL of DR buffer added to 98 µL of liposome solution. This experiment showed that
pure methanol affected the liposomes the least and so methanol was used in subsequent
experiments to test crude extracts (Figure 3.17).
A selection of crude extracts was tested against control liposomes to confirm that they
would not affect control liposomes at the extract concentrations tested. Liposome
solutions were tested with a maximum of 10 µg of extract in 2 µL of methanol added
to the wells, making a 100 µL volume (concentration of extract: 100 µg/mL) with serial
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Figure 3.17. Control liposomes stability in different solvents as shown by their fluorescence
relative to the DR buffer control.
dilutions used from there. The fluorescence of the liposomes was around 15000–20000
in the intact liposome solution. This experiment showed that the extracts chosen had
no significant effect on the control liposomes with fluorescences that were between 93%
and 110% the fluorescence of the solvent controls (Figure 3.18). This experiment also
showed the variation that can be seen in fluorescence measurements between runs, with
fluorescence readings of blank DR buffer control wells (without liposomes) ranging
between 4 and 30 in one plate and between 14 and 53 in the other (data not shown). These
variations in fluorescence were proposed to be insignificant at the level of fluorescence
being measured in this assay.
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Figure 3.18. Control liposomes stability towards crude extracts, tested at various concentrations.
All extracts tested at concentrations of 100 µg/mL and below show no significant effect on the
control liposomes relative to the methanol (solvent) control.
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The LPC was used as a solution in methanol at a concentration of 50 mg/mL (0.1 M).
When 2 µL of this was added to 98 µL of liposome solution (0.002 M LPC) the opening
of MscL was able to be detected. However, this opening was detected by the increase
in the percentage fluorescence of MscL-containing liposomes (relative to the burst
liposomes fluorescence) compared with the control liposomes percentage fluorescence,
when exposed to LPC. The maximum difference in the percentage fluorescence between
the MscL and control liposomes would usually be around 6–8% and so it was questioned
whether this would be significant enough for MscL opening to be distinguished from
the closed controls. The effect of LPC that was generally seen in these assays
was the fluorescence percentage difference between the MscL and control liposomes
increasing until a maximum at around 30 minutes after LPC addition. Following this,
the fluorescence percentage difference would start to decrease as the LPC molecules
equilibrated in the membrane causing the MscL to close again (see Section 2.5 of
Chapter 2). The reason that the fluorescence percentage difference started to decrease
was that the MscL were no longer open and releasing the CF molecules but the control
and MscL-containing liposomes were both still leaking CF molecules due to their poor
stability. LPC molecules were also able to cause leaking in liposomes if enough of them
inserted into the membrane to cause a disruption, this resulted in a steady increase of
the percentage fluorescence of both MscL and control liposomes occurring until lysis of
the liposomes. This leakage caused by LPC resulted in fluctuations in the percentage
fluorescence difference between the control and MscL liposomes.
Experiments were done adjusting the concentration of LPC in order to see if a lower
concentration would cause a more distinctive effect on the MscL-containing liposomes
when compared to controls. It was found that when 0.5 µL of 0.1 M LPC was added
to MscL liposomes, the effect of the increased percentage of fluorescence was more
distinct than in the liposomes that 1 and 2 µL of LPC had been added to. This can be
seen in Figure 3.19, which shows the percentage fluorescence (relative to the TritonTM
control) of the control and MscL liposomes when exposed to varying concentrations of
LPC. The control and MscL liposomes exposed to DR buffer and methanol are also shown
on this graph in order to demonstrate the magnitude of the fluorescence difference. The
graph shows that the 0.5 µL addition of LPC to control liposomes (shown by the green
squares) affects the fluorescence the least and this in turn makes the effect on the MscL
liposomes (shown by green circles) more significant when calculating the difference in
these percentage fluorescences.
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Figure 3.19. Fluorescence (relative to completely burst liposomes) of MscL and control
liposomes when exposed to various concentrations of LPC.
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This led to the LPC solution being diluted to a 0.05 M concentration (25 mg/mL) and
tested again at 0.5, 1 and 2 µL additions. The liposome stability was poor in these
experiments, which meant that the LPC caused all of the liposomes to leak and eventually
burst. Generally, the effect of poor stability is much clearer in the MscL-containing
liposomes as the presence of MscL in the membranes appears to make them weaker
(possibly an indicator that lower amounts of the MscL protein should be incorporated
in the liposomes), though both the control and MscL-containing liposomes were affected
by poor stability in this assay. This meant that the results obtained from this assay were
not conclusive. However, it was decided to proceed using 0.5 µL additions of 0.05 M
LPC as the positive control in assays in the interest of time. This volume was chosen as
it was hoped to have minimal effect on the control liposomes making the LPC effect even
more significant.
In the same assay determining the concentrations of LPC to be used, the concentrations
of liposomes were tested to determine the optimal combination. Liposome concentrations
that exhibited fluorescence at approximately 25000–26000, 15000–16000 and 9000–
10000 in the closed state were used and tested using all of the controls, including the
three different LPC addition volumes. Because of the poor stability in this assay it was not
clear which of the three concentrations tested was optimal. However, it was clear that all
three concentrations were acceptable as they all showed clear differences in fluorescence
between the MscL and control liposomes (making the erratic differences in this assay very
clear). The time taken to set up this assay was longer than usual and so the plates were
only able to be read at 20, 30, 40 and 55 minutes after LPC addition. Despite the erratic
values, it could be seen that the fluorescence percentage difference increased between 20
and 30 minutes for the liposomes at a fluorescence of 25000 and following 30 minutes this
difference began to decrease. For the liposomes at a fluorescence of 15000 and 9000, the
fluorescence percentage differences just decreased from the first reading. This decrease
in the fluorescence difference between the control and MscL liposomes can be seen in
Figure 3.20 by the MscL and control liposome fluorescences at the same concentration
trending towards convergence at 100% fluorescence. This was thought to indicate that the
effect of LPC had been much faster in the lower concentration of liposomes compared
with the higher concentration.
Since a faster LPC effect would mean that the assay plates could be read for a shorter time
period (which is especially useful because of the short time frame of viability for these
liposomes), it was decided to use the lower concentration of liposomes at a fluorescence
of 9000–10000. Additionally, a lower concentration of liposomes would hopefully mean
that they are more sensitive to compounds in the extracts being tested, however, this could
also mean the liposomes are more sensitive to LPC.
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Figure 3.20. Effect of liposome concentration on the fluorescence change (relative to completely
burst liposomes) caused by a 0.5 µL addition of 0.05 M LPC.
From this work, parameters to be used in this assay could be chosen. The CF dilution
curve helped to establish that 20 flashes should be used on the fluorometer when reading
the assay plates. The assay testing different dilutions of liposomes established that
liposomes with a fluorescence of approximately 20000 in the closed state would be a
good starting point for use in this assay with the intact liposomes displaying 38% of the
fluorescence of the burst liposomes. The assay testing control liposomes against different
solvents helped to establish that methanol had the smallest effect on these liposomes and
so would be a good solvent to use in screening assays. The assay testing crude extracts
against control liposomes showed that at a concentration of 100 µg/mL these crude
extracts had no significant effect on these liposomes. This established that 100 µg/mL was
a reasonable concentration to start the extract testing at. The LPC test assays established
that smaller amounts of LPC showed a more significant effect as a lower concentration
of LPC molecules will reduce their effect on the control liposomes. This suggested that
0.05 µL of a 0.05 M LPC solution would be a reasonable amount to use for a positive
control in a screening assay (resulting in a 25 µM concentration of LPC when made up
to 100 µL). This assay to test the LPC concentration to be used also showed that, while
liposome concentrations resulting in fluorescences around 25000, 15000 and 9000 do not
create obvious differences in the effectiveness of the assay, using a smaller concentration
of liposomes may make the effects of LPC and active extracts appear faster, shortening
the time that the plate must be read over. This would be desirable as it would enable
more experiments to be run on one batch of liposomes, therefore a lower concentration of
liposomes resulting in a fluorescence of approximately 10000 was proposed to be used.
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3.2.2 Testing the Assay
Despite the inconsistencies that were observed in some of the experiments due to
instability of the liposomes, several key parameters to be used in the MscL assay were
chosen. These parameters were used when attempting to test the extract library of New
Zealand and Tongan marine invertebrates for activity towards MscL. Unfortunately, the
fragility of the liposomes gave erratic results, leading to no ‘hits’ being identified. It
is possible that no ‘hits’ were identified due to the highly specific nature of the assay.
Probing such a specific mode of action, the likelihood of no Msc-active compounds being
present in the extracts tested is high when compared to assays with multiple targets.
Despite this possibility, the instability and poor reproducibility of the liposomes used
in this assay was a concern as it is an indicator of fragile liposomes. One of the issues that
may have lead to the fragile liposomes was the HEPES buffer (that makes up one tenth of
DR buffer, which is used as the medium for this assay) not being changed often enough.
The growth of microorganisms in the HEPES buffer could have caused contamination in
the DR buffer medium. This is likely to have contributed to some of the inconsistencies
observed, however, it is not thought to be the sole cause. Even when fresh HEPES buffer
was made up and used, the assay gave fragile liposomes and the effect of LPC on the
MscL-containing liposomes was still weak.
There are more parameters that need to be optimised for this assay before it is able to be
used to test extract libraries for Msc-modulating compounds. For example, the amount
of MscL that is added to the liposomes to be incorporated into the membrane needs to be
adjusted in order to find the optimal level of incorporation. Also, the MscL proteins are
suspended in detergent, this means that during the incorporation procedure BioBeads R©
are used to remove the excess detergent that would otherwise make the liposomes more
fragile. The maximum time that the BioBeads R© were left mixing with the liposome
solution in this work was four hours, adjusting this time (most likely by making it longer)
could increase the stability observed in the liposomes.
One very important issue with this assay is that it takes most of a day to prepare
the liposomes so that the experiment can only be run at the end of the day when the
liposome preparation is complete. The experiment also has to be run right after liposome
preparation is complete because the fragile liposomes will burst over time and by the next
day the liposome solution will no longer be viable. If protocols could be modified in
running this assay, allowing the majority of preparation time to be done the day before an
assay is run, this would increase the usefulness and would allow more experiments to be
run with each batch of liposomes. One way that this may be possible is by leaving the
liposomes mixing with the BioBeads R© overnight and separating the liposomes from the
unincorporated CF the next day.
Time did not permit further work on this assay meaning that it has not been explored
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enough to obtain reliable results in the screening of an extract library. Further work
on this assay will need to be done in order to better understand all the variables that
affect liposome preparation and therefore stability. If this can be better understood
then liposomes that are robust enough to provide consistent and reproducible results
and sensitive enough for a clear distinction to be seen between negative controls and a
positive ‘hit’ can hopefully be produced, allowing for this assay to be used reliably in the
identification of bioactive natural products as molecular probes for Msc.
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Chapter 4
3-Alkyl Pyridinium Alkaloids
4.1 Introduction
3-Alkyl pyridinium alkaloids (3-APAs) are potent bioactive compounds that have been
found from sponges of the order Haplosclerida (Figure 4.1). The first 3-APAs to
be isolated and identified were a mixture of polymeric 3-APAs reported in 1978 by
Schmitz et al. called halitoxins.104 3-APAs can be cyclic or linear and can vary in chain
length, unsaturation of the alkyl chain, branching and number of pyridinium units. Linear
3-APAs can also vary in the terminal functional groups of the alkyl chain. No naming
system has been set out for the 3-APAs and this has resulted in some structurally similar
compounds being given very different names and some compounds not being named yet.
This highlights the need for a clear naming system to be set out for these compounds. This
introductory review is limited to isolated cyclic compounds of natural origin that contain
the 3-alkyl pyridinium moiety (15) and does not include polymeric structures or 3-alkyl
pyridines. The 3-APAs reported here are limited to six or less monomeric units. The
compounds that meet these criteria are reported in Tables 4.1 to 4.4. For a comprehensive
review on 3-alkyl pyridine and pyridinium structures that have been identified prior to
2008, including the polymeric halitoxins and amphitoxins, see Turk et al. (2008).105
N
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Phylum:  Porifera 
Class:       Demospongiae 
Subclass: Ceractinomorpha 
Order:     Haplosclerida 
Family: Phloeodictyidae 
Genus: Calyx 
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Genus: Niphates 
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Figure 4.1. Taxonomic classification to genus level of Haplosclerid sponges that 3-APAs have
been isolated from.18,106
4.2 Linear 3-APAs
The linear 3-APAs that have been reported in the literature to date fall into four general
structural categories: the xestamines, niphatoxins, viscosalines and pachychalines, each
one being distinguished by the terminal functional group. The xestamines are usually
isolated as 3-alkyl pyridines, however, three N-methyl pyridinium salts of these have
been isolated. The xestamines have methoxy(methyl)amine terminal groups and have
been isolated with both saturated and unsaturated alkyl chains (including a conjugated
enyne in xestamine F, 16). These compounds inhibit the growth of Staphylococcus aureus,
Bacillus subtilis and Candida albicans.107 There are three known niphatoxins and these
are characterised by terminal pyridines. The niphatoxins that have been isolated all have
one pyridinium unit and unsaturation in the alkyl chain (e.g. niphatoxin A, 17). The
niphatoxins A and B have shown ichthyotoxic and cytotoxic activity against P388 (mouse
leukaemia) cells and niphotoxin C has shown cytotoxic activity against THP-1 (human
leukemic monocyte) cells.108,109
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There have been five different viscosalines reported in the literature to date and these have
a pyridine group at the terminus of the N-alkyl chain of the pyridinium and a β-alanine
group at the terminus of the C-alkyl chain of the pyridinium (e.g. viscosaline B1, 18).
The viscosalines that have been fully characterised all differ in the length of the saturated
alkyl chains.110,111 However, an unsaturated viscosaline has been found by Schmidt et al.
that has not yet been fully characterised.111 The first viscosaline to be isolated inhibited
the growth of several different microorganisms in disk diffusion assays.110
There are seven different pachychalines that have been reported, they are characterised by
terminal amino groups or one terminal amino group and one norspermidine (e.g. pachy-
chaline B, 19). The pachychalines that have been reported have from one to three
pyridiniums (monomer to trimer) and vary in the alkyl chain lengths and saturation
or unsaturation of alkyl chains, showing the most variation among the linear 3-APAs
reviewed here. The pachychalines are also very unusual as the dimer and two of the trimer
pyridiniums are connected by an alkyl chain that links the 3 position of both pyridiniums.
This creates an unusual carbon-alkyl-carbon motif, which can also be seen in the
niphatoxins, rather than the usual nitrogen-alkyl-carbon motif. The pachychalines A–C
showed activity against the cell lines MDA-MB-231 (human breast adenocarcinoma),
A549 (human lung carcinoma) and HT29 (human colon adenocarcinoma).112
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4.3 Cyclic 3-APAs
4.3.1 Monomers
In 1996, the first cyclic 3-APA monomer to be identified, haliclocyclin C (20) was
synthesised in order to confirm the dimeric structure of cyclostellettamine C (see Section
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4.3.2). In this study, haliclocyclin C showed antagonistic activity toward the muscarinic
receptors of rat brain, heart and salivary gland with mean IC50 values of 1.7, 2.8 and
2.9 µg/mL, respectively. In this assay the monomeric haliclocyclin C was less active than
the dimeric cyclostellettamine C, which had mean IC50 values of 90, 89 and 195 ng/mL,
respectively.113 Haliclocyclin C was then accidentally synthesised in 1998 by Kaiser et al.
when devising a new, selective strategy for synthesising 3-APA dimers and oligomers.114
A cyclic 3-APA monomer was not found naturally until 2008 when Ko¨ck and co-
workers reported the isolation of haliclocyclin F (21) from the Arctic marine sponge
Haliclona viscosa. This compound was only isolated in a small amount so it was also
synthesised for biological testing to be performed. Haliclocyclin F was tested against
E. coli tolC, S. aureus and L929 mouse fibroblast cells along with cyclostellettamine C,
viscosamine (see section 4.3.3) and the synthesised haliclocyclin C. Of the compounds
tested in these assays, haliclocyclin F was the most active with an IC50 of 0.3 µg/mL
against mice fibroblasts (showing cytotoxicity) and growth inhibition diameters of 23 and
22 mm against E. coli tolC and S. aureus, respectively, when sample loadings of 20 µg
were used.115 This study also reported that in molar concentrations haliclocyclin C is less
cytotoxic than cyclostellettamine C and viscosamine but haliclocyclin C also had a larger
zone of inhibition in the antibacterial assays than the larger compounds.115 In 2011, Ko¨ck
and co-workers finally isolated haliclocyclin C from H. viscosa. This was the first time
this compound had been isolated from a natural source. In this report they proposed the
naming system for the 3-APA monomers and named the haliclocyclins C and F after the
corresponding cyclostellettamines C and F that also contained C13 and C14 alkyl chains,
respectively.116
Table 4.1. Cyclic Monomer 3-Alkyl Pyridinium Alkaloids.
Structure Name Reported Activity* Reference
N Haliclocyclin C B, N, T 116
20
N
2
Haliclocyclin F B, T 115
21
*B = Antibacterial, N = Neurotoxin, T = General Toxicity
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4.3.2 Dimers
In 1994, the cyclostellettamines A–F (22–27) were first reported to have been isolated
from the marine sponge Stelleta maxima by Fusetani et al.117 Upon re-examination of the
sponge, Fusetani and co-workers concluded that the cyclostellettamines had, in fact, been
isolated from an epiphitic Haliclona sp. in the sample.118 The cyclostellettamines A–F
contain two pyridinium units connected by two saturated alkyl chains with 12 to 14
carbon units. They showed potent antagonistic activity toward the muscarinic receptors
of rat brains, hearts and salivary glands with IC50 values in the range of 0.03 to
0.47 µg/mL.117 The next cyclostellettamines to be isolated were isolated by the same
group (Fusetani and co-workers) in 2004 from the marine sponge Xestospongia sp. The
group re-isolated cyclostellettamine A as well as isolating one new saturated 3-APA dimer
cyclostellettamine G (28) and the two dehydrocyclostellettamines D (29) and E (30),
which contain a Z-geometry alkene in one of the alkyl chains.118 These compounds were
tested for inhibitory activity towards the histone deacetylase enzyme (HDAC), derived
from K562 human leukemia cells, as well as for cytotoxic activity against HeLa (human
cervix carcinoma), P388 (mouse leukemia) and 3Y1 (rat fibroblastic) cell lines. The IC50
values against HDAC were in the range of 17 to 80 µM. The cytotoxicity against the
cancer cell lines P388 and HeLa had IC50 values in the range of 0.6 to 2.8 µM and the
cytotoxicity against the 3Y1 fibroblasts had IC50 values in the range of 3.2 to 11 µM.118
De Oliveira et al. isolated more cyclostellettamines, also in 2004. From the marine
sponge Pachychalina sp. the known cyclostellettamines A–G (22–28) were isolated along
with the new cyclostellettamines H, I, K and L (31–34). These new cyclostellettamines
were very similar to those previously identified with the differences being the number
of methylene units in the alkyl chain, which ranged from 10 to 14 units. The name
cyclostellettamine J was reserved for a cyclostellettamine with C11 and C13 carbon chains
that has not yet been reported but would be expected to exist given the pattern of the
cyclostellettamines isolated to date.119 The cyclostellettamines A–F (22– 27) isolated
from Pachychalina sp. and the synthesised cyclostellettamines G–I (28–32), K (33) and
L (34) were subjected to biological testing in antimicrobial assays. The compounds were
tested against S. aureus (ATCC 25923), E. coli (ATCC 25922), Pseudomonas aeruginosa
(ATCC 27853), Oxacillin-resistant S. aureus strain 8, Oxacillin-resistant S. aureus strain
108, P. aeruginosa 13 (which produces biofilms and is resistant to some antibiotics),
P. aeruginosa P1 (also produces a biofilm and is resistant to some antibiotics), C. albicans
(ATCC 10231) and Mycobacterium tuberculosis H37Rv. However, cyclostellettamine A
and B were not tested against C. albicans as there was insufficient mass of these
compounds isolated. Cyclostellettamine A, overall, appeared to be the least active as
an MIC of no lower than 32 µg/mL was found in any of the assays performed and so will
be excluded from the following discussion of activity. The most activity was seen against
S. aureus with MIC values ranging from 0.3 to 2.4 µg/mL. The compounds also displayed
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good activity against E. coli with MIC values ranging from 1.2 to 9.5 µg/mL (excluding
cyclostellettamine G, which gave an MIC of 39.1 µg/mL). Against M. tuberculosis, MIC
values in the range of 4.0–11.0 µg/mL were observed. In the C. albicans assay only
cyclostellettamines C–F showed any activity with MIC values of 0.12 to 0.7 µg/mL. In
all the other assays the activities observed ranged from poor to good with the activity
apparently being highly dependant on the length of the alkyl chains.120
In 2005, Ondeyka et al. isolated a new dehydrocyclostellettamine with the two
pyridinium rings connected by two C10 alkyl chains, one of which contained an
E-alkene (35).121 This new 3-APA was not named by the authors. Compound 35 was
an antagonist of the CXCR3 receptor that is expressed during certain inflammatory
processes, with an IC50 of 0.69 µM, meaning it could play a role in modulation
of the immune system. This could make it a useful drug in treatments relating to
organ transplantation and diseases such as multiple sclerosis.121 In 2006, Teruya et al.
identified cyclohaliclonamine A (36) as part of a mixture of dimeric, trimeric, tetrameric,
pentameric and hexameric 3-APAs isolated from a marine sponge Haliclona sp. This
compound had an E-alkene in each of the C10 alkyl chains connecting the two pyridinium
units.122 In 2007, Xu et al. then isolated a similar E-geometry, unsaturated 3-APA
with two C11 alkyl chains, 8,8’-diene-cyclostellettamine (37) from the marine sponge
Amphimedon compressa. This compound differed from cyclohaliclonamine A not only
in the alkyl chain lengths but also in the different position of the alkene functionalities,
which were only one methylene away from the 3-position on the pyridiniums rather than
two methylenes away from the nitrogen.123 8,8’-diene-cyclostellettamine was a potent
antifungal and antibacterial with IC50 values in the range of 0.25–2.5 µg/mL against
C. albicans, E. coli, Pseudomonas aeruginosa, Cryptococcus neoformans, MRSA and
Aspergillus fumigatus.123 An isomer of 8,8’-diene-cyclostellettamine was isolated in 2009
by Casapullo et al. from the sponge Haliclona sp. (38), this structure only differed from
37 in the geometry of the alkene groups, which were both Z.124 Compound 38 showed
weak cytotoxicity with IC50 values greater than 20 µg/mL in assays against J774.A1
(murine macrophage), HEK293 (human embryonic kidney), and WEHI-164 (murine
fibrosarcoma) cell lines.124
The first cyclic 3-APAs with branched chains were isolated by Laville et al. in
2009 from the sponge Reniera sp. along with an isomer of cyclohaliclonamine A.
Njaoaminium A (39) has Z-alkenes at the C-13 to C-14 and C-13’ to C-14’ positions
whereas cyclohaliclonamine A (36) has E-alkenes at the C-9 to C-10 and C-9’ to C-10’
positions. Njaoaminium B (40) has the same basic structure as njaoaminium A (39)
with the addition of two R-configuration methyl groups at the C-8 and C-8’ positions.
Njaoaminium C (41) is similar to both njaoaminium A and B with the exception
of only one R-configuration methyl group being present at the C-8 position.125 The
njaoaminiums were tested against A549 (lung carcinoma), HT29 (colon adenocarcinoma)
and MDA-MB-231 (breast adenocarcinoma) human cell lines. Njaoaminium A and C did
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not show cytotoxicity at concentrations below 10 µM and so were considered to have poor
activity. Njaoaminium B had moderate activity with IC50 values of 4.1, 4.2 and 4.8 µM
against the lung, colon and breast tumour cell lines, respectively.125
In 2012, Lee et al. isolated 10 new cyclostellettamines from the sponge Haliclona sp.
They reported two of these compounds, cyclostellettamines N (42) and Q (43), as
known compounds as they had previously been synthesised, however, this was the first
report of these compounds being isolated from natural sources.126 Cyclostellettamine Q
was synthesised by Grube et al. in 2006 in order to improve understanding of these
compounds and cyclostellettamines N and Q were synthesised by Schmidt et al. in 2009
in order to confirm the structure of haliclamines (tetrahydropyridinium equivalents of
the cyclostellettamines).127,128 Cyclostellettamines N and Q contain C9/C10 and C10/C11
saturated alkyl chains, respectively. Two new cyclostellettamines with C8/C10 (44) and
C10/C10 (45) saturated alkyl chains were also isolated.126 None of the new compounds
reported in this paper were named. Compounds 46–51 were dehydrocyclostellettamines
that varied in chain length and alkene position and geometry.126 These compounds
were tested for cytotoxic activity toward A549 (lung cancer) cell lines, as well as
for inhibitory activity towards the growth of S. aureus (ATCC 6538p), B. subtilis
(ATCC 6633), Micrococcus luteus (IFO 12708), Salmonella typhimurium (ATCC 14028),
Proteus vulgaris (ATCC 3851), E. coli (ATCC 35270), pathogenic fungal strains and the
microbial enzymes isocitrate lyase, sortase A and Na+/K+-ATPase. With IC50 values
greater than 100 µg/mL and 100 µM against the pathogenic fungi, E. coli and microbial
enzymes, these compounds were concluded to not be active in these assays.126 MIC values
of 12.5 to 50 µg/mL were observed against S. aureus, 3.125 to 100 µg/mL were observed
against M. luteus, 25 to 100 µg/mL were observed against B. subtilis, S. typhimurium
and P. vulgaris. Against the lung cancer cell lines, all the compounds tested proved to
be moderately cytotoxic, with IC50 values in the range of 14.7 to 28.9 µM for all of the
compounds except 48, which appeared to be poorly cytotoxic with an IC50 of 89.4 µM.126
4.3.3 Trimers
The first naturally occurring trimeric 3-APA was isolated from the sponge H. viscosa
by Volk and Ko¨ck in 2003. This trimeric 3-APA was named viscosamine (52) and
was isolated as a mixture with cyclostellettamine C. Viscosamine has three saturated
C13 alkyl chains and so is the trimeric 3-APA equivalent of cyclostellettamine C.129
Viscosamine was synthesised and tested for antiprotozoal activity as well as cytotox-
icity in 2011 by Rodenko et al.130 The antiprotozoal assays were performed against
Trypanosoma brucei (the blood stream form), the drug resistant T. brucei s427 ∆TbAt1
and T. brucei s427 clone B48, Leishmania major promastigotes, Leishmania mexicana
axenic amastigotes and Plasmodium falciparum. Cytotoxicity was tested against HEK293
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Table 4.2. Cyclic Dimer 3-Alkyl Pyridinium Alkaloids.
Structure Name (Alkyl Chain Lengths) Reported Activity* Reference
22 Cyclostellettamine A (C12/C12) B, C, N, T 117
23 Cyclostellettamine B (C12/C13) B, N 117
24 Cyclostellettamine C (C13/C13) B, F, N 117
25 Cyclostellettamine D (C12/C14) B, F, N 117
26 Cyclostellettamine E (C13/C14) B, F, N 117
27 Cyclostellettamine F (C14/C14) B, F, N 117
28 Cyclostellettamine G (C12/C11) B, C, T 118,119
29 Dehydrocyclostellettamine D (C12/C14) C, T 118
30 Dehydrocyclostellettamine E (C13/C14) C, T 118
31 Cyclostellettamine H (C12/C10) B 119
32 Cyclostellettamine I (C13/C10) B 119
33 Cyclostellettamine K (C14/C10) B 119
34 Cyclostellettamine L (C14/C11) B 119
35 (C10/C10) I 121
36 Cyclohaliclonamine A (C10/C10) T 122
37 8,8’-Diene-cyclostellettamine (C11/C11) B, F 123
38 (C11/C11) C, T 124
39 Njaoaminium A (C10/C10) 125
40 Njaoaminium B (C10/C10) C 125
41 Njaoaminium C (C10/C10) 125
42 Cyclostellettamine N (C9/C10) B, C 126
43 Cyclostellettamine Q (C10/C11) B, C 126
44 (C8/C10) B, C 126
45 (C10/C10) B, C 126
46 (C10/C10) B, C 126
47 (C10/C10) B, C 126
48 (C10/C11) B, C 126
49 (C10/C11) B, C 126
50 (C10/C12) B, C 126
51 (C10/C12) B, C 126
*B = Antibacterial, F = Antifungal, C = Anticancer, I = Immunomodulatory,
N = Neurotoxin, T = General Toxicity
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(human embryonic kidney) cell lines and this was used to calculate a selectivity index
of the antiprotozoal activities. The assay showed that viscosamine had good activity
against the Trypanosoma and Leishmania parasites with EC50 values ranging from
0.28 to 0.81 µM. Viscosamine proved to be the most active of the compounds tested
against P. falciparum with an EC50 of 53 nM, however, this was still much less active
than the reference compound chloroquine, which had an EC50 of 0.67 nM. The IC50
against HEK293 cells of 26 µM showed that viscosamine is a potent antiprotozoal at
concentrations that do not cause cytotoxicity, with a 493-fold selectivity for P. falciparum
over HEK293 cells.130 Viscosamine was later renamed to viscosamine C, in order to
follow the nomenclature of the cyclostellettamines and haliclocyclins.116
In 2006, when Teruya et al. isolated the dimeric cyclohaliclonamine A (36) from
the sponge Haliclona sp., it was part of a mixture that included the trimeric cyclo-
haliclonamine B (53). Cyclohaliclonamine B is the trimeric 3-APA equivalent of
cyclohaliclonamine A and so, like the dimer, the pyridinium moieties are connected by
C10 alkyl chains with an E-geometry alkene at the C-9 to C-10 positions.122 In 2009,
Casapullo et al. isolated the dimeric 38 as well as its trimeric equivalent 54 from the
marine sponge Haliclona sp. This trimer had C11 alkyl chains connecting the pyridinium
units with Z-geometry alkenes in the C-15 to C-16 positions. Like its dimeric equivalent,
trimer 54 showed weak cytotoxic activity with IC50 values greater than 20 µg/mL in
assays against J774.A1 (murine macrophage), HEK293 (human embryonic kidney), and
WEHI-164 (murine fibrosarcoma) cell lines.124 Currently, the 3-APA trimers that have
been isolated are C3 symmetric, meaning that they are comprised of three identical
subunits. This is in contrast with the dimeric cyclostellettamines, which have been
isolated as both C2 symmetric and non-symmetric compounds.
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Table 4.3. Cyclic Trimer 3-Alkyl Pyridinium Alkaloids.
Structure Name (Alkyl Chain Lengths) Reported Activity* Reference
52 Viscosamine C (C13) P, T 129
53 Cyclohaliclonamine B (C10) T 122
54 (C11) C, T 124
*C = Anticancer, P = antiprotozoal, T = General Toxicity
N
N
N
9
99
52
N
N
N
4
4
4
53
6
6
N6
N
N
54
4.3.4 Oligomers
Three larger 3-APA oligomers have been isolated along with the mixture of dimer 36
and trimer 53 from Haliclona sp. These compounds were the tetrameric, pentameric and
hexameric equivalents of 36 and 53. This meant the subunits of these oligomers were
pyridinium units connected by C10 alkyl chains with an E-geometry alkene in the C-9 to
C-10 positions. The mixture of 3-APAs proved to be difficult to separate and so they were
tested for toxicity against brine shrimp as a mixture, this gave an LD50 of 65 µg/mL. This
is the only report of naturally isolated tetrameric, pentameric and hexameric 3-APAs to
date.122
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Table 4.4. Cyclic Oligomer 3-Alkyl Pyridinium Alkaloids.
Structure Name (Subunits x Alkyl Chain Lengths) Reported Activity* Reference
55 Cyclohaliclonamine C (4 x C10) T 122
56 Cyclohaliclonamine D (5 x C10) T 122
57 Cyclohaliclonamine E (6 x C10) T 122
*T = General Toxicity
N
N
N
N
55
N
N
N
N
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N
N
N
N
N
N
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4.3.5 Structural Elucidation
Despite their simplicity, structural elucidation of cyclic 3-APAs can be a difficult
task. Most cyclic 3-APAs produce very similar NMR spectra, especially in the
1H NMR spectrum. This usually consists of aromatic resonances from the 1,3-substituted
pyridinium/s, which includes a singlet that is the most downfield (H-2), two doublets
(H-4 and H-6) and a doublet of doublets or triplet that is the most upfield of the aromatic
resonances (H-5), these all occur between 7.9 and 9.3 ppm (see Figure 4.2 for compound
numbering). Next in the 1H NMR spectrum are the methylene units adjacent to the
pyridinium nitrogen (H-7, a triplet between 4.5 and 4.9 ppm) and the 3-position carbon
(H-n+1, a triplet between 2.8 and 3.0 ppm), as well as the methylenes adjacent to them
(H-8 between 1.9 and 2.1 and H-n between 1.6 and 1.8). Finally, there is a methylene
envelope of all the remaining methylene units that are in a similar environment (a broad
unresolved resonance between 1.0 and 1.4 ppm). This similarity across the 1H NMR
spectra is broken up when an alkene is present producing alkene resonances (around 5.3
to 5.7 ppm) and shifting the allylic methylenes downfield, however a methylene envelope
will still usually be present (this can make it hard to determine the exact position of the
alkene). The spectra can also be more distinctive in the case of a non-symmetric 3-APA,
the variation in the alkyl chains can cause differences in the 1H NMR spectrum, allowing
the various subunits to be distinguished.
N1
2
3
4
5
6
7
8
n+1
n
Figure 4.2. Compound numbering of an exemplary cyclic 3-APA,
n = the number of carbon atoms in the structure.
The 13C NMR spectrum can confirm the environments inferred from the proton spectrum
as well as revealing the presence of the fully substituted carbon of the pyridinium
(C-3). The 13C NMR spectrum can also be very important in the determination of the
geometry of any double bond that is present, as the allylic methylene chemical shifts
in the carbon spectrum can be used to distinguish between an E-geometry (from 30
to 35 ppm, usually around 33 ppm) and Z-geometry (from 26-30 ppm, usually around
27 ppm).122,126,131–134 The COSY spectrum of a 3-APA (especially one that is symmetric)
will provide little information on the structure, methylene units adjacent to functional
groups can be identified but they will eventually couple to the methylene envelope
preventing further determination of the position of that functional group.117 TOCSY
experiments can be useful in distinguishing methylene units in the alkyl chain and can
also be used to prove that substructures identified (the 1,3-substituted pyridinium structure
and any alkene groups) are part of the same compound structure.108 The multiplicity-
edited HSQC will clearly show whether any methyl groups are present in a 3-APA while
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providing information on the direct attachments of protons to carbons. The HMBC
experiment is one of the most important NMR experiments for structural elucidation of
3-APAs, the long-range information can indicate which signals in the 1H NMR spectrum
are from H-2, H-4, H-5 and H-6 in the pyridinium ring. Also, the HMBC information can
help with connecting two functional group substructures if correlations between the key
resonances of these groups can be seen in the HMBC.117,124
The most essential tool for determining the final structure of 3-APAs is mass spectrometry
(MS).105,127,135 This is able to provide information of the molecular mass of the 3-APA
that, in turn, can be used to deduce the length of the alkyl chain. Further information that
can be gained from MS is the number of subunits in the 3-APA structure (e.g. monomer,
dimer, trimer etc.).122 The mass spectrum of some compounds is complicated by the
M+ mass to charge ratio (m/z) reported for equivalent monomers, dimers, trimers and
oligomers being the same value due to each subunit being charged. One can, however,
distinguish between these by looking at the higher isotopomer peaks, these will also be
divided by the total charge of the molecule thus altering the spacing between these peaks.
For example, a monomer will have a normal M+ followed by an M+1 and an M+2, a dimer
will have an M+ followed by an M+1
2
and an M+1, a trimer will have an M+ followed by
an M+1
3
and an M+2
3
etc. MS can also be used to determine the purity of a 3-APA, which
might not be clear from NMR if the impurity is another 3-APA.114
The mass spectrum can be further complicated by the presence of counter ions in the
3-APA and also by fragmentations occurring in the mass spectrometer.113,117 A common
in-source generated fragment that is found in mass spectra of cyclic 3-APAs is the product
of a Hofmann elimination, which produces an [M-H](n−1)+ as the major product, where
n is the number of charged subunits in the 3-APA (Figure 4.3).113,117,119,122,124,127,136 In
fact, only the Hofmann elimination product is observed in the mass spectrum of some
cyclic 3-APAs.115 The occurrence of this Hofmann elimination product is thought to be
dependant on the counter-ion of the 3-APA.136 3-APAs give characteristic and reliable
tandem mass spectrometry (MS/MS) fragmentations. MS/MS has been used extensively
to determine the length of the alkyl chains of 3-APAs and can also be used in order to
identify or confirm the substructures of a 3-APA.111,112,117,119,124,126,137 Two well known
fragments that occur from 3-APAs during MS/MS are the onium reaction and McLafferty
rearrangement products (Figure 4.3). When only one of these fragmentations occurs
in a cyclic 3-APA the mass observed will not necessarily change, however, when a
combination of fragmentations occur, masses characteristic of the alkyl chain length can
be observed.111,127 MS in combination with MS/MS is also useful in the determination of
the position of a double bond after an oxidative cleavage has been performed.118,135
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Figure 4.3. Examples of Hofmann elimination, onium reaction and McLafferty rearrangement
fragmentations modelled on cyclostellettamine A (22).
4.4 3-APAs Isolated
In this study, one known and two new 3-APA cyclic monomers were isolated from the
marine sponge Haliclona sp. This is also the first report of unsaturated 3-APA cyclic
monomers to our knowledge. The 3-APAs were found in the more polar 20%, 40%
and 60% acetone in water fractions from crude separation on an HP20 column. This
was indicated in the 1H NMR spectra (Figure 3.2) that all showed the same resonances
characteristic of 3-APAs (see Section 4.3.5 for characteristic 3-APA resonances), and
the fractions all had similar approximate IC50 values of 1.5 µg/mL when tested against
S. cerevisiae.
Further purification of the 20% acetone in water fraction (VD1 96A) was attempted
using HP20ss, however the 3-APAs all eluted in the 50% methanol in water wash of
the column (VD2 373B). Diol was then used to further purify the 3-APAs and they
were collected in eight separate fractions over the 25%, 50% and 75% methanol in ethyl
acetate elutions (VD2 384G-N). Of these fractions, the sample with the largest mass was
VD2 384G with 6.7 mg, so this sample was chosen to be purified further using reversed-
phase (C18) HPLC. A gradient of acetonitrile in water (both with 0.1% formic acid) was
used to separate out the 3-APAs. The 3-APAs were collected as samples VD2 394F and
VD2 394G with masses of 1.1 and 2.3 mg, respectively. Full sets of NMR spectra were
run on these compounds. The isolation procedure of VD2 394 F and G from MNP 0999
is shown in Scheme 4.1.
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MNP_0999 (189 g)
extracted twice in MeOH
HP20 (Me2CO/H2O)
20% 
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80% 
VD1_96D
160.8 mg
IC50: 10.2
60% 
VD1_96C
447.5 mg
IC50: 1.5
Further fractionation
(see Scheme 4.3)
5% 
VD2_373H/I
< 1 mg
30% 
VD2_373C/D
< 1 mg
10% 
VD2_373G
< 1 mg
100% 
VD2_373A
52.0 mg
20% 
VD2_373E/F
< 2 mg
50% 
VD2_373B
24.3 mg
HP20ss (MeOH/H2O)
100% H 
VD2_384A
50% EA/H 
VD2_384B
100% EA  
VD2_384E
25% M/EA 
VD2_384F/G/H
50% M/EA 
VD2_384
I/J/K/L/M
75% M/EA 
VD2_384N
100% M
VD2_384O
25% H2O/M
VD2_384C
50% H2O/M 
VD2_384D
Diol Hexanes(H)/Ethyl Acetate (EA)       EA/MeOH(M)       M/H2O
VD2_384G
6.7 mg
HPLC C18 25-50% MeCN/H2O
(with 0.1% Formic Acid)
VD2_394A-E
~1.4  mg
VD2_394F
1.1 mg
VD2_394G
2.3 mg
VD2_394H-K
~0.5 mg
Further fractionation by HPLC to give 
Dehydrohaliclocyclins C and F
and Haliclocyclin C
see Scheme 4.2
Scheme 4.1. Isolation procedure for 3-APAs from the sponge MNP 0999. Note that IC50 values
are approximate (µg/mL).
The structure of VD2 394F was elucidated as will be described in section 4.4.1, this was
a C18 unsaturated monomer and was named dehydrohaliclocyclin C (58). VD2 394F
was further purified using the same conditions on reversed-phase HPLC (VD3 86B) for
biological testing to be performed and to unambiguously establish the geometry of the
double bond. Over the course of NMR experiments used to determine the geometry of
the double bond VD3 86B accumulated some impurity and so needed to be cleaned up
again using reversed-phase HPLC. This purification used 53% methanol in water (with
0.1% formic acid in both), this produced the final compound VD4 33C that was identified
as the new compound dehydrohaliclocyclin C (58). Quantitative NMR was performed on
this sample to give a final mass of 0.36 mg and this was submitted for biological testing
against the clinically relevant fungus C. albicans.
VD2 394G was found to be a mixture of 3-APAs and so was further purified using
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reversed-phase HPLC with the same acetonitrile in water gradient used previously. The
3-APAs came off as one peak that showed two shoulders in the UV/Vis trace, indicating
that there may be at least three different 3-APAs in the sample. The major peak was
collected as two fractions in order to try to separate out the 3-APAs better. The first
part of this peak (VD3 87C) showed a cleaner 1H NMR spectrum than the second half
(VD3 87D), VD3 87C appeared to also have a larger mass than VD3 87D as shown
by the 1H NMR spectra. A full set of NMR experiments were run on VD3 87C and
these showed that there were two 3-APAs that were the major compounds in this sample.
The mass spectrum of this fraction suggested that the compounds were a C19 unsaturated
monomer that was named dehydrohaliclocyclin F (59), and a C18 saturated monomer that
was the known compound haliclocyclin C (20).
N
2
59
N
20
In order to separate out the two compounds in fraction VD3 87C (for biological testing
and to determine the position and geometry of the alkene), reversed-phase HPLC was
utilised using an isocratic elution of 53% methanol in water (both containing 0.1%
formic acid). The 3-APA peaks in the UV/Vis trace were overlapping but the majority
of the mass was able to be separated. A full set of NMR experiments were run on
the samples VD4 32A (the C19 unsaturated monomer dehydrohaliclocyclin F, 59) and
VD4 32B (the C18 saturated monomer haliclocyclin C, 20) that allowed their structures
to be elucidated. The isolation procedure for the dehydrohaliclocyclins C and F and
haliclocyclin C is shown in Scheme 4.2. Following the structural elucidation of these
3-APAs, a successful oxidative cleavage of the alkene of 59 was performed in order to
determine the location of the double bond using MS. Quantitative NMR was performed on
these samples to give a final mass of 0.25 mg for 59 (dehydrohaliclocyclin F) and 0.16 mg
for 20 (haliclocyclin C). These samples were then submitted for biological testing against
the clinically relevant fungus C. albicans.
Attempts were also made to purify the 40% acetone in water fraction (VD1 96B) from
the crude HP20 column separation. An HP20ss column was the first stage of purification
and 3-APAs eluted off the column throughout the 60%, 70%, 80% and 100% methanol in
water elutions. The cleanest fraction that also had the largest mass was the 80% methanol
in water fraction that had been collected in bulk (VD2 356C), 22.4 mg of this was
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VD4_32A
Dehydrohaliclocyclin F
0.25 mg
VD4_33B VD4_33C VD4_33D
VD4_33C
Dehydrohaliclocyclin C
0.36 mg
Scheme 4.2. Isolation procedure for the dehydrohaliclocyclins C (58) and F (59) and
haliclocyclin C (20) from the fraction VD2 384G that was isolated from the sponge MNP 0999
(see Scheme 4.1).
recovered. When tested against S. cerevisiae this sample had an IC50 of 2.4 ± 1.0 µg/mL.
This sample was then subjected to semi-preparative reversed-phase HPLC using an
isocratic 62% methanol in water elution (with 0.1% formic acid in both solvents) with an
80% methanol strip incorporated in the run. The UV/Vis and ELSD traces showed three
broad overlapping peaks with low intensities that became hard to distinguish as injection
volumes were increased. 1H NMR was run on all of the fractions collected and 3-APAs
were identified in nine out of the ten fractions. Fractions VD4 43E and F with masses
of 3.3 and 3.8 mg, respectively, were recombined and renamed VD4 46A on the basis of
1H NMR. Poor solubility occurred in these 3-APA samples when running 1H NMR so the
counter-ion was exchanged using NaCl, this gave a much clearer spectrum of the sample
(VD4 47A). A full set of NMR experiments were run on this sample, these showed that
the sample was not completely pure as some of the 13C NMR resonances were broad and
there were minor resonances in the 1H and 13C NMR spectra. The contaminants appear
to be other 3-APAs thus demonstrating the difficulty in separating these compounds. A
potential structure was proposed for the major component of VD4 47A, however, the
mass spectrum was not able to confirm this. No clear M+ peak was detected in the mass
spectrum making it impossible to identify the molecular formula of the major compound
in VD4 47A. This meant that the final structure of this 3-APA was not able to be solved
due to time constraints. The isolation of VD4 47A from the sponge MNP 0999 is shown
in Scheme 4.3.
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Scheme 4.3. Isolation procedure for unknown 3-APA (VD4 47A) from the sponge MNP 0999.
Note that IC50 values are approximate (µg/mL).
4.4.1 Dehydrohaliclocyclin C
N
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Dehydrohaliclocyclin C (58) was isolated as a colourless oil. Positive ion mode
HRESIMS showed a singly charged molecular ion of m/z 258.2216 (m/z ∆ = 0.0000)
that indicated a molecular formula of C18H28N+ with an IHD of 5.5; this indicated a
natively charged structure with six double bonds and/or cyclic moieties. The 13C NMR
spectrum was used in combination with the 1H NMR and multiplicity-edited HSQC
spectra to reveal four aromatic methines (δC 145.2, 144.1, 143.6, and 128.5), one aromatic
non-protonated carbon (δC 143.4), two alkene methines (δC 130.5 and 129.8), one
deshielded methylene (δC 62.7) and 10 other methylene groups (δC 32.3, 31.1, 29.0,
28.41, 28.36, 27.3, 27.1, 26.6, 25.2 and 25.1). The resonances of protons attached to
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these carbons, determined using the multiplicity-edited HSQC spectrum, can be seen in
Table 4.5. Proton integration indicated that all of the hydrogen atoms in the formula were
attached to carbon, therefore there were no exchangeable protons in the structure. The
absence of any methyl groups in the 13C NMR and multiplicity-edited HSQC spectra
suggested a cyclic structure, this was in agreement with the molecular formula proposed
(and the degrees of unsaturation calculated from this) and was confirmed by the NMR
data described below.
The multiplicity of the aromatic protons in the 1H NMR spectrum (δH 9.60, broad doublet;
8.83, singlet; 8.17, doublet; 8.03, broad triplet) indicated a 1,3-disubstituted benzene-like
structure. The 13C NMR spectrum only contained five aromatic carbon resonances, this
indicated the presence of an atom other than carbon at the 1-position. In the HMBC
spectrum, it could be seen that the proton at 8.83 ppm (H-2) correlated to the downfield
methylene at 62.7 ppm (C-7), the most downfield regular methylene at 32.3 ppm (C-19)
and the non-protonated aromatic carbon at 143.4 ppm (C-3). This indicated that this
proton was attached to the carbon at the 2-position of the aromatic ring as it correlated
to both of the methylene substituents and the 3-position. The most downfield proton at
9.60 ppm (H-6) also showed an HMBC correlation to C-7, suggesting that this proton
was attached to the carbon on the other side of the 1-position. The proton resonance
at 8.17 ppm (H-4) showed an HMBC correlation to the methylene substituent C-19,
indicating that this proton was attached to the carbon at the 4-position of the aromatic
ring. This left the aromatic methine at 8.03 ppm, with the most upfield shift in both the
1H and 13C NMR spectra, to be in the 5-position of the aromatic ring. This proposed
structure was consistent with the observed proton multiplicities and COSY correlations,
which showed long-range coupling for most of the aromatic protons (Figure 4.4).
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Figure 4.4. Key COSY and HMBC correlations establishing the 3-APA pyridinium substructure
of dehydrohaliclocyclin C.
From the downfield shifts of the resonances of the protons in the vicinity of the 1-position
(H-2, H-6 and H-7), a charged nitrogen was proposed to be in the 1-position, this
would make a 1,3-substituted pyridinium structure. A search of the MarinLit database
of a 1,3-substituted pyridinium structure showed that this was a well known class of
compounds with very similar aromatic resonances in the 1H NMR spectrum: the 3-alkyl
pyridinium alkaloids. This 3-APA was unusual as the H-2 singlet is usually the most
downfield resonance in the 1H NMR spectrum (8.85–9.14 ppm) followed by the H-6
doublet (8.75–8.98 ppm), however, in 58 this was not the case. The H-6 doublet resonance
of 58 had been shifted downfield to 9.60 ppm and was followed by the typical H-2 singlet
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resonance at 8.83 ppm. The reason for this difference between the spectra has not been
determined. All other pyridinium resonances of this compound were consistent with a
3-APA structure (see Section 4.3.5).
A contiguous chain of methylenes (H-7 to H-11) were then established from mutual,
resolved COSY correlations. Allylic proton H-11 showed further COSY correlations to
the alkene proton at 5.17 ppm that coupled to the other alkene proton at 5.23 ppm, placing
the alkene at C-12 and C-13. The alkene proton H-13 coupled to the methylene proton
at 1.94 ppm (H-14) that led to another contiguous chain of methylenes (H-14 to H-19)
established from mutual, resolved COSY correlations. This allowed the final structure of
58 to be proposed (Figure 4.5). The structure proposed based on this COSY information
is further supported by the remaining HMBC correlations. This structure, which was able
to be proposed entirely on the basis of NMR data, is also in agreement with the molecular
formula proposed on the basis of mass spectral data.
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Figure 4.5. Key COSY and HMBC correlations establishing the structure of
dehydrohaliclocyclin C (58).
It is very unusual for the alkyl chain resonances in a 3-APA to be completely resolved
using the COSY spectrum, even at 600 MHz, the methylene group resonances usually
overlap in the 1H NMR spectrum to give a methylene envelope. In this case, the position of
the double bond in the alkyl chain seems to have shifted the proton resonances enough so
that each one could be distinguished from the other in the 1H NMR spectrum (Figure 4.6).
This was clearly shown by the individual, closely spaced multiplets in the 1H NMR
spectrum that all integrated for two protons, with the exception of the multiplet from
1.98 to 1.92 ppm that integrated for four protons (as the proton resonances at 1.94 and
1.96 ppm were overlapping but distinguishable in the 2D NMR spectra). The proton
resonances from the alkene were also clearly distinguished in the 1H NMR spectrum as
two separate multiplets that integrated for one proton each.
Several approaches were initially taken to determine the geometry of the double bond.
The first was to look at the 13C chemical shifts of C-11 and C-14 (δC 27.1 and
25.2, respectively) that suggested a Z-geometry.122,126,131–134 The next approach used
a 1D NOESY to see if the two alkene protons had diagnostic through-space (nOe)
correlations. It was expected that if an alkene had a Z-geometry the two alkene protons
would share nOe correlations and if the alkene had an E-geometry, there would be no
nOe correlations between the protons. Furthermore, if the alkene had an E-geometry, nOe
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Figure 4.6. 1H NMR spectrum of dehydrohaliclocyclin C showing expanded views of important
regions (600 MHz, CDCl3).
correlations should be seen from the alkene proton to the allylic methylene group attached
to the other alkene group (e.g. an H-12 correlation to H-14 and an H-13 correlation to
H-11 should be seen for an E-geometry alkene). However, this 1D NOESY experiment
was unsuccessful due to the close shifts of the two alkene protons making it difficult to
irradiate one resonance without some irradiation of the other, this made it impossible to
distinguish an nOe correlation between the alkene protons from the initial irradiation. The
1D NOESY was repeated in C6D6 (having previously been run in CDCl3), however this
did not separate out the alkene shifts and the low solubility of dehydrohaliclocyclin C in
C6D6 made the resolution of this experiment poor.
A 2D NOESY experiment was run to try and determine the geometry of the dehydro-
haliclocyclin C alkene (Figure 4.7). This experiment appeared to show correlations from
one alkene proton to the other (implying a Z-geometry, supporting the 13C chemical shift
argument), however, the correlations were weak and so close to the diagonal that this was
not conclusive. Next, a fully coupled HSQC (which shows all couplings both hetero- and
homonuclear to a proton and can be used to measure the coupling constants) was used
to extract the coupling constants between the two alkene protons. For a Z-geometry the
coupling between the alkene protons would be between 6 and 12 Hz (typically 10 Hz) and
for an E-geometry the coupling would be between 12 and 18 Hz (typically 17 Hz).138 The
coupled HSQC showed a coupling of 10 Hz between the major resonances (Figure 4.8),
this provided further evidence for a Z-geometry. Finally, the most conclusive evidence
for the Z-geometry of the double bond came from a homonuclear decoupling 1H NMR
experiment (Figure 4.9). In this experiment, the allylic protons were irradiated (these
proton resonances were conveniently overlapping in the 1H NMR, allowing both to be
irradiated at the same time), nullifying the coupling between the methylene and alkene
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protons. This experiment was able to resolve the alkene protons from multiplets into
doublets and from these doublets a mutual coupling constant of 10.8 Hz was observed.
This coupling constant is in the range of a Z-geometry alkene, confirming what had
already been proposed from the 13C NMR, 2D NOESY and coupled-HSQC data, that
the alkene of dehydrohaliclocyclin C had a Z-geometry. This information, together with
the singly charged molecular ion identified in the HRESIMS, led to the proposal of 58 as
the structure for dehydrohaliclocyclin C.
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Figure 4.7. 2D NOESY NMR spectrum of dehydrohaliclocyclin C with an expanded view of the
weak alkene proton correlations (600 MHz, CDCl3).
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Figure 4.8. Expanded view of the alkene correlations in the coupled HSQC of
dehydrohaliclocyclin C (600 MHz, CDCl3). The measured splitting (10 Hz) from the coupling
between the alkene protons is indicated (arrows).
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Figure 4.9. Homonuclear decoupled 1H NMR spectrum of dehydrohaliclocyclin C (58)
(600 MHz, CDCl3) showing an expanded view of the original (top) and decoupled (bottom)
spectra highlighting alkene (A) and irradiated (B) resonances.
Table 4.5. 13C (150 MHz) and 1H (600 MHz) NMR data (CDCl3) for
dehydrohaliclocyclin C (58).
N 1
3
6
7
19
12
13
58
13C 1H HMBC
Position δ (ppm) 1JCH (Hz) δ (ppm) mult. J (Hz) int. COSY (1H to 13C)
2 144.1 189 8.83 s 1 4,6,19 3,4,7,19
3 143.4
4 145.2 171 8.17 d 7.8 1 2,5,6,19 2,5,6,19
5 128.5 171 8.03 br t 5.7 1 4,6 4,3
6 143.6 9.60 br d 5.3 1 2,5 2,4,5,7
7 62.7 150 5.01 m 2 8 2,6,8,9
8 31.1 124 2.06 m 2 7,9 7,9
9 25.1 121 1.04 m 2 8,10 7,8,10,11
10 28.41 124 1.36 m 2 9,11 8,9,11,12
11 27.1 125 1.96 m 4 10,12 9,10,12,13
12 129.8 154 5.17 m 1 11,13 10,11,14
13 130.5 154 5.23 m 1 12,14 11,14,15
14 25.2 124 1.94 m 4 13,15 12,13,15,16
15 28.36 124 1.42 quin 6.5 2 14,16 13,14,16,17
16 27.3 118 1.27 m 2 15,17 14,15,17,18
17 26.6 122 1.17 m 2 16,18 15,16,18,19
18 29.0 127 1.81 m 2 17,19 3,16,17,19
19 32.3 130 2.94 m 2 18,2 2,3,4,17,18
4.4.2 Dehydrohaliclocyclin F
Dehydrohaliclocyclin F (59) was isolated as a colourless oil. Positive ion mode HRESIMS
showed a singly charged molecular ion of m/z 272.2378 (m/z ∆ = 0.0005) that indicated
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a molecular formula of C19H30N+ with an IHD of 5.5, indicating a natively charged
structure with six double bonds and/or cyclic structures. The 13C NMR spectrum was
used in combination with the 1H NMR and multiplicity-edited HSQC spectra to reveal
four aromatic methines (δC 147.1, 145.8, 143.3, and 129.4), one aromatic non-protonated
carbon (δC 145.3), two alkene methines (δC 130.9 and 130.7), one deshielded methylene
(δC 63.2) and 11 other methylene groups (δC 33.3, 31.6, 30.8, 30.2, 30.1, 29.1,
28.9, 27.8, 26.83, 26.78, 25.7). The resonances of protons attached to these carbons,
determined using the multiplicity-edited HSQC spectrum, can be seen in Table 4.6.
As for dehydrohaliclocyclin C, the absence of any methyl groups in the 13C NMR and
multiplicity-edited HSQC spectra indicated a cyclic structure.
The NMR spectra of dehydrohaliclocyclin F closely resembled the spectra of dehydrohal-
iclocyclin C. In the 1H NMR spectrum there was a singlet at 8.95 ppm (H-2), a doublet at
8.87 ppm (H-6), another doublet at 8.51 ppm (H-4) and a triplet-like multiplet at 8.07 ppm
(H-5). This pattern of a singlet, doublet, doublet and triplet moving from downfield to
upfield is typical of 3-APA structures. The 1H NMR data, together with the five aromatic
carbon resonances, clearly indicated that this was another 3-APA structure. Therefore,
the HMBC spectrum could once again be used to determine the proton attachments at
the 2-, 4- and 6-positions of the pyridinium ring. The proton singlet at δH 8.95 had
HMBC correlations to the carbons at δC 63.2 and 33.3 (C-7 and C-20) and the carbon at
δC 145.3 (C-3), indicating that this was the proton attached to the carbon at the 2-position.
The proton doublet at δH 8.87 had an HMBC correlation to the C-7 carbon at δC 63.2
indicating that this proton was attached to the carbon at the 6-position in the pyridinium.
Finally, the proton doublet at δH 8.51 had HMBC correlations to the C-20 carbon at
δC 33.3 and the C-3 carbon at δC 145.3, indicating that this proton was attached to the
carbon at the 4-position of the pyridinium. This left the proton triplet at δH 8.07 to be in
the 5-position of the pyridinium as expected from its upfield shift and multiplicity in the
1H NMR spectrum (Figure 4.10).
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Figure 4.10. Key COSY and HMBC correlations establishing the 3-APA pyridinium
substructure of dehydrohaliclocyclin F.
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Unlike the clearly resolved 1H NMR spectrum of dehydrohaliclocyclin C, the spectrum
of dehydrohaliclocyclin F had a methylene envelope that is typical of long unsaturated
alkyl chains (as is almost always seen in the 1H NMR spectra of 3-APAs). This meant
that the structure could not be solved so easily using the COSY spectrum as the protons
next to functional groups (whose resonances had been shifted downfield in the 1H NMR
spectrum) would eventually show COSY correlations to the methylene envelope; this
made it hard to determine the position of the double bond and the length of the alkyl
chain. In the COSY spectrum, the protons in the 7-position at 4.68 ppm (as shown from
the HMBC and HSQC correlations) coupled to the protons at 2.03 ppm (H-8) that then
coupled to the methylene envelope from 1.14 to 1.23 ppm that further coupled to the other
methylene envelope from 1.29 to 1.37. The H-20 protons at 2.96 ppm showed COSY
correlations to the protons at 1.78 ppm (H-19) that further coupled to the methylene
envelope from 1.14 to 1.23 ppm as well. Finally, the overlapping alkene protons at
5.34 ppm showed COSY correlations to the protons at 1.89 ppm that showed further
correlations to the methylene envelope from 1.29 to 1.37 ppm. This spectral data gave the
substructures shown in Figures 4.10 and 4.11 that were confirmed by HMBC correlations.
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Figure 4.11. Key COSY and HMBC correlations of the alkene substructure of
dehydrohaliclocyclin F.
1D TOCSY experiments were then used to prove that the 3-APA substructure and alkene
substructure were connected (Figures 4.12, 4.13 and 4.14). Three of these experiments
were performed, each one irradiating a different proton resonance of the compound. The
20-position protons at δH 2.96 (Figure 4.12) and the 7-position protons at δH 4.68
(Figure 4.13) were irradiated to see if a connection to the alkene protons at δH 5.34 could
be inferred. The alkene protons were also irradiated (Figure 4.14) to see if a connection to
the 20- and 7-position protons could be inferred. The 1D TOCSY experiments were run
using an array of mixing times from 15 to 150 ms. This allowed the resonance of each
proton down the alkyl chain from the irradiated protons to be seen sequentially until the
weak resonances of the alkene protons at δH 5.34 (Figures 4.12 and 4.13) or the 20- and
7-position protons at δH 2.96 and 4.68 (Figure 4.14) were observed, proving that the two
substructures were connected by a saturated alkyl chain.
Finally, the position and geometry of the alkene in dehydrohaliclocyclin F needed to be
determined. As for dehydrohaliclocyclin C (58), a Z-geometry alkene was indicated by
the 13C chemical shifts of C-12 and C-15 (both δC 26.8). A homonuclear decoupling
experiment was also performed, with both sets of protons adjacent to the alkene
being decoupled (Figure 4.15). The result of this experiment was not as clear as for
dehydrohaliclocyclin C, producing what is thought to be two overlapping doublet of
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Figure 4.12. 1D TOCSY array irradiating the 20-position proton resonances (2.96 ppm) with
mixing times from 15 (bottom) to 150 (top) milliseconds (600 MHz, CD3OD). The alkene
resonance at 5.34 ppm is circled.
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Figure 4.13. 1D TOCSY array irradiating the 7-position proton resonances (4.68 ppm) with
mixing times from 15 (bottom) to 150 (top) milliseconds (600 MHz, CD3OD). The alkene
resonance at 5.34 ppm is circled.
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Figure 4.14. 1D TOCSY array irradiating the alkene proton resonances (5.34 ppm) with mixing
times from 15 (bottom) to 150 (top) milliseconds (600 MHz, CD3OD). The H-7 proton resonance
at 4.68 ppm is indicated by the circle and the H-20 proton resonance at 2.96 ppm is indicated by
the square.
doublets from the highly second order multiplet. Despite this unclear resonance, the
coupling that was measured between the very small outer peaks and inner peaks was
between 10 and 11 Hz and could not be greater than 12 Hz, this supported the proposal
of a Z-geometry alkene. A fully coupled HSQC experiment was also performed and this
showed that the coupling between the major resonances was 11.0 Hz (Figure 4.16), thus
also indicating a Z-geometry for the alkene. With the evidence from these experiments a
Z-geometry was proposed for the alkene in dehydrohaliclocyclin F.
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Figure 4.15. Homonuclear decoupled 1H NMR spectrum of dehydrohaliclocyclin F (59)
(600 MHz, CD3OD) showing an expanded view of the original (top) and decoupled (bottom)
spectra highlighting the alkene (A) and irradiated (B) resonances.
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Figure 4.16. Expanded view of the alkene correlations in the coupled HSQC of
dehydrohaliclocyclin F (600 MHz, CD3OD).
To determine the position of the double bond, an oxidation was performed using ruthe-
nium trichloride and sodium periodate in a chloroform/acetonitrile/water solution.139–141
This successfully oxidatively cleaved the alkene to the dial (60) as shown by the MS peak
detected at m/z 304.2269. MS/MS analysis was then performed on the dialdehyde in order
to identify the fragment peaks whose masses are determined by the alkyl chain lengths.
The reproducible fragment mass of m/z 192.1382 was characteristic of a pyridinium
with an alkyl chain length of seven, terminating with an aldehyde (61). This fragment
is proposed to be the product of an onium reaction or the [M+H]+ of a Hofmann
elimination on the dialdehyde, this would indicate that the alkene links carbons 13 and 14
of dehydrohaliclocyclin F.
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Table 4.6. 13C (150 MHz) and 1H (600 MHz) NMR data (CD3OD) for
dehydrohaliclocyclin F (59).
N
2
1
3
6
7 13
14
20
59
13C 1H HMBC
Position δ (ppm) 1JCH (Hz) δ (ppm) mult. J (Hz) int. COSY (1H to 13C)
2 145.8 189 8.95 s 1 4,6 3,4,6,7,20
3 145.3
4 147.1 177 8.51 d 8.0 1 2,5,6 2,3,6,20
5 129.4 176 8.07 m 1 4,6 3,6
6 143.3 200 8.87 d 6.1 1 2,4,5 2,4,5,7
7 63.2 147 4.68 t 6.1 2 8 2,6,8,9
8 31.6 123 2.02 m 2 7,9 7,9
9a 25.7 116 1.20 m 4 8,10 10,11
10b 30.2 122 (1.29-1.37) m 8 9,11 9,11
11c 29.1 123 (1.29-1.37) m 8 10,12 9,10
12d 26.83 123 1.89 m 4 11,13 10,11,13,14
13e 130.9 159 5.34 m 2 12 12/15
14e 130.7 159 5.34 m 2 15 12/15
15d 26.78 123 1.89 m 4 16,14 13,14,16,17
16c 28.9 123 (1.29-1.37) m 8 17,15 17,18
17b 30.1 122 (1.29-1.37) m 8 16,18 16,18
18a 27.8 1.19 m 4 17,19 16,17,19
19 30.8 1.78 m 2 18,20 3,18,20
20 33.3 130 2.96 m 2* 19 2,3,4,18,19
aInterchangeable
bInterchangeable
cInterchangeable
dInterchangeable
eInterchangeable
4.4.3 Haliclocyclin C
N
20
The compound haliclocyclin C (20) is known both naturally and synthetically (see
Section 4.3.1). In the current research it was isolated as a colourless oil. Positive ion mode
HRESIMS showed a singly charged molecular ion of m/z 260.2381 (m/z ∆ = 0.0008)
that indicated the molecular formula C18H30N+ with an IHD of 4.5, indicating a natively
charged structure with five double bonds and/or cyclic structures. Only 0.16 mg of this
compound was isolated so the 13C, HSQC and HMBC NMR spectra were very weak, this
meant that some resonances and correlations were not visible in these spectra. Some very
weak correlations in the HSQC and HMBC spectra could only be found amongst the noise
of the spectrum, these correlations were often still distinct from the surrounding noise,
but could be easily missed if not specifically looking for them. Another concern was the
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contamination of this compound that occurred after quantitative 1H NMR experiments
that resulted in a monosubstituted benzene compound being present in this full set of
spectra. These contamination correlations were luckily isolated and distinct from the
haliclocyclin C correlations and so were ignored in the structural elucidation.
The 13C NMR spectrum was used in combination with the 1H NMR, multiplicity-edited
HSQC and HMBC spectra to reveal the four aromatic methines (δC 147.2, 145.5, 143.6,
and 129.1), one aromatic non-protonated carbon (δC 145.0), one deshielded methylene
(δC 62.7) and 12 other methylene groups (δC 32.6, 31.3, 30.1, 28.1, 28.0, 27.94, 27.90,
27.50, 27.49, 27.4, 27.3, 25.2). As for dehydrohaliclocyclin C and F, the absence of any
methyl groups in the 13C NMR and multiplicity-edited HSQC spectra indicated a cyclic
structure.
The proton resonances at δH 8.97, 8.86, 8.50 and 8.06 in the singlet, doublet, doublet and
doublet of doublets pattern from downfield to upfield, were characteristic of a 3-APA. As
expected, the singlet resonance at 8.97 ppm (H-2) in the 1H NMR spectrum had HMBC
correlations to the 7 and 19-position carbons (δC 62.7 and 32.6, respectively) indicating
that it was the proton attached to the carbon at the 2-position of the pyridinium. The
doublet at 8.86 ppm (H-6) had an HMBC correlation to the 7-position carbon indicating
that it was the proton attached to the carbon in the 6-position. The doublet at 8.50 ppm
(H-4) had an HMBC correlation to the 19-position carbon, indicating that this was the
proton attached to the carbon at the 4-position and this left the doublet of doublets
at 8.06 ppm as the proton attached to the carbon in the 5-position of the pyridinium
(Figure 4.17).
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Figure 4.17. Key COSY and HMBC correlations establishing the 3-APA pyridinium
substructure of haliclocyclin C (20).
As for the compounds dehydrohaliclocyclin C and F, the carbon attached to the nitrogen
at the 7-position and its protons had characteristic chemical shifts (δC 62.7 and δH 4.67)
and could be unambiguously identified using the HMBC and multiplicity-edited HSQC
spectra. The COSY spectrum showed correlations from these protons at 4.67 ppm (H-7) to
the protons at 2.07 ppm (H-8) that showed further correlations to the methylene envelope
between 1.14 and 1.19 ppm that showed correlations to the other methylene envelope
between 1.27 and 1.36 ppm. The carbon and attached protons at the 19-position could
similarly be identified using the HMBC correlations in combination with the multiplicity-
edited HSQC (δC 32.6 and δH 2.96). The COSY spectrum showed correlations from the
80
protons at 2.96 ppm (H-19) to the protons at 1.84 ppm (H-18) that had further correlations
to the methylene envelope between 1.14 and 1.19 ppm as well. This gave the typical
3-APA substructure shown in Figure 4.17. The lack of any unsaturation in the alkyl
chain of this 3-APA (as shown by no major resonances in the 1H NMR spectrum around
5.3 ppm) meant that the alkyl chain length could only be solved using MS. The HRESIMS
peak of m/z 260.2381, therefore, established the structure of this compound as the known
compound haliclocyclin C (20). All spectroscopic data were consistent with that reported
in the literature.113,114,116
4.4.4 VD4 47A
VD4 47A was isolated as a yellow oil. The 13C NMR spectrum of this sample was used
in combination with the 1H NMR and multiplicity-edited HSQC spectra to reveal four
aromatic methines (δC 146.7, 145.3, 143.4, and 129.0), one aromatic non-protonated
carbon (δC 145.7), one deshielded methylene (δC 62.9) and several other methylene
groups that were indistinguishable from minor component resonances. Some of these
resonances observed in the 13C NMR spectrum were broad, indicating that this sample
was not purely one 3-APA. The methylene resonances that were distinguishable from
the overlapping minor resonances and proposed to be part of the major component due to
their intensity and characteristic 3-APA shifts were δC 33.5, 32.5 and 31.6. The 13C NMR
spectrum also contained six alkene methines (δC 131.3, 131.2, 130.9, 130.7, 130.3, 130.2)
that all showed a single combined correlation to a proton multiplet between 5.31 and
5.41 ppm in the HSQC spectrum.
From these correlations it was unclear whether the alkenes were part of the major 3-APA
as the resonances all had lower intensities in the 13C NMR spectrum and they showed
a 1:1 integration ratio with the aromatic protons in the 1H NMR spectrum (indicating
there is only one alkenyl proton for every pyridinium group in the structure). The HMBC
spectrum could not be used to clarify this as the alkene proton correlations to an impurity
structure could not be differentiated from correlations to the major compound. From this
information it was proposed that the alkene is not part of the major 3-APA since it would
be expected that the proton multiplet of the alkene would have a greater than 1:1 ratio with
the aromatic protons, since it is obviously the overlapping resonance of several alkenes as
shown by the 1H, 13C and multiplicity-edited HSQC NMR spectra. There is a possibility
that this integration ratio is due to a double bond being present in just one alkyl chain of
a dimer (as in seen in the dehydrocyclostellettamines 29, 30, 35 and 46–51). However,
this would indicate that the impurity also had the same motif due to the integration ratio
being 1:1 despite the overlapping resonances. As for dehydrohaliclocyclin C and F and
haliclocyclin C, the absence of any methyl groups in the 13C NMR and multiplicity-edited
HSQC spectra indicated a cyclic structure.
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As for the previous compounds, the HMBC spectrum could be used to confirm that the
proton singlet resonance at δH 8.98 was of the proton attached to the carbon in the
2-position, the doublet resonance at δH 8.87 was of the proton attached to the carbon in
the 6-position, the doublet resonance at δH 8.47 was of the proton attached to the carbon
in the 4-position and the triplet resonance at δH 8.03 was of the proton attached to the
carbon in the 5-position. The COSY spectrum could be used to show that the 7-position
protons at 4.63 ppm coupled to the protons between 2.00 and 2.04 ppm that then coupled
to the methylene envelope between 1.27 and 1.39 ppm. The COSY spectrum also showed
that the protons attached to the methylene carbon that was adjacent to the 3-position of the
pyridinium, at 2.89 ppm, coupled to the protons at 1.73 ppm that further coupled to the
methylene envelope. Further information to delineate the structure could not be obtained,
however, it is proposed that further purification of the sample is required before a final
structure can be identified. This work was not able to be completed in the current study
due to time constraints.
4.4.5 Biological Activity
The 3-APAs isolated were originally identified by testing for the inhibition of S. cerevisiae
growth. They showed potent activity in initial assays, as described in Section 4.4.
However, upon the isolation of the pure 3-APA compounds, there was not enough mass
to test for activity against both S. cerevisiae and C. albicans. It is for this reason
that the inhibitory activity of the pure 3-APA monomers was not measured against
S. cerevisiae in favour of more clinically relevant biological evaluation. Unfortunately,
dehydrohaliclocyclin C (58), dehydrohaliclocyclin F (59) and haliclocyclin C (20) showed
no activity against C. albicans when tested at 0.2, 2 and 20 µg/mL concentrations in a
disc diffusion assay. Possible reasons for this observation are that the samples tested were
too dilute, the 3-APAs had poor diffusion through the agar medium or that these 3-APA
monomers are simply inactive against C. albicans.
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Chapter 5
Concluding Remarks
The marine environment is a rich source of interesting and unusual compounds that
have potent biological activities. This makes it the ideal environment to explore in
the search for new biologically active compounds to be used as potential drug leads.
In the current study two new and three known compounds have been isolated using
a bioassay and NMR-guided approach. Crude extract libraries of New Zealand and
Tongan marine invertebrates were screened against S. cerevisiae and ‘hits’ from this were
validated. Three New Zealand sponges and one Tongan ascidian were identified as having
inhibitory activity towards the growth of S. cerevisiae. These invertebrates were extracted
and chromatographic methods were used to purify bioactive and structurally interesting
compounds as shown by the bioassays and 1H NMR spectra used to guide the isolation
process.
The known trihydroxylated steroid (14) was isolated from a calcareous sponge that
has been tentatively identified as Leucosolenia sp. The fractionation of this sponge
used a bioassay-guided approach, however, poor activity was observed. A mixture of
trihydroxylated steroids that differed in the side chain were isolated and this was purified
further to allow the structure of one steroid to be solved as a representative of the mixture.
The mass of steroid 14 isolated, in combination with the poor activity observed and time
constraints, meant that it was not submitted for biological testing. A fatty acid and mixture
of phthalate esters were isolated from an unidentified Tongan ascidian. The fatty acid was
tentatively assigned as cis-vaccenic acid (13) based on the comparison of 1H and 13C NMR
spectra. These compounds were not pursued further in the interest of time, due to a lack
of activity and the well-known nature of these compound classes.
An assay that targets bacterial MscL was also being developed in this study for its use at
VUW to test against the extract library of New Zealand and Tongan marine invertebrates.
Some parameters were able to be established for use in this assay and others were
proposed but further work had to be done to confirm them. Unfortunately, the liposomes
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that were prepared for this assay were fragile and yielded inconsistent results in both the
optimisation of the parameters and attempts at screening the extract library, resulting in no
‘hits’ being identified. It is possible that there were no compounds present in the extract
library screened that interact with the very specific MscL target, however, this cannot be
concluded with certainty without a clearer distinction between MscL active and inactive
compounds being observed in the assay. More work needs to be done to understand the
effect of each aspect of the liposome preparation on the stability of the liposomes so that
more robust liposomes can be made. Once the liposome preparation has been optimised
the ideal parameters to be used in the assay can be better determined to allow for clear
distinctions between positive ‘hits’ and negative controls. This would allow the assay to
be more effective in identifying bioactive natural products as molecular probes for Msc.
One known and two new 3-APAs were isolated from a New Zealand sponge identified
as Haliclona sp. Initially, this was done using a bioassay-guided approach that allowed
3-APAs to be identified as the active components and, following this, an NMR-guided
approach was used to isolate the pure compounds. A range of biological activities
have been reported for 3-APAs, including antibacterial, antifungal and cytotoxic activity.
The known 3-APA monomer isolated, haliclocyclin C (20), was previously reported to
show potent antibacterial, neurotoxic and cytotoxic activity, however, when tested against
C. albicans in the present study, no activity was found. The new 3-APA monomers
dehydrohaliclocyclin C (58) and dehydrohaliclocyclin F (59) are the first examples of
3-APA cyclic monomers with unsaturation in the alkyl chain. Their structures were
elucidated using a combination of NMR spectroscopy, MS and an oxidative alkene
cleavage for dehydrohaliclocyclin F. When tested for inhibition of C. albicans growth,
dehydrohaliclocyclins C and F showed no activity at the concentrations tested. It is
possible that the lack of activity that was observed for these compounds was due to the
samples tested being too dilute, poor diffusion of the 3-APAs in agar or the monomers
isolated were simply inactive against C. albicans.
Future work on this project would involve further purifying the sample VD4 47A so
that the 3-APAs present can be identified and fully characterised. It would also involve
purifying other fractions isolated from Haliclona sp. that contained 3-APAs in order to
identify the 3-APAs present (for example the 60% acetone in water fraction from the
initial HP20 column). It would also be useful to extract and purify more Haliclona sp. to
isolate more of the compounds dehydrohaliclocyclin C and F for more biological testing
as well as to identify and characterise other 3-APAs present. Alternatively, a synthetic
approach could be taken to collecting more of the compounds dehydrohaliclocyclin C
and F for more biological testing. It would also be interesting to extract and purify
more Leucosolenia sp. in order to isolate more trihydroxylated steroids so that more
of the structures could be fully elucidated and the steroids isolated could be submitted to
biological testing. Finally, the liposome preparation in the MscL assay will need to be
optimised in future studies so that more stable and reproducible liposomes are available
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for use in the assay. This can be done by adjusting aspects such as the amount of drying
time given to remove all of the chloroform from the azolectin film, the amount of time
the solution is sonicated for in creating the liposomes, the amount of MscL added to
liposome solutions and the amount of time the liposome solutions spend mixing with
Biobeads R©. The possibility of leaving the liposome solution mixing with Biobeads R©
overnight should also be explored as this would allow more experiments to be run with
one batch of liposomes in a day.
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Chapter 6
Experimental
6.1 General Experimental
Marine invertebrates were collected from various locations in New Zealand and Tonga
by the Marine Natural Products group at VUW. These sponges were stored in a freezer at
−20 ◦C until required. Crude extracts from New Zealand and Tongan marine invertebrates
that were tested in assays had been sampled into 3 × 96-well plates. These master plates
were then subsampled into daughter plates with approximately 50 µg of extract in each
well and these were stored in the fridge until required.
Normal-phase column chromatography was performed using Supelco Discovery R© DSC-
DIOL functionalised silica: 3-(2,3-Dihydroxy-propoxy)-propyl-silica (Diol). Reversed-
phase column chromatography was performed using Supelco Diaion R© HP20 and HP20ss
poly(styrene-divinylbenzene) (PSDVB) resins. Two separate HPLC systems were used,
the first using a Rainin Dynamax SD-200 solvent delivery system with 25 mL pump
heads and a Varian Prostar 335 photodiode array detector for UV/Vis detection. The
second HPLC system was an Agilent Technologies 1260 Infinity HPLC equipped with a
quaternary pump, a thermostatted column compartment and diode array detector (DAD).
Following the DAD, a QuicksplitTM flow splitter directs 5% of the flow to an Agilent
380-evaporative light scattering detector (ELSD) with 95% of the flow directed towards
collection. For HPLC purification a Phenomenex analytical (5.0× 250 mm, 5 µm particle
size) custom-packed Diol column was used for normal-phase. For reversed-phase, C18
analytical (Phenomenex Prodigy, 4.6 × 250 mm, 5 µm particle size) or semi-preparative
(Phenomenex Prodigy, 10.0 × 250 mm, 10 µm particle size) columns were used.
All solvents used were HPLC-grade (purchased from Fisher Scientific) with the exception
of hexanes and dichloromethane, which were Optima R© grade. Water was distilled prior
to use and in the case of HPLC the water was further filtered through a membrane with
a pore size of 0.45 µm before use. The solvent compositions used are all reported as
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the % v/v. TLC analyses were performed using Machery-Nagel Polygram R© Sil G/UV254
plates and visualised under UV light (λ = 254 nm and 350 nm). TLC plates were then
visualised by dipping in 5% conc. H2SO4 in methanol (v/v%) followed by 0.1% vanillin
in ethanol (w/v%) and heated for analysis.
NMR spectra were obtained using a Varian DirectDrive spectrometer equipped with a
triple resonance HCN cryogenic probe operating at 600 MHz for 1H and 150 MHz for
13C nuclei. The chemical shifts of 1H and 13C spectra were referenced to the residual
solvent peaks (CDCl3: δC 77.0, δH 7.26; CD3OD: δC 49.0, δH 3.31). All NMR
solvents were purchased from Aldrich with the exception of deuterated methanol, which
was purchased from Cambridge Isotope Laboratories Inc. NMR quantification of final
compounds were performed with an internal nitromethane (CH3NO2) standard and using
the acquisition parameters described by West.142 HRESIMS results were obtained from
an Agilent 6530 Q-TOF mass spectrometer equipped with an Agilent 1260 HPLC for
solvent delivery utilising a JetStreamTM electrospray ionisation source in positive and
negative ion modes. Water and acetonitrile (MeCN) solvents were both made up as 5 mM
solutions with ammonium formate. CID was performed using nitrogen as collision gas at
various energies (10-100, arbitrary units). Where a column was used it was a C18 Zorbax
Extend (2.1 × 50 mm, 1.8 µm particle size). A typical MS run using a column started
at 5% MeCN for 0.5 minutes followed by a 3.5 minute gradient up to 100% MeCN,
the solvent composition was held at 100% MeCN for 0.5 minutes and then there was
a 0.05 minute gradient back down to 5% MeCN, the composition was then held at 5%
MeCN for 2.45 minutes.
For sponge identification, the organic matter was dissolved by immersing small samples
(≤ 1 cm3) in concentrated HNO3 or 12.5% NaOCl (for calcareous sponges). Any
spicules that remained after this were then washed by suspending them in water and then
centrifuging them to allow the water to be decanted, this process was repeated several
times. The spicules were then imaged using an Olympus R© Research Microscope AX70
Provis equipped with an Olympus R© DP70 Digital Microscope Camera and these images
were compared with descriptions in the literature to classify the sponge.
6.2 Saccharomyces cerevisiae Assay
The Saccharomyces cerevisiae yeast strains BY4742 (wild type) and yCG 117 were used
in this work. yCG 117 was used to screen the crude extracts initially and after extraction
BY4742 was used to guide the fractionation. Both of these strains were streaked out from
a 15% glycerol stock that was stored at −80 ◦C onto 10 cm agar plates containing either
synthetic complete (SC) media or yeast extract peptone dextrose (YPD) media. These
plates were then incubated at 30 ◦C for 48 hours, allowing single yeast colonies to form,
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the plates were then stored at 4 ◦C. Single colonies from these plates were then used in
making up liquid culture for bioassays as required. Cycloheximide was used as a positive
control in all of the S. cerevisiae assays. Cell growth in assays was quantified using optical
density (OD) measurements acquired on a Perkin Elmer Wallac EnVision 2102 Multilabel
Plate Reader. Plates were vortexed using an Eppendorf MixMate plate mixer.
Table 6.1. Yeast Strains Used
Strain Ploidy Genotype Origin
yCG 117 haploid
MATα
Starting lab strain
can1∆1::STE2pr-Sp his5
lyp1∆
ura3∆0::NatR
leu2∆0
his3∆1
met15∆0
LYS2+
BY4742 haploid
MATα
Starting lab strain
his3∆1
leu2∆0
lys2∆0
ura3∆0
6.2.1 Extract Library Screening Protocol
For screening the extract library against yeast a 100 µg/mL concentration of crude extract
was used. In order to do this, 20 µL of 1:1 DMSO to water was added to each well of
the daughter plates that contained approximately 50 µg of the crude extract and the plates
were vortexed. This gave a crude extract concentration of 2.5 mg/mL and from this 4 µL
from each extract well was added to 96 µL of yeast culture to give an extract concentration
of 100 µg/mL in each well.
The yeast culture was made up using a single colony of yeast from an agar plate added to
5 mL of SC liquid media and incubated overnight at 30 ◦C on a shaker to saturation. A
10 µL aliquot of this culture was then diluted by adding it to 990 µL of water and vortexing
before placing 10 µL of this diluted culture on to a microscope slide grid to count. The
cells on the grid were counted using a haemocytometer and from this the concentration
of the saturated yeast culture could be calculated. The saturated yeast culture was then
diluted to a concentration of 5× 105 cells/mL using fresh SC media and this was vortexed.
The 96-well plates for the assay were then set up using 96 µL of this SC media plus cells
mixture and 4 µL of extract in 1:1 DMSO to water was added to this. A positive control,
solvent control, cell blank and media blank were also used in each plate of the assay in
order to determine the growth (measured by OD) of cells with and without solvent, the
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OD of cells that have not grown and the OD and sterility of the media. The positive
control was cycloheximide and 0.3 µL of a 1 mM solution in DMSO was added to four
wells containing the media plus cells mixture. The solvent control was 4 µL of 1:1 DMSO
to water and this was also added to four wells of the media plus cells mixture. The cell
blank and media blank were four wells each of plain media plus cells mixture and plain
media, respectively. The wells were mixed by vortexing the plates at 950 RPM for one
minute and these plates were then incubated at 30 ◦C for 18 hours.
When incubation was complete the yeast cells were resuspended by vortexing the
plate at 950 RPM for one minute and the growth was then measured using OD at
590 nm. OD effects of the media were then subtracted from the remaining wells by
subtracting the optical density of the average of the media blank from the optical density
of the yeast growth wells to get a normalised value. The residual growth was then
calculated by dividing the normalised growth of the experimental wells by the normalised
growth of the solvent control wells and multiplying by 100 to give percentage growth
((ODexp norm./ODsolv. norm.) × 100). From this a percentage inhibition could be calculated
by subtracting the percentage growth from 100. A ‘hit’ was considered to be a minimum
of 35% growth inhibition of S. cerevisiae. This data was processed using Microsoft Excel
2010.
6.2.2 Dose-Response Assay Protocol
‘Hits’ were validated using a dose-response assay. The validations were performed using
subsamples of crude extracts that had been stored in vials in the fridge. The highest
concentration used in the validation assays was 100 µg/mL and serial dilutions were
performed in blank media. Subsequent assays used to guide the isolation of natural
products used the same protocol as the validation assays, with the exception that the initial
concentrations used in the dose-response curves were adjusted according to the potency
of the extracts or fractions.
For dose-response assays yeast cultures were made two-fold higher in cell concentration
(10 × 105 cells/mL) using the same protocols used for extract library screening. Serial
dilutions of extracts were made in media and yeast culture was then added to the
extract/media mixture. The dilutions were performed by placing 92 µL of media in
column two of a 96-well plate, and 50 µL of media in columns 3–11 (columns one and
12 and rows A and H were used for controls). To column two, 8 µL of extract in a 1:1
DMSO to water solution, at a concentration of 2.5 mg/mL was added to the wells in
triplicate. This resulted in a concentration of 200 µg/mL in the column two wells. Taking
50 µL from these wells, two-fold dilutions were carried out in subsequent columns until
column 11. Following the serial dilutions, 50 µL of yeast cell culture was added to the
extract/media wells, resulting in final extract concentrations of 100 µg/mL through to
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0.2 µg/mL.
The dose-response assay plates were mixed and incubated using the same protocol
used for the screening assay. The same controls were also used, this time with the
solvent and positive controls being performed as dose-response curves alongside the
experimental wells. Percentage growth and inhibition were calculated from these results
using Microsoft Excel 2010. IC50 values reported for this data were determined using
a non-linear regression on GraphPad Prism version 5.00 where the concentration values
had been transformed to a logarithmic scale.143
6.3 Candida albicans assay
The purified samples of dehydrohaliclocyclin C (0.36 mg), dehydrohaliclocyclin F
(0.30 mg) and haliclocyclin C (0.16 mg) had 9.0, 7.5 and 4.0 mL of methanol added
to them, respectively, to make up a concentration of 40 µg/mL. These stock solutions
were then diluted to 0.2, 2 and 20 µg/mL concentrations and 10 µL aliquots of these
dilutions were spotted on to sterile filter paper discs. These discs were placed on malt
yeast agar (MYA) plates that had been inoculated with a culture of C. albicans. As a
positive control, 10 µg of rapamycin was spotted on to a disk and as a negative control,
sterile water was spotted on to a disk. The plates were incubated for 24 hours at 37 ◦C and
zones of inhibition were measured. This work was performed by Jason Ryan at Callaghan
Innovation.
6.4 MscL Assay
Azolectin, N-2-Hydroxyethylpiperazine-N’-2-ethanesulfonic acid (HEPES) and TritonTM
X-100 were purchased from Sigma, 5,6-carboxyfluorescein (CF) was purchased from
Fluka and n-dodecyl-β-D-maltopyranoside (DDM, analytical grade) was purchased from
Affymetrix Anatrace. Avestin polycarbonate membranes with 400 nm pore diameters
were purchased from ATA Scientific, BioBeads R© SM-2 adsorbent were purchased from
Bio-Rad and 1-oleoyl-2-hydroxy-sn-glycero-3-phosphocholine (LPC) was purchased
from Avanti R© Polar Lipids, Inc. These were kindly supplied to us by Prof. Boris Martinac
at the Victor Chang Cardiac Research Institute via Dr. Penny Truman at ESR. Also
supplied was an Avestin LiposoFast-Basic lipid extruder with a LiposoFast-Stabilizer
used to give uniform liposome sizes. As well as the MscL protein suspended in DDM
buffer at a concentration of 394 µg/mL and a control DDM buffer. The DDM buffer had
been made up using 1 mM DDM in phosphate buffered saline (PBS).
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The chloroform used in preparing the liposomes was HPLC-grade and purchased from
Panreac. Water was distilled and deionised using a Milli-Q water filtration system.
HEPES buffer was made up to 50 mM HEPES in water where the pH was adjusted to
7.2–7.4 using KOH, this was stored in the fridge. DR buffer was made up as required
using one part 1 M KCl, one part 50 mM HEPES buffer and eight parts water. The CF
buffer was made up using a 50 mM concentration of CF in DR buffer, adjusting the pH
to 7.2 using 5 M KOH. The CF buffer was stored in the fridge. The LPC was made up
using 100 mg of LPC dissolved in 2 mL of methanol (0.1 M). This was later diluted
to a concentration of 0.05 M by adding an equal volume of methanol to the amount
remaining in the vial. The LPC in methanol solution was stored in the freezer at −20 ◦C.
A 10% TritonTM solution was made up using approximately 1 mL of TritonTM X-100
dissolved in 9 mL of water. Gel filtration of the liposomes was performed using Sephadex
G-25 medium in Bio-Rad disposable columns, these were equilibrated in water and stored
in the fridge.
To detect the liposomes in this assay a Perkin Elmer EnSpireTM 2300 Multilabel Plate
Reader with quad-monochromator based fluorescence intensity detection was used. All
MscL assays were run in 96-well black plates.
6.4.1 Assay Protocol
The protocol used for the MscL assay was modified from a protocol provided by
Dr. Penny Truman (ESR) in order to create MscL-containing liposomes at VUW. To
make the liposomes, 20 mg of azolectin was dissolved in 2 mL of chloroform in a small
sample vial and this was then dried using a rotary evaporator to leave a thin film of
azolectin in the vial. Once the sample was dry it was placed on the freeze drier for
10 to 15 minutes to remove any residual chloroform. To this azolectin film, 1 mL of CF
buffer was added and the solution was vortexed for one minute then sonicated in an ice
water bath for 20 minutes. The solution was then passed through a membrane with a pore
size of 400 nm using a lipid extruder. The liposome solution was then divided into two
eppendorfs, 300 µL of the solution was placed in each eppendorf and 10 µL of MscL in
DDM buffer was added to one and 10 µL of DDM buffer to the other. The eppendorfs
were then inverted by rotation at 20 RPM, to mix the solutions, for one hour.
After mixing for one hour, a volume of BioBeads R© (washed three times with methanol
and three times with water), approximately one third the volume of the liposome solutions,
was added to the eppendorfs. The solutions were then mixed again for two to four
hours. After mixing, the liposomes were separated from unincorporated CF buffer using
gel filtration in a column that had been equilibrated in DR buffer. The liposomes were
eluted from the column using DR buffer and were easily identifiable as the fast moving
fluorescent material in the column. The liposomes collected from this were then ready to
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be diluted and used in an assay.
Liposomes were diluted to three different concentrations using DR buffer (usually 1
5
, 1
10
and 1
20
dilutions) and tested with 98 µL of liposome dilution and 2 µL of DR buffer or
10% TritonTM in triplicate to read the fluorescence of intact and burst liposomes. From
these readings dilutions were adjusted to achieve the desired fluorescence. Assays were
performed using the buffer, solvent, LPC and TritonTM controls tested against both MscL
and control liposomes in triplicate. The wells were made up using 98 µL of the liposome
solution with 2 µL of control (DR buffer, methanol, 10% TritonTM) or test extract, with
the exception of LPC, which was added in amounts varying from 0.5 µL to 2 µL at
the concentrations of 0.1 M and 0.05 M as specified in the assay description. Using
liposome solutions in DR buffer, dose-response assays were set up in a similar fashion to
the S. cerevisiae assays, replacing the solvent 1:1 DMSO in water with methanol.
Assays were read at 5 or 10 minute intervals after LPC addition for up to 30–60 minutes.
The fluorescence percentage (F%) was calculated from the average fluorescence of the
controls or tests (Favg.) divided by the average fluorescence of the TritonTM controls
(FT.avg.) and multiplying the result by 100 (F% = (Favg./(FT.avg.) × 100). These calcula-
tions were only used with the controls from the same liposome types (e.g. MscL liposomes
fluorescence were compared to MscL liposomes TritonTM control fluorescence only). The
percentage fluorescence could then be compared between the control (F%C) and MscL
(F%M ) liposomes by subtracting the percentage fluorescence of the control liposomes
from the percentage fluorescence of the MscL liposomes to give a fluorescence percentage
difference, D% (D% = F%M− F%C). A difference in percentage fluorescences of the MscL
and control solvent controls (D%Solv.) could also be calculated and this could then be
subtracted from the differences in the percentage fluorescences of the LPC-containing
test or extract test wells (D%LPC), this would allow the data to be corrected for the
relative fragility of the MscL and control liposomes (D%corr. = D%LPC − D%Solv.). Data
processing was done using Microsoft Excel 2010.
6.5 Isolation of 3-APAs from MNP 0999
Frozen Haliclona sp. (MNP 0999, 189 g) was extracted twice in methanol (250 mL).
These extracts were then filtered through a pad of celite to remove any solid material. The
methanol extracts were cyclic loaded onto 75 mL of cleaned HP20 resin with the second
extract being run through the column followed by the first extract. The eluent from this
was collected together and 500 mL of water was added to it to make a 50% methanol
solution. This solution was then passed through the column again and 1 L of water was
added to the eluent to make a 25% methanol solution. This 25% methanol solution was
then passed through the column. The column, which was now loaded with the MNP 0999
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extract, was then eluted using 225 mL of 0%, 20%, 40%, 60%, 80% and 100% acetone in
water.
The 20%, 40%, 60% and 80% acetone in water fractions were each backloaded on to
25 mL of cleaned HP20 resin in order to remove the water. To do this, the fractions were
diluted with a further 225 mL of water and run through the column slowly to load the
extract fraction onto the column. The column was then eluted with 75 mL of methanol
followed by 75 mL of acetone, these elutions were collected together and the solvent
removed in vacuo. The 100% acetone fraction was also dried in vacuo. The 20%, 40%,
60%, 80% and 100% fractions were labelled VD1 96A, B, C, D and E, respectively.
These fractions were transferred to pre-weighed sample vials using methanol (VD1 96A,
B and C) or 20% CH2Cl2 in methanol (VD1 96D and E). The fractions were dried
in vacuo (VD1 96A and B) or under a stream of compressed air (VD1 96C, D and E)
to recover masses of 127.9 mg (VD1 96A), 388.4 mg (VD1 96B), 447.5 mg (VD1 96C),
160.8 mg (VD1 96D) and 91.3 mg (VD1 96E).
These fractions were then tested against S. cerevisiae in a dose-response assay testing
a maximum concentration of 200 µg/mL. This assay gave approximate IC50 values of
1.5 ± 1.0 µg/mL for VD1 96A and B, an IC50 of 1.5 µg/mL with a very large margin of
error for VD1 96C, an IC50 of 10.2± 1 µg/mL for VD1 96D and showed no inhibition for
VD1 96E. 1H NMR spectra were also collected for all of these fractions and they showed
that VD1 96A, B and C all contained similar compounds (3-APAs) whereas VD1 96D
and E did not. Fractions VD4 96A and B were purified further.
6.5.1 Dehydrohaliclocyclin C and F and Haliclocyclin C
Fraction VD1 96A was further fractionated using 30 mL of cleaned HP20ss resin and
eluted with 100 mL of 5%, 10%, 20%, 30%, 50% and 100% methanol in water. This
produced samples VD2 373A–I and 1H NMR were run on these. This fractionation
was NMR-guided in order to identify the compounds producing interesting multiplet
resonances occurring around 5.1 and 5.2 ppm in the 1H NMR spectrum. Fraction
VD4 373B, which was isolated from the 50% methanol in water elution, showed the
resonances of interest in the 1H NMR spectrum and had a mass of 24.3 mg. Further
purification of VD2 373B was done using a 16 mL Diol column, eluting with 50 mL
of 100%, 50% and 0% hexanes in ethyl acetate followed by 25%, 50%, 75% and 100%
methanol in ethyl acetate, finally the column was stripped with 25% and 50% water in
methanol. This produced fractions VD2 384A–O, the 1H NMR of these showed that
3-APAs were present in fractions VD2 384G–N. The multiplet resonances of interest
were present in fractions VD2 384G–I and of these VD2 384G had the highest mass of
6.7 mg.
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Further purification of VD2 384G was performed using reversed-phase (C18) analytical
HPLC, eluting with acetonitrile in water (both with 0.1% formic acid) with a flow rate
of 1 mL/min. This was performed on the Rainin HPLC system. The method held the
solvent mixture at 25% acetonitrile for four minutes followed by an eight minute ramp to
50% acetonitrile, holding at 50% for five minutes, there was then a two minute ramp to
100% acetonitrile, a hold at 100% for five minutes followed by a two minute ramp back
down to 25% acetonitrile and finally the solvent mixture was held at 25% acetonitrile
for six minutes (32 minutes total). The elution profile was followed using the UV/Vis
trace at 210 and 270 nm and fractions VD2 394A–K were collected. The fractions of
interest were VD2 394F and G, which had strong, sharp peaks in the UV/Vis trace and so
were expected to be the 3-APAs, this was confirmed using 1H NMR. Fraction VD2 394F
was sufficiently pure that a full set of NMR data could be run on this, resulting in the
identification of dehydrohaliclocyclin C (58). A full set of NMR data was also run of
VD2 394G revealing a mixture of 3-APAs. Both VD2 394F and G were further purified
using HPLC.
The same HPLC conditions used in the purification of VD2 384G were used for the
purification of VD2 394F, with the exception that the hold at 50% acetonitrile in water
for five minutes in the run was shortened to a three minute hold, shortening the run
time to 30 minutes. The UV/Vis trace of this showed one strong peak (VD3 86B)
and one weaker peak (VD3 86D). Fraction VD3 86B (0.8 mg) was the compound
dehydrohaliclocyclin C as shown by the 1H NMR spectrum. 1D and 2D NOESY,
coupled-HSQC and homonuclear decoupling NMR experiments were all run on this
compound allowing its geometry to be assigned. Over the course of these experiments
the sample accumulated some impurity and so needed to be purified again. This time
the purification was done on the Agilent HPLC system using a reversed-phase (C18)
analytical column and eluting with methanol in water (both with 0.1% formic acid) and
with a flow rate of 1 mL/min. The purification used an isocratic 10 minute run of 53%
methanol in water and the elution profile was followed using the UV/Vis trace at 210 and
270 nm. There was only one strong, major peak in the UV/Vis trace and from this the
fraction VD4 33C was isolated, its mass was then measured using quantitative NMR and
it was submitted for biological analysis against C. albicans. Fraction VD4 33C (0.36 mg)
was the pure compound dehydrohaliclocyclin C (58).
Fraction VD2 394G was purified using the same HPLC conditions used to purify
VD2 384G. The UV/Vis trace showed one major peak that had two shoulders, the peak
was collected as two fractions in order to aid separation of the compounds. The first part
of the major peak (VD3 87C) showed a cleaner 1H NMR spectrum as well as appearing to
have a larger mass in the 1H NMR than the second part of the major peak (VD3 87D). A
full set of NMR experiments were run on VD3 87C and these revealed two 3-APAs, which
MS data suggested were dehydrohaliclocyclin F (59) and haliclocyclin C (20). To separate
out these two compounds, reversed-phase (C18) analytical HPLC was used, eluting with
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methanol in water (both with 0.1% formic acid) and using a flow rate of 1 mL/min.
This HPLC purification was performed in two halves. The first half of purification
used the Rainin HPLC and collected fractions VD4 27A–E and the second half of the
purification used the Agilent HPLC and the fractions VD4 31A–D were collected. A
15 minute isocratic run of 53% methanol in water was used in both separations. 1H NMR
spectra showed that VD4 27C and VD4 31C were both the same compound and that
VD4 27B and VD4 31B were both the same compound. The matching compounds were
recombined and VD4 27 and 31C were renamed to VD4 32A and VD4 27 and 31B were
renamed to VD4 32B. The masses of these compounds were measured using quantitative
NMR and they were then submitted for biological analysis against C. albicans. VD4 32A
(0.25 mg) was the new compound dehydrohaliclocyclin F (59) and VD4 32B (0.16 mg)
was the known compound haliclocyclin C (20).
Dehydrohaliclocyclin C (58): Colourless oil, 0.36 mg; 1H NMR (CDCl3, 600 MHz)
δ 9.60 (br d, J=5.3 Hz, 1H, H-6), 8.83 (s, 1H, H-2), 8.17 (d, J=7.8 Hz, 1H, H-4), 8.03
(br t, J=5.7 Hz, 1H, H-5), 5.23 (m, 1H, H-13), 5.17 (m, 1H, H-12), 5.01 (m, 2H, H-7),
2.94 (m, 2H, H-19), 2.06 (br m, 2H, H-8), 1.98-1.93 (m, 4H, H-11 & H-14), 1.81 (m,
2H, H-18), 1.42 (quin, J=6.5 Hz, 2H, H-15), 1.36 (m, 2H, H-10), 1.27 (m, 2H, H-16),
1.17 (m, 2H, H-17), 1.04 (m, 2H, H-9); 13C NMR (CDCl3, 150 MHz) δ 145.2 (C-4),
144.1 (C-2), 143.6 (C-6), 143.4 (C-3), 130.5 (C-13), 129.8 (C-12), 128.5 (C-5), 62.7
(C-7), 32.3 (C-19), 31.1 (C-8), 29.0 (C-18), 28.41 (C-10), 28.36 (C-15), 27.3 (C-16), 27.1
(C-11), 26.6 (C-17), 25.2 (C-14), 25.1 (C-9); Further NMR data presented in Table 4.5;
HRESIMS [M]+ m/z 258.2216 for C18H28N+ (calculated 258.2216, m/z ∆ = 0), [M+1]+
m/z 259.2250 (calculated 259.2249, m/z ∆ = 0.0001).
Dehydrohaliclocyclin F (59): Colourless oil, 0.25 mg; 1H NMR (CD3OD, 600 MHz)
δ 8.95 (s, 1H, H-2), 8.87 (d, J=6.1 Hz, 1H, H-6), 8.51 (d, J=8.0 Hz, 1H, H-4), 8.07
(m, 1H, H-5), 5.35 (m, 2H, H-13 & H-14), 4.68 (t, J=6.1 Hz, 2H, H-7), 2.96 (m,
2H, H-20), 2.02 (m, 2H, H-8), 1.89 (m, 4H, H-12 & H-15), 1.78 (m, 2H, H-19),
1.37-1.29 (m, 8H, H-10, H-11, H-16 & H-17), 1.23-1.14 (m, 4H, H-9 & H-18);
13C NMR (CD3OD, 150 MHz) δ 147.1 (C-4), 145.8 (C-2), 145.3 (C-3), 143.3 (C-6),
130.9 (C-13/14), 130.7 (C-13/14), 129.4 (C-5), 63.2 (C-7), 33.3 (C-20), 31.6 (C-8), 30.8
(C-19), 30.2 (C-10/17), 30.1 (C-10/17), 29.1 (C-11/16), 28.9 (C-11/16), 26.83 (C-12/15),
26.78 (C-12/15), 27.8 (C-18), 25.7 (C-9); Further NMR data presented in Table 4.6;
HRESIMS [M]+ m/z 272.2378 for C19H30N+ (calculated 272.2373, m/z ∆ = 0.0005),
[M+1]+ m/z 273.2412 (calculated 273.2406, m/z ∆ = 0.0006), [M+2]+ m/z 274.2443
(calculated 274.2439, m/z ∆ = 0.0004), [M+3]+ m/z 275.2463 (calculated 275.2471,
m/z ∆ = −0.0008).
Haliclocyclin C (20): Colourless oil, 0.16 mg; 1H NMR (CD3OD, 600 MHz) δ 8.97
(s, 1H, H-2), 8.86 (d, J=6.1 Hz, 1H, H-6), 8.50 (d, J=8.2 Hz, 1H, H-4), 8.06 (dd,
J=7.9, 6.3 Hz, 1H, H-5), 4.67 (t, J=6.1 Hz, 2H, H-7), 2.96 (m, 2H, H-19), 2.07 (m, 2H,
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H-8), 1.84 (m, 2H, H-18), 1.36-1.27 (m, 8H), 1.19-1.14 (m, 10H); 13C NMR (CD3OD,
150 MHz) δ 147.2 (C-4), 145.5 (C-2), 145.0 (C-3), 143.6 (C-6), 129.1 (C-5), 62.7 (C-7),
32.6, 31.3, 30.1, 28.1, 28.0, 27.94, 27.90, 27.50, 27.49, 27.4, 27.3, 25.2; HRESIMS
[M]+ m/z 260.2381 for C18H30N+ (calculated 260.2373, m/z ∆ = 0.0008), [M+1]+
m/z 261.2413 (calculated 261.2406, m/z ∆ = 0.0007), [M+2]+ m/z 262.2452 (calculated
262.2439, m/z ∆ = 0.0013).
6.5.2 Oxidation of Dehydrohaliclocyclin F
In a biphasic solution of CHCl3 (2 mL), MeCN (2 mL) and H2O (3 mL), 100 µg of
dehydrohaliclocyclin F was dissolved. To this, 5 mg of NaIO4 and 1 mg of RuCl3 was
added. The solution was stirred for two hours then filtered, washing with CHCl3 and
MeCN. The CHCl3 (VD4 49A) and MeCN/H2O (VD4 49B) layers were separated and
the solvent removed in vacuo. Samples were submitted for analysis by MS.
Dehydrohaliclocyclin F Oxidation Product (60): HRESIMS [M]+ m/z 304.2269 for
C19H30NO2+ (calculated 304.2271, m/z ∆ = −0.0002); MS/MS fragments m/z 192.1382
for C12H18NO+ (calculated 192.1383, m/z ∆ = −0.0001), m/z 176.1427 for C12H18N+
(calculated 176.1434, m/z ∆ = −0.0007), m/z 162.1268 for C11H16N+ (calculated
162.1277, m/z ∆ = −0.0009), m/z 120.0805 for C8H10N+ (calculated 120.0808, m/z ∆
= −0.0003), m/z 106.0649 for C7H8N+ (calculated 106.0651, m/z ∆ = −0.0002).
6.5.3 VD4 47A
A 104.5 mg subsample of VD1 96B was further fractionated using a 30 mL column of
cleaned HP20ss resin and eluted with 100 mL of 20%, 30%, 40%, 50%, 60%, 70%,
80% and 100% methanol in water followed by 100% acetone. This produced fractions
VD2 356A–N that were tested against S. cerevisiae (with the exception of the acetone
wash VD2 356E) and 1H NMR were run. Fraction VD2 356C had the highest mass
(22.4 mg) and was amongst the most active fractions (IC50 2.4 ± 1.0 µg/mL). A full set
of NMR experiments were run on this fraction to reveal a mixture of 3-APAs. Further
purification of this extract was performed using reversed-phase (C18) semi-preparative
HPLC, eluting with methanol in water (both containing 0.1% formic acid) with a flow
rate of 4 mL/min. This was performed on the Agilent HPLC system. The compounds
were eluted using a 62% methanol isocratic run for 20 minutes followed by a one minute
ramp to 80% methanol, the solvent mixture was held at 80% methanol for five minutes
before a one minute gradient brought the solvent mixture back down to 62% methanol
where it was held for nine minutes (37 minutes total). The elution profile was followed
using the ELSD trace and the fractions VD4 43A–J were collected. 1H NMR spectra were
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collected for the fractions and 3-APAs were identified in almost all of them. Fractions
VD4 43D (3.3 mg) and VD4 43E (3.8 mg), which were collected from two of three broad
overlapping peaks, appeared to be the same compound in the 1H NMR spectrum and so
these were recombined and renamed to VD4 46A.
Samples VD4 43D and E were found to be poorly soluble when running NMR experi-
ments using CD3OD so the counter-ion of the combined VD4 46A was exchanged using
NaCl. This was done by cyclic loading VD4 46A on to 2 mL of cleaned HP20ss resin.
The sample was dissolved in 2 mL of methanol and run through the HP20ss column
slowly, the eluent was collected and diluted with 2 mL of water to make a 50% methanol
solution and this was run through the column again. This process was continued with
eluent from the column being collected and diluted by 50% after each loading until a
3.125% methanol solution was run through the column. A saturated NaCl solution was
then slowly passed through the column (2 × 15 mL) and the column was washed with 5
× 30 mL of water. The column the finally eluted with 20 mL of methanol (VD4 47A)
followed by 20 mL of acetone (VD4 47B). 1H NMR spectra showed that VD4 47A, with
a mass of 4.4 mg, contained the 3-APA. A full set of NMR experiments was therefore
run on this fraction, however the structure was not able to be elucidated in this study, see
Section 4.4.4.
6.6 Extraction of MNP 1001
Frozen Callyspongia sp. (MNP 1001, 112 g) was extracted twice in methanol (200 mL).
These extracts were then filtered through a pad of celite to remove any solid material. The
methanol extracts were cyclic loaded onto 45 mL of cleaned HP20 resin with the second
extract being run through the column followed by the first extract. The eluent from these
extractions was collected together and 400 mL of water was added to this to make a 50%
methanol solution. This solution was then passed through the column again and 800 mL
of water was added to the eluent to make a 25% methanol solution. This 25% methanol
solution was then passed through the column. The column, which was now loaded with
the MNP 1001 extract, was then eluted using 135 mL of 0%, 20%, 40%, 60%, 80% and
100% acetone in water.
The 20%, 40%, 60% and 80% acetone in water fractions were each backloaded on to
15 mL of cleaned HP20 resin in order to remove the water. To do this, the fractions were
diluted with a further 135 mL of water and run through the column slowly to load the
extract fraction onto the column. The column was then eluted with 45 mL of methanol
followed by 45 mL of acetone, these elutions were collected together and the solvent
removed in vacuo. The 100% acetone fraction was also dried in vacuo. The 20%, 40%,
60%, 80% and 100% fractions were labelled VD1 91A, B, C, D and E, respectively.
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These fractions were transferred to pre-weighed sample vials using methanol (VD1 91A,
B and C) or 20% CH2Cl2 in methanol (VD1 91D and E) and dried in vacuo. To
recover masses of 4.9 mg (VD1 91A), 9.0 mg (VD1 91B), 10.0 mg (VD1 91C), 32.9 mg
(VD1 91D) and 72.3 mg (VD1 91E).
These fractions were tested against S. cerevisiae in a dose-response assay twice, testing
maximum concentrations of 200 µg/mL and 100 µg/mL. These assays both showed that
the fractions had no activity against S. cerevisiae, including for a recombined fraction
tested in the second assay. The lack of activity and low masses recovered of from this
sponge extraction resulted in this work being discontinued.
6.7 Isolation of Compounds from PTN3 40G
The ascidian PTN3 40G (17.92 g) was completely extracted in methanol (100 mL) and the
small amount of remaining solid was then reextracted (25 mL). These extracts were then
filtered to remove the minor solid material remaining. The methanol extracts were cyclic
loaded onto 25 mL of cleaned HP20 resin, with the second extract being run through the
column followed by the first. The eluent from these extractions was collected together
and 125 mL of water was added to this to make a 50% methanol solution. This solution
was then passed through the column again and 250 mL of water was added to the eluent
to make a 25% methanol solution. This 25% methanol solution was then passed through
the column. The column, which was now loaded with the PTN3 40G extract, was then
eluted using 75 mL of 30%, 75% and 100% acetone in water.
The 30% and 75% acetone in water fractions were each backloaded on to 10 mL of
cleaned HP20 resin in order to remove the water. In order to do this, the fractions were
diluted with a further 75 mL of water and run through the column slowly, the eluent
was then diluted with another 80-100 mL of water and run through the column again to
load the extract fraction onto the column. The column was then eluted with 50 mL of
methanol followed by 50 mL of acetone, these elutions were collected together and the
solvent removed in vacuo. The 100% acetone fraction was also dried in vacuo. The 30%,
75% and 100% fractions were labelled VD3 64A, B and C, respectively. These fractions
were transferred to pre-weighed sample vials using 20% CH2Cl2 in methanol and dried
in vacuo. To recover masses of 9.5 mg (VD3 64A), 51.1 mg (VD3 64B) and 213.9 mg
(VD3 64C). These fractions were tested against S. cerevisiae in a dose-response assay,
testing a maximum concentration of 100 µg/mL. This assay showed that the fractions had
poor activity against S. cerevisiae with 27% of yeast growth inhibited at a concentration
of 100 µg/mL for VD4 64A and B and no inhibition observed for VD4 64C.
Fraction VD3 64B was further fractionated using 11 mL of cleaned HP20ss resin and
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eluted with 33 mL of 20%, 40%, 60%, 80% and 100% methanol in water and 100%
acetone. This produced samples VD3 80A–H that were tested against S. cerevisiae
and 1H NMR were run. Poor to no inhibition was found in these fractions again so
an NMR-guided approach was used for further fractionation. Fraction VD3 80C that
had been isolated from the acetone strip of the HP20ss column had a mass of 14.1 mg
and showed some interesting resonances in the 1H NMR spectrum so it was selected
for further purification. Further purification of VD3 80C was done using a 12 mL Diol
column, eluting with 40 mL of 100%, 50% and 0% hexanes in ethyl acetate followed by
25%, 50%, 75% and 100% methanol in ethyl acetate, finally the column was stripped with
25% and 50% water in methanol. This produced fractions VD3 98A–O, the 1H NMR of
these fractions enabled the fatty acid VD3 98G and the phthalate ester VD3 98E to be
selected for full characterisation. A full set of NMR experiments were run on the fatty
acid VD3 98G, strengthening the proposal that the structure was a fatty acid.
Before a full set of NMR experiments could be run on the VD3 98E, it needed to be
further purified using normal-phase (Diol) analytical HPLC purification, eluting with
ethyl acetate in hexanes. This was performed on the Rainin HPLC system. A 15 minute
isocratic elution of 7% ethyl acetate in hexanes was used with a flow rate of 1 mL/min
in this fractionation. The elution profile was followed using the UV/Vis trace at 210 and
270 nm, the fractions VD4 17A, B and C were collected. The strong major peak in the
UV/Vis trace was collected as VD4 17B, this was thought to be the phthalate ester. A full
set of NMR experiments was run on VD4 17B (3.2 mg) revealing that this fraction was a
mixture of phthalate ester structures.
Fatty Acid VD3 98G tentatively assigned as cis-vaccenic acid (13): White solid,
1.3 mg; 1H NMR (CDCl3, 600 MHz) δ 5.35 (t, J=4.5, 2H), 2.22 (t, J=7.7 Hz, 2H), 2.01
(d, J=6.6 Hz, 4H), 1.63 (quin, J=7.4 Hz, 2H), 1.35-1.24 (m, 22H), 0.88 (t, J=7.1 Hz, 3H);
13C NMR (CDCl3, 150 MHz) δ 175.6, 130.1, 130.0, 36.1, 32.1, 29.9, 29.8, 29.75, 29.7,
29.68, 29.6, 29.49, 29.48, 29.4, 27.4, 25.7, 22.9, 14.3.
Phthalate Ester Mixture VD4 17B: Colourless oil, 3.2 mg; 1H NMR (CD3OD,
600 MHz) δ 7.72 (m, 2H), 7.62 (m, 2H), 4.36-4.26 (m), 1.81-1.08 (indistinguishable
multiplets), 1.06-0.79 (indistinguishable multiplets); the 13C NMR (CD3OD, 150 MHz)
had many broad and overlapping resonances due to the mixture of compounds and so is
not reported (see Appendix D.3).
6.8 Isolation of Steroids from PTN2 67C
Frozen Leucosolenia sp. (PTN2 67C, 93 g) was extracted twice in methanol (250 mL).
These extracts were then filtered through a pad of celite to remove any solid material.
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The methanol extracts were cyclic loaded onto 40 mL of cleaned HP20 resin, with the
second extract being run through the column followed by the first. The eluent from these
extractions was collected together and 500 mL of water was added to this to make a 50%
methanol solution. This solution was then passed through the column again and 1 L of
water was added to the eluent to make a 25% methanol solution. This 25% methanol
solution was then passed through the column. The column, which was now loaded with
the PTN2 67C extract, was then eluted using 120 mL of 30%, 75% and 100% acetone in
water.
The 30% and 75% acetone in water fractions were each backloaded on to 15 mL of
cleaned HP20 resin in order to remove the water. To do this, the fractions were diluted
with a further 120 mL of water and run through the column slowly, the eluent was then
diluted with another 240 mL of water and run through the column again to load the extract
fraction onto the column. The column was then eluted with 60 mL of methanol followed
by 60 mL of acetone, these elutions were collected together and the solvent removed
in vacuo. The 100% acetone fraction was also dried in vacuo. The 30%, 75% and 100%
fractions were labelled VD3 68A, B and C, respectively. These fractions were transferred
to pre-weighed sample vials using 20% CH2Cl2 in methanol and dried under a stream
of compressed air to recover masses of 30.5 mg (VD3 68A), 185.5 mg (VD3 68B) and
209.7 mg (VD3 68C). These fractions were tested against S. cerevisiae in a dose-response
assay testing a maximum concentration of 100 µg/mL. This assay gave approximate IC50
values of 16 ± 1 µg/mL for VD3 68A and 25 ± 1 µg/mL for VD3 68B and showed no
inhibition for VD2 68C. 1H NMR spectra were also collected for all of these fractions.
Fraction VD3 68B was chosen for further purification because of its activity and high
mass. Fraction VD3 68A was not pursued further because of its relatively low mass.
A 92.8 mg subsample of VD3 68B was further fractionated using a 12 mL column of
cleaned HP20ss resin and eluted with 36 mL of 20%, 40%, 60%, 80% and 100% methanol
in water followed by 100% acetone. This produced fractions VD3 79A–F that were tested
against S. cerevisiae and 1H NMR were run. Fraction VD3 79B had the highest mass
(30.1 mg) and was the most active fraction (IC50 94 ± 2 µg/mL). Further purification
of VD3 79B was done using a 13 mL Diol column, eluting with 40 mL of 0%, 25%,
50%, 75% and 100% ethyl acetate in hexanes followed by 25%, 50%, 75% and 100%
methanol in ethyl acetate, finally the column was stripped with 25% and 50% water
in methanol. This produced fractions VD4 05A–Y, the 1H NMR of these showed that
fractions VD4 05K, L and M all contained a steroid structure so these fractions were
combined and a full set of NMR experiments were run on this combined fraction. The
NMR data showed a mixture of trihydroxylated steroids were present in the combined
VD4 05KLM fraction so further purification was required.
Further purification of VD4 05KLM was performed using reversed-phase (C18) analyti-
cal HPLC, eluting with methanol (containing 0.1% formic acid) in water and using a flow
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rate of 1 mL/min. This was performed on the Agilent HPLC system. The compounds
were eluted using a 15 minute 90% methanol isocratic run followed by a one minute
ramp to 100% methanol, the solvent mixture was held at 100% methanol for five minutes
before a one minute ramp brought the solvent mixture back down to 90% methanol where
it was held for eight minutes (30 minutes total). The elution profile was followed using
the ELSD trace and the fractions VD5 71A–M were collected. 1H NMR spectra were
collected for the fractions. VD5 71J was selected to run a full set of NMR experiments
on, in order to solve the structure, because it was a clean fraction with the largest mass
(0.3 mg). The structure of VD5 71J (14) was proposed based on the NMR data and this
was found to be a known compound.
Trihydroxylated steroid VD5 71J: Colourless oil, 0.3 mg; 1H NMR (CD3OD, 600 MHz)
δ 5.27 (m, 1H, H-7), 5.21-5.19 (m, 2H, H-22 & H-23), 3.97 (tt, J=11.4, 4.8 Hz, 1H,
H-3), 3.54 (m, 1H, H-6), 2.12-2.08 (m, 1H, H-4a), 2.04 (s, 1H, H-20), 2.01 (s, 1H, H-9),
1.98-1.94 (m, 1H, H-14), 1.84 (q, J=6.6 Hz, 1H, H-24), 1.81-1.74 (m, 2H, H-2a), 1.69
(ddd, J=13.3, 4.8, 2.0, 1H, H-4b), 1.63-1.54 (m, 4H, H-1a, H-11a & H-11b), 1.53-1.44 (m,
3H, H-1b, H-2b & H-25) 1.32 (m, 1H, H-17), 1.06 (s, 3H, H-19), 1.03 (d, J=6.6 Hz, 3H,
H-21), 0.94 (d, J=6.8 Hz, 3H, H-28), 0.87 (d, J=6.8 Hz, 3H, H-26), 0.85 (d, J=6.8 Hz, 3H,
H-27), 0.65 (s, 3H, H-18); 13C NMR∗ (CD3OD, 600 MHz) δ 137.0 (C-22), 133.0 (C-23),
118.8 (C-7), 68.1 (C-3), 73.9 (C-6), 57.0 (C-17), 55.6 (C-14), 44.3 (C-24), 44.0 (C-9),
41.7 (C-20), 34.2 (C-25), 76.6 (C-5), 44.4 (C-13), 37.8 (C-10), 40.1 (C-4), 33.6 (C-1),
31.5 (C-2), 40.4 (C-12), 21.4 (C-21), 20.4 (C-26), 19.8 (C-27), 18.6 (C-19), 18.4 (C-28),
12.4 (C-18); HRESIMS [M+Na]+ m/z 453.3305 for C28H46O3Na+ (calculated 453.3345,
m/z ∆ = −0.0040).
∗obtained from HSQC and HMBC spectra
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Appendix A
NMR Spectra of Dehydrohaliclocyclin C
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Fully coupled HSQC spectrum of dehydrohaliclocyclin C (58) (600 MHz, CDCl3)
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Appendix B
NMR Spectra of Dehydrohaliclocyclin F
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Appendix C
NMR Spectra of Known Compounds
C.1 Haliclocyclin C
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* = contamination
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C.2 Steroid VD5 71J
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1H NMR spectrum of the steroid VD5 17J (600 MHz, CD3OD)
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C.3 Steroid Mixture VD4 05KLM
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1H NMR spectrum of the steroid mixture VD4 05KLM (600 MHz, CDCl3)
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Appendix D
NMR Spectra of Discontinued Projects
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D.2 Fatty Acid VD3 98G
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D.3 Phthalate Ester VD4 17B
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